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ABSTRACT 
The overall objective of my dissertation is to develop alternative therapies 
for seizure emergencies. Status epilepticus is a condition defined as a 
convulsive seizure lasting more than 5 minutes and is considered a seizure 
emergency due to the increased risk for neuronal damage and mortality (Trinka 
et al. 2015). Although relatively effective, first-line therapy fails to terminate status 
epilepticus in 26-57% of cases, leading to increased risk of seizure refractoriness 
and use of second- and third-line therapies that may increase the risk of systemic 
complications and mortality (Treiman et al. 1998; Alldredge et al. 2001; Silbergleit 
et al. 2012; Chamberlain et al. 2014). Three drugs were studied: 
allopregnanolone (ALLO), lacosamide (LCM) and topiramate (TPM). The 
pharmacokinetics and pharmacodynamics of investigational allopregnanolone 
formulations following intravenous and intramuscular delivery were assessed for 
the development as an early rescue therapy for seizure emergencies (Project 1). 
I also explored the relationship between lacosamide and PR prolongation in the 
critically-ill population to identify a subpopulation in whom it can be used safely 
(Project 2). Finally, for topiramate, the pharmacokinetics and pharmacodynamics 
of an investigational intravenous formulation was evaluated for adjunctive 
therapy in seizure emergencies (Project 3). 
Allopregnanolone, a progesterone derivative and GABAA positive allosteric 
modulator, has demonstrated potential to treat status epilepticus in preclinical 
models and pediatric and adult patient case reports. Given that first-line therapy 
fails in the majority of cases, more effective early treatments are necessary to 
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prevent downstream seizure refractoriness and systemic complications. The 
specific aims for Project 1 were to characterize the pharmacokinetics, 
pharmacodynamics and safety following intravenous and intramuscular ALLO in 
dogs. Five dogs (one on phenobarbital therapy) received single doses of ALLO: 
one- to four-mg/kg intravenously, or one- to six-mg/kg intramuscularly, with a 
washout period of at least one week. Plasma samples were collected pre-dose 
and at regular intervals up to six hours post-dose. Clinical response was 
assessed by behavioral response and intracranial electroencephalographic 
(iEEG). I found that with IV ALLO, drug exposure and peak plasma concentration 
increased proportionally with dose within the doses studied. Behavioral 
responses and iEEG data illustrate the rapid onset of effect following IV ALLO 
administration. The results of this study indicate that IV ALLO is a promising 
agent for the early treatment of seizure emergencies, with evidence of rapid 
penetration into the brain and a high safety profile. IM ALLO has great potential 
to be useful as a first-line treatment for SE, but the current formulations do not 
attain high enough plasma concentrations predicted to confer iEEG changes. 
Therefore, alternative approached would be needed for a viable IM ALLO 
product.  
Intravenous LCM has shown safety and some efficacy as an adjunctive 
therapy in refractory convulsive and non-convulsive status epilepticus. Outside of 
seizure emergencies, it is also used in the critically-ill population to treat acute 
breakthrough seizures or to maintain seizure control in patients who are unable 
to take oral medications. Lacosamide is particularly appealing in this patient 
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population due to its low potential for drug-drug interactions and serious systemic 
complications. However, there are reports of PR interval prolongation, which 
raises concern for patients who have a higher risk for developing cardiac 
arrhythmias or conduction abnormalities. The specific aim of Project 2 was to 
estimate the prevalence of PR prolongation in the critically-ill patient population 
following intravenous LCM administration. I performed a retrospective chart 
review and defined PR interval prolongation as a shift from normal to high PR 
interval or an increase of 20% or more in PR interval from baseline. Logistic 
regression analysis was performed in order to identify clinical factors that help 
predict an increase in PR interval 20%. Eight percent of my patient sample 
experienced PR prolongation, which is 20-times higher than the prevalence of 
0.4% reported in ambulatory patients with epilepsy. The logistic regression 
analysis suggested that the occurrence of PR prolongation following IV LCM 
administration is positively associated with age, the total daily dose of LCM, and 
serum potassium levels. However, considering that these results are generated 
from a small number of events (n=7/88), the true impact of these predictors on 
PR prolongation in this patient population needs to be explored further. 
In addition to finding alternative early treatments for seizure emergencies, 
better adjunctive treatments during refractory stages of status epilepticus are 
also needed. Topiramate’s many mechanisms of action and preclinical evidence 
of neuroprotection, which make it an ideal candidate to treat status epilepticus 
that has become resistant to first-line therapies. Intravenous administration of 
TPM offers an alternative that would allow more drug to get into the body and at 
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a faster rate than current methods of its administration. The specific aims of 
Project 3 were to characterize the pharmacokinetics, pharmacodynamics and 
safety following intravenous TPM in dogs. Five dogs (three on phenobarbital 
maintenance therapy) were used in this study. Ten and twenty mg/kg of stable-
labeled topiramate were infused intravenously over five minutes. One hour 
following the 10 mg/kg infusion, each dog also received a 5 mg/kg dose of 
unlabeled oral topiramate. Plasma samples were collected pre-dose and at 
regular intervals up to nine hours post-dose. Sixteen electrode channels were 
continuously recorded. Topiramate concentration-time data were analyzed using 
noncompartmental and population compartmental approaches. Concentration-
time data were best fit by a two-compartment model, and co-medication with 
phenobarbital was associated with a 5.6-fold higher clearance. The estimated 
absolute oral bioavailability ranged from 62-102%.  Statistically significant 
increases in iEEG activity were observed within 30 minutes of infusion, which is 
essential when treating seizure emergencies. Simulations suggest a different 
dosing strategy for dogs on phenobarbital may be necessary to optimize drug 
exposure. The results of this study indicate that development of an intravenous 
TPM formulation with evidence of penetration into the brain and good tolerability 
is feasible. 
My research suggests that there are promising therapies in development for 
the management of SE, which will significantly improve patient lives by offering 
safer use of current antiseizure drugs or more effective therapies. There are 
many pathways into which these projects can take, including conducting clinical 
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trials in dogs with naturally-occurring SE and single- and multiple-ascending dose 
studies in patients. 
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CHAPTER 1  
 
INTRODUCTION  
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1.1 Introduction and Orientation 
Status epilepticus (SE) is a life-threatening condition that requires rapid treatment 
in order to prevent systemic complications and irreversible brain damage. 
Although there are evidence-based guidelines for the management of convulsive 
SE, including the use several antiseizure drugs with different mechanisms of 
action, the case fatality rate within 30 days of the SE event ranges from 21-39% 
(Logroscino et al. 1997; Vignatelli, Tonon, and Alessandro 2003).  
 
As the duration of a seizure lengthens, the seizure becomes less likely to 
terminate on its own and more difficult to treat with current therapies (J. W. Chen 
and Wasterlain 2006; Fujikawa 1996; Mazarati, Baldwin, et al. 1998). After 30 
minutes of prolonged seizure activity, the risk for neuronal cell damage 
escalates. Therefore, time is essential in the management of SE, and rapid 
intervention with the goal of seizure termination is key. Even with relatively 
effective first-line therapies, roughly 30% of cases fail to respond and progress to 
more serious conditions (Treiman et al. 1998). The current treatment of SE is 
suboptimal, especially earlier on in treatment algorithm. There is a need for safe 
and effective alternatives to better manage this condition.  
 
In general, the rapid intervention of SE is determined by the routes of drug 
administration. For this condition, the ideal intervention is one that can be 
administered with ease and achieve therapeutic drug concentrations in the brain 
within a short amount of time. For this to be possible, the drug must be able to be 
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formulated in a solution that allows for intravenous and depending on its 
physicochemical properties, intramuscular, intranasal or subcutaneous 
administration. While enteral and rectal routes of administration have been used 
for SE treatment, they are limited by slower rates of absorption (and 
consequently lower and delayed peak drug concentrations) and decreased social 
acceptance, respectively (Bhattacharyya, Kalra, and Gulati 2006; Brigo et al. 
2015). Thus, in this dissertation, the focus will be on parenteral formulations of 
central nervous system-active (CNS-active) drugs.  
 
The overarching objective of my dissertation is to develop alternative 
therapies for seizure emergencies, which will have a significant impact on the 
patients and families of those affected by offering safer use of current treatments 
or more effective treatments. As part of this work, I will present a review of 
human epilepsy and SE, followed by canine epilepsy and SE, and the 
translatability of therapeutic and mechanistic research between the two diseases. 
Although my primary focus is on treatment alternatives for SE and not the 
management of epilepsy syndromes, it is essential to understand the underlying 
pathophysiology of seizures and epileptogenesis before attempting to treat 
prolonged seizures. The prospective therapies under development range in their 
stages in the drug development pipeline, as well as their potential place in the 
management of seizure emergencies. These include: 
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- Project 1: Allopregnanolone, a naturally-occurring neurosteroid that is a 
positive allosteric modulate GABAA receptors, with potential as an early 
treatment of SE 
o Hypothesis: Allopregnanolone would be beneficial in the early 
treatment of SE based on its novel mechanism of action and ability 
to get into the brain quickly 
o Specific aim: To characterize the pharmacokinetics, 
pharmacodynamics, and safety/tolerability following 
intravenous and intramuscular allopregnanolone in dogs 
- Project 2: Lacosamide, an antiseizure drug that enhances the slow 
inactivation of voltage-gated sodium channels, with potential as a treatment 
for established SE but has concerns for cardiac safety 
o Hypothesis: Intravenous lacosamide increases the risk for PR 
prolongation, especially in the critically-ill population 
o Specific aim: To estimate the prevalence of PR prolongation in 
the critically-ill patient population following intravenous 
lacosamide administration 
- Project 3: Topiramate, an antiseizure drug that potentiates GABA current and 
antagonize AMPA/kainite receptors, with potential as an adjunctive treatment 
for refractory SE 
o Hypothesis: Intravenous topiramate would be beneficial as an 
adjunctive treatment for refractory SE based on its multiple 
mechanisms of action and low potential for drug-drug interactions 
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o Specific aims: To characterize the pharmacokinetics, 
pharmacodynamics, and safety/tolerability following 
intravenous topiramate in dogs 
 
As part of the review, I will refer to ratings of evidence and levels of 
recommendation which are categorized based on systematic reviews conducted 
by Glauser et al 2016 and Podell et al 2016. In general, these authors rate 
evidence depending on the type of clinical studies conducted. High level of 
evidence is from a prospective, blinded, randomized, controlled clinical trial 
(RCT) with masked outcome assessment in a representative population. 
Moderate level of evidence is from a prospective randomized matched group 
cohort study. Low level of evidence is from uncontrolled studies, case series, 
case reports, or expert opinion. Consequently, the level of recommendation for 
specific therapies are based on the level of evidence available for an indication. 
For example, a high recommendation is given if treatment is established with 
high level of evidence as effective and should be given, while a moderate 
recommendation is given if the treatment is probably effective and should be 
considered (Glauser et al. 2016).  
 
1.2 Human Epilepsy and Seizure Emergencies 
1.2.1 Human Epilepsy 
Epilepsy is a disease of the brain that is characterized by the presence and/or 
predisposition for seizures. An epileptic seizure is a passing occurrence of 
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symptoms due to abnormal electrical brain activity (Fisher et al. 2005). The 
International League Against Epilepsy (ILAE) is an organization founded in 1909 
whose goals are to advance the knowledge of epilepsy, promote its research and 
education, and improve the care of patients with epilepsy (About International 
League Against Epilepsy 2019). As part of their mission, the ILAE is tasked with 
defining and classifying seizures and epilepsy. In 2014, a practical definition of 
epilepsy was established to aid in the diagnosis of the disease. Epilepsy is 
diagnosed by the presence of any of the following: “1) at least two unprovoked 
(or reflex) seizures occurring more than 24 hours apart; 2) one unprovoked 
(reflex) seizure and a probability of further seizures similar to the general 
recurrence risk (at least 60%) after two unprovoked seizures occurring over the 
next 10 years; or 3) diagnosis of an epilepsy syndrome (Fisher et al. 2014).” 
Moreover, epilepsy is considered “resolved” for patients who had age-dependent 
epilepsy syndrome and are now past the applicable age, or those who have been 
seizure-free for the past ten years without anti-seizure drugs (ASDs) for the last 
five years.  
 
1.2.1.1 Prevalence and Etiology 
According to the Epilepsy Foundation, epilepsy is the fourth most common 
neurological disorder. Its prevalence has been reported to be range between 2.3-
22.8 cases of epilepsy per 1,000 people in the general population worldwide 
(0.23-2.3%), and 6.8-8.5 cases in 1,000 of insured people in the United States 
alone (Bell, Neligan, and Sander 2014; H. Kim et al. 2016; Fiest et al. 2017; 
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Helmers et al. 2015). In 2017, ILAE commissioned a new classification system 
for seizure types and epilepsy types to improve the intuitiveness of the 
classification in addition to allowing for inclusion of previously unclassifiable 
seizure and epilepsy types (Figure 1.2.1-1) (Falco-Walter, Scheffer, and Fisher 
2018). These will be discussed in more detail in the following section. Along each 
step of the diagnostic pathway, the ILAE recommends that the clinician should 
attempt to identify the etiology of the patient’s epilepsy (Scheffer et al. 2017). 
Within the new classification system, there are six non-hierarchical etiological 
categories with management implications, including: structural (i.e. neuroimaging 
finding inferred to cause the patient’s seizures which may have resulted from a 
stroke, infection, trauma, genetic malformation, etc.), genetic (i.e. a known or 
presumed specific disease-causing gene variant believed to be pathogenic for 
 
Figure 1.2.1-1 ILAE Framework for Classification of Epilepsies. Reproduced with persmission 
from Scheffer et al 2017. 
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epilepsy), infectious (i.e. refers to a patient with seizures due to resolved 
infection), metabolic (e.g. uremia, pyridoxine-dependent seizures, cerebral folate 
deficiency), immune (i.e. when an autoimmune disease is the cause of new-
onset epilepsy, like anti-NMDA receptor encephalitis), and unknown. A patient’s 
epilepsy may be classified into more than one etiologic category, and the 
importance of each etiological group may depend on the patient’s circumstance 
(e.g. a patient with tuberous sclerosis has a structural and genetic etiology, which 
would be critical for surgical and pharmacological considerations).  
 
1.2.1.2 Seizure Semiology and Clinical Diagnosis 
The starting point of the classification framework (Figure 1.2.1-1) is the 
operational identification of the seizure type, outlined in Figure 1.2.1-2 (Fisher et 
al. 2017). A seizure type is a grouping of seizure qualities for the purposes of 
communication in research, clinical care, and education. The framework is non-
hierarchical, so that levels can be skipped or omitted with no other elaboration. 
However, use of additional classifiers are encouraged. Classification starts with 
the determination of the initial onset of the seizures (focal or generalized onset) 
and allows for classifications of seizures where the onset may be missed or 
obscured (unknown onset). If both motor and nonmotor seizures are present, the 
motor signs are usually overshadowing, unless the non-motor symptoms are 
obvious. Moreover, if a single seizure presents with a sequence of signs and/or 
symptoms, then the initial sign/symptom is used for the naming of the seizure. 
Finally, a seizure type of unknown onset can be classified at a later time with 
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additional clinical history and/or diagnostic tools. This may be more 
commonplace in settings where there is no access to EEG, video, or imaging 
technology.  
 The second step of the framework is epilepsy type. Diagnoses are made 
on clinical evaluation and is supported by EEG findings. Generalized epilepsy is 
typically diagnosed by the presence of interictal generalized spike-wave activity 
on EEG, while focal epilepsies can have unifocal/multifocal origins or seizures 
involving one hemisphere with interictal EEG showing focal epileptiform 
discharges. A new type of epilepsies, combined generalized and focal epilepsies, 
are for patients who have both epilepsy types (e.g. Dravet syndrome and 
Lennox-Gaustaut syndrome). Complementary to the updated epilepsies 
 
Figure 1.2.1-2 ILAE Operation Classificaiton of Seizure Types. Reproduced with permission 
from Fisher et al 2017. 
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categorization is an EEG diagnostic system composed by the ILAE 
Neurophysiology Task Force that can be applied to all epilepsy syndromes 
(Koutroumanidis et al. 2017). This system allows the clinician to determine the 
strength of EEG diagnosis and suggest further EEG tests where conclusive 
evidence is still lacking. Similar to seizure type classification, an unknown 
epilepsy type exists here if the clinician is unable to determine the type based on 
insufficient information (i.e. lack of EEG, or uninformative EEG).  
 Determination of an epilepsy syndrome is the last step of the framework. 
An epilepsy syndrome refers to a group of seizure types, age-dependent, EEG 
abnormalities, and imaging features that occur together. A syndrome may also 
have distinctive associated co-morbidities such as developmental impairment 
and/or psychiatric dysfunction. These features taken together may have 
associated prognostic and treatment implications.  
 
1.2.1.3 Management of Epilepsy 
As evidenced by the updated ILAE diagnosis criteria for epilepsy, estimating the 
recurrence risk following the first unprovoked seizure is essential not only to the 
diagnosis of epilepsy, but also for deciding whether treatment should be initiated. 
However, it should be noted that the decision to diagnose epilepsy is different 
and separate from the decision to treat. When considering whether treatment 
should be initiated, the clinician should be aware that the risk for a recurrent 
seizure is greatest within the first two years after the first seizure (21-45%), 
especially in the first year (Krumholz et al. 2015; Hauser et al. 1990; Annegers et 
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al. 1986; Hauser et al. 1982). The factors that have the highest level of evidence 
to be associated with an increased risk for seizure recurrence are having a prior 
brain insult and the presence of EEG epileptiform abnormalities (Krumholz et al. 
2015). This risk for recurrent seizures appears to be lower for patients who are 
treated with antiseizure drug (ASD) therapy (Krumholz et al. 2015).  
Antiseizure drugs are the mainstay of initial treatment for the majority of 
patients with epilepsy (Tables 1.2.1.1-4). Figure 1.2.1-3 depicts the different 
mechanisms of action of FDA-approved antiseizure drugs. In general, these 
mechanisms will result in decreased excitability of the postsynaptic neuron by 
decreasing excitatory input, increasing inhibitory input, or antagonizing voltage-
gated cation channels.  
Table 1.2.1-1 Drugs for the Management of Epilepsy (Part 1) 
Antiseizure 
Drug 
Antiseizure Mechanism(s) of 
Action 
FDA-Approved Indications 
Brivaracetam Inhibition of synaptic vesicle 
protein 2A 
Focal onset seizures, 4+ years 
Cannabidiol GPR55 antagonist and inhibition 
of VDAC1 
Seizures associated with LGS or 
Dravet, 2+ years 
Carbamazepine Inhibition of voltage-gated 
sodium channels 
Focal onset seizures with complex 
symptomatology, generalized onset 
tonic-clonic seizures, mixed seizure 
patterns. Not to be used for absence 
seizures. 
Clobazam GABAA receptor agonist Adjunctive treatment of seizures 
associated with LGS, 2+ years 
Clonazepam GABAA receptor agonist Absence seizures in those who failed 
succinimides, seizures associated 
with LGS, akinetic and myoclonic 
seizures 
Eslicarbazepine Inhibition of voltage-gated 
sodium channels  
Focal onset seizures, 4+ years 
GPR55: G protein-coupled receptor; VDAC1: adenosine reuptake channel; LGS: Lennox-
Gastaut Syndrome; GABA: -aminobutyric acid. 
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Table 1.2.1-2 Drugs for the Management of Epilepsy (Part 2)  
Antiseizure 
Drug 
Antiseizure Mechanism(s) of 
Action 
FDA-Approved Indications 
Ethosuximide Inhibition of T-type calcium 
channels 
Absence seizures 
Felbamate NMDA receptor antagonist, 
inhibition of L-type calcium- and 
sodium-channels 
Adjunctive treatment of focal- and 
generalized-onset seizures 
associated with LGS in children 2-14 
years old; focal onset seizures with 
or without bilateral tonic-clonic. Not 
indicated for first-line. 
Gabapentin Inhibition of L-type calcium 
channels  
Adjunctive treatment of focal onset 
seizures with or without bilateral 
tonic-clonic, 3+ years 
Lacosamide Enhance slow inactivation of 
sodium channels 
Focal onset seizures, 4+ years 
Lamotrigine Inhibition of voltage-gated sodium 
channels 
Adjunctive treatment of focal onset, 
primarily GTC, and generalized 
seizures of LGS in children 2+ years; 
focal onset seizures and seizures 
associated with LGS in adults 
Levetiracetam Inhibition of synaptic vesicle 
protein 2A  
Adjunctive treatment of focal onset 
seizures, 1+ month; adjunctive 
treatment of myoclonic seizures 
associated with juvenile myoclonic 
epilepsy, 12+ years; adjunctive 
treatment of primary GTC seizures, 
6+ years 
NMDA: N-methyl-D-aspartate; LGS: Lennox-Gastaut Syndrome; GTC: generalized tonic-
clonic 
 
Figure 1.2.1-3 Mechanisms of Action of FDA-Approved Antiseizure 
Drugs. Reproduced with permission from C. Landmark 2008 
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The selection of drug therapy will depend on patient-specific variables (e.g. 
gender, age, co-morbidities, co-medications, insurance coverage and/or financial 
situation) as well as ASD-specific variables (e.g. seizure type and/or epilepsy 
syndrome specific effectiveness, teratogenicity, pharmacokinetics, interaction 
potential, formulations, adverse effects) (Glauser et al. 2006). Non-
pharmacological therapies for specific subpopulations of patients with epilepsy 
include a ketogenic diet (van der Louw et al. 2016; Nei et al. 2014), resective 
surgery (Kwon et al. 2016; West et al. 2015), and neurostimulation (i.e. vagal 
nerve stimulation, responsive neurostimulation) (Orosz et al. 2014; Hamilton et 
al. 2018; H. Chen et al. 2017; Skarpaas, Jarosiewicz, and Morrell 2019). 
Table 1.2.1-3 Drugs for the Management of Epilepsy (Part 3) 
Antiseizure 
Drug 
Antiseizure Mechanism(s) of Action FDA-Approved Indications 
Oxcarbazepine Inhibition of voltage-gated sodium- 
and N-type calcium channels  
Focal onset seizures, 4+ years; 
adjunctive treatment of focal onset 
seizures, 2+ years 
Perampanel AMPA receptor antagonist Focal onset seizures with or 
without bilateral tonic-clonic, 4+ 
years; adjunctive treatment of 
primary GTC seizures, 12+ years 
Phenobarbital GABAA receptor agonist  
Phenytoin Inhibition of voltage-gated sodium 
channels  
GTC and psychomotor seizures 
Pregabalin Inhibition of L-type calcium 
channels 
Adjunctive treatment of focal onset 
seizures, 1+ month 
Primidone GABAA receptor agonist GTC, psychomotor, and focal 
seizures 
GTC: generalized tonic-clonic; AMPA: -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; 
GABA: -aminobutyric acid  
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1.2.2 Seizure Emergencies: Status Epilepticus (SE) 
1.2.2.1 Definition of Status Epilepticus: Differentiating from Acute Repetitive 
Seizures and Seizure Clusters 
The ILAE recently commissioned an updated definition of status epilepticus (SE) 
that includes two operational dimensions indicating when treatment should be 
initiated and when long-term consequences may appear (Trinka et al. 2015). 
Status epilepticus is defined as “a condition resulting from either failure of 
Table 1.2.1-4 Drugs for the Management of Epilepsy (Part 4) 
Antiseizure 
Drug 
Antiseizure Mechanism(s) of 
Action 
FDA-Approved Indications 
Rufinamide Prolongs inactive state of voltage-
gated sodium channels 
Adjunctive treatment of seizures 
associated with LGS, 1+ year 
Tiagabine Inhibition of GAT-1 Adjunctive treatment of focal onset 
seizures, 12+ years 
Topiramate GABAA receptor agonist, 
AMPA/kainate receptor 
antagonist, inhibition of L-type 
calcium channels, inhibition of 
carbonic anhydrase (isozymes II 
and IV) 
Focal onset or primary GTC 
seizures, 2+ years; adjunctive 
treatment for seizures associated 
with LGS, 2+ years 
Vigabatrin Irreversible inhibition of ABAT Adjunctive treatment of refractory 
focal onset impaired awareness 
seizures, 10+ years; infantile 
spasms, 1 month-2 years 
Valproic Acid Inhibition of voltage-gated sodium 
channels and metabolism of 
GABA (via ABAT, ALDH5A1, and 
OGDH) 
Focal onset impaired awareness 
seizures, absence seizures, and 
adjunctive treatment for patients with 
multiple seizure types that include 
absence, 10+ years 
Zonisamide Inhibition of T-type calcium 
channels, inhibition of carbonic 
anhydrase 
Adjunctive treatment of focal onset 
seizures in adults 
GTC: generalized tonic-clonic; GABA: -aminobutyric acid; AMPA: -amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid; LGS: Lennox-Gastaut Syndrome; GAT-1: GABA transporter 
1; ABAT: GABA transaminase; ALDH5A1: succinate semialdehyde dehydrogenase; OGDH: 
alpha-ketoglutarate dehydrogenase 
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mechanisms responsible for seizure termination or from the initiation of 
mechanisms, which lead to abnormally prolonged seizures (after time point t1). It 
is a condition, which can have long-term consequences (after time point t2), 
including neuronal death, neuronal injury, and alternation of neuronal networks, 
depending on the type and duration of seizures.” It is considered a life-
threatening condition due to its risk for systemic complications and permanent 
brain injury. Tonic-clonic SE is defined as 5 minutes of tonic-clonic seizure 
activity, with a high risk for irreversible brain damage after 30 minutes of 
continued seizure activity. Both time points were determined from animal 
experiments and clinical research of convulsive SE, however, there is a lack of 
data for the other forms of SE. Focal SE with impaired consciousness is defined 
as 10 minutes of seizure activity, with a high risk for long-term consequences 
after at least 60 minutes. Finally, research is still ongoing and active to determine 
the time frame for prolonged absence seizure activity, and the time point at which 
long-term consequences is likely following absence SE.  
 Status epilepticus should be differentiated from another type of seizure 
emergency, called seizure clusters. Like SE, the failure of seizure terminating 
mechanisms appears to be the common pathophysiology in seizure clusters. 
However, unlike SE, there has not been a consensus on the definition of seizure 
clusters and is not listed in the ILAE Commission on Classification and 
Terminology (Fisher et al. 2017). Often also referred to as “acute repetitive 
seizures,” “flurries,” “cyclical, serial, repetitive, crescendo, and recurrent 
seizures,” seizure clusters is generally defined as an acute series of seizures that 
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have short interictal periods with recovery of consciousness, have a recognizable 
onset, and whose pattern is different from the patient’s usual seizure pattern 
(Dreifuss et al. 1998). Many clinical definitions are based on a seizure rate, for 
example, three or more seizures within 24 hours (Haut 2015). If left untreated, 
seizure clusters can progress into SE, increase emergency room visits, and is 
implicated as a risk for postictal psychosis (Haut 2015; Buelow et al. 2016; 
Jafarpour et al. 2019).  
 
1.2.2.2 Prevalence and Etiology 
In the United States alone, SE diagnosis accounted for 0.07% of over one billion 
hospitalizations recorded in the National Hospital Discharge Survey (NHDS) 
between 1979-2010 (Dham, Hunter, and Rincon 2014). Within this sample, the 
incidence increased from 3.5 to 12.5 per 100,000 person-years without a 
significant change in in-hospital mortality over the study period (9.2%). The 
incidence of SE has a bimodal distribution, with highest incidences in the first 
decade of life and after the fifth decade of life. The increase in estimated 
incidence has been attributed to more transparent and intuitive diagnostic 
criteria, increase in longer-living elderly population, and wider availability of EEG 
use in emergency departments (Betjemann et al. 2015; Leitinger et al. 2019). 
Similarly, a meta-analysis consisting of 47 international studies comprising of 
80,307 SE cases also reported a crude annual incidence rate of 12.6 per 
100,000 person-years (Lv et al. 2017). From these studies, stroke, nonadherence 
to antiseizure drug regimen, central nervous system infection, and trauma were 
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among the most significant causes of SE (Dham, Hunter, and Rincon 2014; 
Leitinger et al. 2019; Lv et al. 2017).  
 
1.2.2.3 Status Epilepticus Subtypes and Clinical Diagnosis 
Status epilepticus is classified by four axes: semiology, etiology, EEG correlates, 
and age (Trinka et al. 2015).  
Axis 1: The semiology is the backbone of SE classification and refers to its 
clinical presentation, namely whether there are motor symptoms (i.e. convulsive 
versus nonconvulsive) and the degree of consciousness.  
Axis 2: The etiology of SE is classified into whether the underlying cause is 
known. SE may result from known causes such as stroke, intoxication, trauma, 
brain tumor, or inappropriate ASD treatment.  
Axis 3: Although there are no EEG criteria for SE and none of the ictal patterns is 
specific to a particular type of SE, EEG is still essential for the diagnosis of 
nonconvulsive SE. Specifically, the ILAE proposed the following terminology to 
describe EEG patterns in SE: 1) location (generalized, lateralized, bilateral 
independent, multifocal); 2) name of the pattern (periodic discharges, rhythmic 
delta activity or spike-and-wave/sharp-and-wave and subtypes); 3) morphology 
(sharpness, number of phases, polarity, absolute and relative amplitude); 4) time-
related features (prevalence, frequency, duration, daily pattern, onset, dynamics; 
5) modulation (stimulus-induced or spontaneous); and 6) effect of intervention on 
EEG.  
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Axis 4: Some forms of SE are seen more often in specific age groups (Table 
1.2.2-1), some as a fundamental part of the electroclinical syndrome, while 
others occur when specific triggers are present.  
 In addition to basing SE subtypes on clinical presentation of the condition, 
SE can also be characterized by its responsiveness to drug therapy. Once 
seizure activity is considered prolonged, the patient is considered to have “early 
SE.” If the seizures still persist after an adequate dose of a benzodiazepine (first-
line drug therapy), the patient would have “established SE.” Similarly, patients 
failing second-line drug therapies have “refractory SE.” Finally, if patients are 
Table 1.2.2-1 Status Epilepticus in Certain Electroclinical 
Syndromes. Reproduced with permission from Trinka et al 
2015. 
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unable to be weaned off of their anesthetizing third-line agent and/or have 
breakthrough seizures while on third-line agent(s), they have “super-refractory 
SE.”  
 
1.2.2.4 Pathophysiology of Status Epilepticus and Mechanisms of Drug 
Resistance 
It has become increasingly recognized by the scientific community that SE 
results from the failure of a seizure to hypothetically cross the transition from an 
ictal to post-ictal state (Figure 1.2.2-1) (Walker 2018). Walker proposed that 
seizure termination is dependent on the presence of ictal and post-ictal states, 
and that the critical transition must occur in order to reach the post-ictal state. By 
encouraging this transition, ASDs can facilitate moving the brain state towards 
the post-ictal state. In addition, increased seizure duration has been shown to 
 
Figure 1.2.2-1 Ictal, Transition, and Post-Ictal States. Ictal, Transition, and Post-Ictal States.  
D) Example of a seizure that successfully transitions into the post-ictal state; E) example of a 
seizure that is able to reach but not cross the transition into the post-ictal state; F) example of 
a seizure that remains in the ictal state due to the mechanisms of seizure promotion or where 
there is no post-ictal state due to SE etiology or neuronal network damage. Reproduced with 
permission from Walker M 2018. 
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increase the chance of self-sustained seizure activity in animal models of SE and 
patients with SE (Mazarati, Wasterlain, et al. 1998; Shinnar et al. 2008; 
Delorenzo et al. 1999).  
The self-sustaining nature of SE is reminiscent of long-term potentiation 
(LTP), the phenomenon behind memory and learning. LTP is a process 
characterized by the strengthening of synaptic connections between neurons 
following frequent stimulation (Purves et al. 2001). Following a strong 
depolarization of the postsynaptic neuron and with continued stimulation, there is 
increased surface expression of postsynaptic -amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) receptors allowing for a stronger connection 
between the two neurons. In fact, the perforant path stimulation model of SE is 
followed by increased LTP in the perforant pathway (Mazarati, Wasterlain, et al. 
1998; Reddy and Kuruba 2013).  
Pathophysiological changes on the cellular and molecular level promote 
continued seizure activity and pharmacoresistance. Following prolonged seizure 
activity, N-methyl-D-aspartate (NMDA) receptors increase in surface expression 
(Naylor et al. 2013), presynaptic adenosine A1 receptor, neuronal potassium-
chloride cotransporter (KCC2) and GABAB receptor activities become 
downregulated (Avsar and Empson 2004; Hamil, Cock, and Walker 2012; 
Silayeva et al. 2015; Kaila et al. 2014; Chandler et al. 2003; Leung 2019), and 
AMPA receptors lose their GluA2 subunit (Rajasekaran, Todorovic, and Kapur 
2012; Malkin et al. 2016). These AMPA receptors then become permeable to 
calcium, amplifying the accumulation of intracellular calcium and increasing the 
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risk for neuronal death (Cull-Candy, Kelly, and Farrant 2006). Taken together, 
these observations support the concept that continued seizure activity can 
strengthen seizure-promoting and/or deplete seizure-terminating mechanisms 
(Table 1.2.2-2). 
 When seizures become self-sustaining, resistance to drugs, particularly 
benzodiazepines, develops progressively over time (Kapur and Macdonald 
1997). Synaptic -aminobutyric acid (GABA)A receptors (those containing a -
subunit) internalize after one hour of lithium/pilocarpine-induced SE in vivo 
(Naylor, Liu, and Wasterlain 2005). This phenomenon explains why 
benzodiazepines are highly effective within the first five minutes of seizure 
activity, but not effective after 45 minutes (Kapur and Macdonald 1997). This 
process is initiated by the activation of NMDA receptors and consequently the 
calcium-dependent internalization of synaptic GABAA receptors (Rice and 
Delorenzo 1999; Niquet et al. 2016). As shown in vivo, the decrease in inhibitory 
post-synaptic potentials from the loss of synaptic GABAA receptors causes a loss 
Table 1.2.2-2 Factors that Promote/Diminish Self-Sustaining Seizure Activity. Reproduced 
with permission from Niquet et al 2016. 
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in inhibitory tone of hippocampal circuits and promotes a pro-seizure state 
(Naylor, Liu, and Wasterlain 2005). 
 
1.2.2.5 Management and Prognosis of Convulsive Status Epilepticus 
While the optimal therapy for convulsive SE is still uncertain (i.e. there is no 
intervention that is successful in 100% of cases), there are established guidelines 
for its management. In 2016, the American Epilepsy Society and Epilepsy 
Foundation published a treatment algorithm consisting of the best current 
medical management of convulsive SE based off of clinical trial evidence 
(Glauser et al. 2016). In total, 38 relevant published randomized, controlled trials 
and four meta-analyses were identified, and pharmaceutical companies provided 
information on three randomized, controlled trials. The following is a summary of 
the consensus guidelines (Figure 1.2.2-2), whereas safety and effectiveness of 
specific therapies are discussed in the next section. 
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Figure 1.2.2-2 Algorithm for Management of Convulsive Status Epilepticus. Reproduced with permission from Glauser et al 2016. 
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1.2.2.5.1 Early SE 
Within the first five minutes of a convulsive seizure, patients should be stabilized 
(airway, breathing, circulation), blood glucose should be evaluated, intravenous 
(IV) access should be attempted for collection of serum electrolytes, complete 
blood count, toxicology screen, ASD level (if applicable), and administration of 
drugs. The goal of these early assessments is to rectify any reversible causes for 
seizure activity (e.g. hypoglycemia, drug withdrawal, electrolyte disturbance).  
After five minutes of convulsive seizure activity, a benzodiazepine should 
be given either intravenously (lorazepam 0.1 mg/kg/dose or diazepam 0.15-0.2 
mg/kg/dose, may repeat once) or intramuscularly (IM; midazolam 10 mg if >40 
kg, given once). The goal of drug therapy is rapid termination of seizures and 
prevention of recurrent seizure activity. Benzodiazepines (BZDs) have 
demonstrated their safety, efficacy, and tolerability as the first-line therapy for SE 
with a high level of evidence from four RCTs (Treiman et al. 1998; Alldredge et 
al. 2001; Silbergleit et al. 2012; Chamberlain et al. 2014). Looking across these 
studies, 43-74% of cases successfully terminated within 20 minutes of 
benzodiazepine administration, 11-39% of these cases had seizure recurrence 
within the study period, 29-57% of all cases required intensive care unit 
admissions, and up to 27% of all cases resulted in death.  
Most of the clinical trials were conducted using the IV route of 
administration, requiring a trained technician to establish IV access. Ideally, SE 
treatment would be administered immediately following the start of seizure 
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activity and likely in the pre-hospital setting by a parent or caregiver. The Rapid 
Anticonvulsant Medication Prior to Arrival Trial (RAMPART) demonstrated that 
rapid administration of treatment impacts outcome (Silbergleit et al. 2012). 
RAMPART compared the efficacy of intramuscular midazolam (IM MDZ) to 
intravenous lorazepam (IV LZP) in stopping SE prior to emergency department 
arrival without requiring rescue therapy, and showed that although the time until 
seizure termination was similar in both treatment groups, the time saved by using 
the IM route significantly affected its efficacy positively.  
A disadvantage of BZD use is that common side effects include impaired 
cognition, psychomotor slowing and sleepiness that can last into the next day, 
decreasing the patient’s ability to return to school or work (Roehrs et al. 1986; 
Kay et al. 2016; Griffin et al. 2013). Furthermore, BZDs like diazepam and 
midazolam are metabolized by the cytochrome P450 isozyme 3A4 (CYP3A4), 
and are vulnerable to drug-drug interactions with common ASDs like phenytoin, 
phenobarbital, carbamazepine (Griffin et al. 2013; Indiana University Department 
of Medicine Clinical Pharmacology 2019). In addition, as seizure duration 
increases, synaptic GABAA receptors become increasingly internalized, and 
BZDs lose their efficacy (Wasterlain and Chen 2008). Therefore, although 
effective in most cases, the first-line management of SE could be improved. The 
development of an alternative therapy that can be administered either 
intravenously or intramuscularly has the potential to improve outcomes in 
patients with SE. 
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1.2.2.5.2 Established SE (ESE) 
Second-line therapies include IV fosphenytoin (20 mg phenytoin-equivalent /kg, 
single dose), valproic acid (40 mg/kg, single dose), or levetiracetam (60 mg/kg, 
single dose). The goal of drug therapy is rapid termination of seizures and 
prevention of recurrent seizures. There is a moderate level of evidence 
demonstrating lack of significant difference in efficacy between these three 
therapies (Malamiri et al. 2012; Agarwal et al. 2007; W. B. Chen et al. 2011; U. 
Misra, Kalita, and Maurya 2012; Lyttle et al. 2019; Dalziel et al. 2019; Gujjar et al. 
2017; Mundlamuri et al. 2015; Nene et al. 2019). Across these studies, 50-88% 
of cases successfully terminated without seizure recurrence within at least six 
hours following study drug administration, 20-73% of these cases had seizure 
recurrence within 24 hours, 23-64% of all cases required intensive care unit 
admissions, and up to 43% of cases resulted in death. There is large variability in 
response depending primary outcomes of interest, and possibly in the open-label 
nature of the studies.  
The use of these second-line therapies do not come without risks. 
Systemic complications such as systemic hypotension, Stevens-Johnson 
Syndrome, hyperammonemia, and hematologic abnormalities (e.g. 
thrombocytopenia, pancytopenia, agranulocytosis) have been reported in clinical 
trials and post-marketing settings for these ASDs (KEPPRA® [package insert] 
2017; Depacon [package insert] 2019; CEREBYX® [package insert] 2019). 
These observations emphasize the need for more effective therapies to prevent 
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the large proportion of intensive care unit admissions following failure of second-
line therapies.  
1.2.2.5.3 Refractory SE (RSE) 
There is currently insufficient evidence to guide therapy due to the rarity of the 
condition and difficulty in the interpretation of findings due to the complex 
interaction of drugs used in parallel and co-morbidities at this later stage of SE. 
Third-line therapies provided in the guidelines include repeating second-line 
therapy or anesthetic medications including IV midazolam, thiopental, 
pentobarbital, or propofol. Due to the ethical challenges in randomization of 
interventions in intensive care settings, there is a lack of prospective, 
randomized, blinded and controlled studies in refractory SE. Instead, numerous 
small, prospective, open-label studies that compare the safety and effectiveness 
of ketamine, continuous infusion of midazolam or diazepam, propofol, and 
barbiturates are available (Rosati et al. 2012; Rossetti et al. 2011; Morrison et al. 
2006; Mehta, Singhi, and Singhi 2007; Koul et al. 2002; Ulvi et al. 2002). Without 
the rigorous controlled trials, registries and audits could also provide useful 
information on general consensus of the management of refractory SE with some 
limitations. Early results of a multinational, prospective audit of 488 patients with 
refractory and super-refractory SE reported that the most widely used anesthetic 
as first-choice is midazolam, followed by propofol and barbiturates (Ferlisi et al. 
2015). From this survey, 74% of cases recovered from RSE, 22% died, and 4% 
had treatment withdrawn due to futility. Although anesthetic agents are useful in 
suppressing seizures, they are associated with a higher risk of systemic 
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complications death independent of underlying medical conditions (Sutter et al. 
2014). There is an unmet need for better control of refractory SE, ideally before 
the need for burst-suppression.  
1.2.2.5.4 Super-refractory SE (SRSE) 
There remains no standard of care for the treatment of SRSE for reasons similar 
to refractory SE. Interventions that have been evaluated at this stage of SE 
include perampanel (Beretta et al. 2018; Rohracher et al. 2015; Brigo et al. 
2018), allopregnanolone (Broomall et al. 2014; Rosenthal et al. 2017), ketamine 
(Höfler et al. 2016), stiripentol (A. Strzelczyk et al. 2015; Uchida et al. 2018), 
rufinamide (Thompson and Cock 2016), cannabidiol oil (Rosemergy, Adler, and 
Psirides 2016), inhaled anesthetics, barbiturates, electroconvulsive therapy 
(Pinchotti, Abbott, and Quinn 2018; Chan et al. 2018), thalamic deep brain 
stimulation (Lehtimäki et al. 2017), and ketogenic diet (Farias-Moeller et al. 2017; 
Appavu et al. 2016; Thakur et al. 2014).  
 
1.3 Using Canine Status Epilepticus as a Model of Human Status Epilepticus 
1.3.1 Canine Epilepsy 
1.3.1.1 Prevalence and Etiology 
Canine epilepsy is practically defined as having at least two unprovoked epileptic 
seizures greater than 24 hours apart (Mette Berendt et al. 2015). In veterinary 
practice, dogs with epilepsy are among the most common neurological diagnosis. 
The true prevalence of epilepsy in dogs is unknown but has been estimated to 
range between 0.55-5.7% in the general dog population (Loscher et al. 1985; 
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Heske et al. 2014; Kearsley-Fleet et al. 2013; Michael Podell, Fenner, and 
Powers 1995). The etiology of canine epilepsy as varied as that of human 
epilepsy. Following the classification and terminology system published by the 
ILAE for human epilepsy, the International Veterinary Epilepsy Task Force 
(IVETF) has adopted proposals for the canine epilepsy classification and 
terminology system that reflect the evolving understanding of the human disease. 
Epilepsy classified by etiology are divided into two categories: idiopathic (purely 
genetic, a combination of genetic and epigenetic influences, or unknown cause 
and no indication of structural epilepsy), and structural (identified cerebral 
pathology) (Mette Berendt et al. 2015). In contrast, human epilepsy etiology is 
broken into six categories (i.e. structural, genetic, infectious, metabolic, immune, 
and unknown) and more than one category can be used to describe a patient’s 
epilepsy (Scheffer et al. 2017). Some breeds with suggested inherited idiopathic 
epilepsies include Beagles, Boxers, Border Collies, German Shepherds, 
Labrador Retrievers, and Vizlas (Monteiro et al. 2012; Ekenstedt, Patterson, and 
Mickelson 2012; Bielfelt, Redman, and McClellan 1971; Nielen, Janss, and Knol 
2001; Jaggy et al. 1998; Patterson et al. 2003).  
 
1.3.1.2 Seizure Semiology and Clinical Diagnosis 
Epileptic seizures are classified as either focal (clinical signs indicating activity 
starts in a localized area in the brain), generalized (clinical signs indicating 
activity starts in both cerebral hemispheres from the start), and focal epileptic 
seizure evolving to become generalized (clinical signs indicating activity starts in 
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a localized area in the brain and spreads to involve both cerebral hemispheres) 
(Mette Berendt et al. 2015). Focal epileptic seizures can present as motor (e.g. 
facial twitches, repeated rhythmic jerks of one extremity, or rhythmic blinking), 
autonomic (e.g. dilated pupils, hypersalivation, vomiting), or behavioral (e.g. 
episodic change in behavior such as anxiousness, unexplainable fear reactions, 
or abnormal attention seeking). Generalized epileptic seizures most often present 
as tonic, clonic or tonic-clonic epileptic seizures in dogs sometimes with 
expulsion of urine or feces. Non-convulsive generalized epileptic seizures 
(atonic) in dogs, called ‘drop attacks’, are caused by the sudden loss of muscle 
tone. Finally, the most common seizure type observed in dogs is focal epileptic 
seizures evolving into generalized epileptic seizures. The focal epileptic seizure 
is brief (seconds to minutes) and is followed by a convulsive stage with bilateral 
tonic, clonic, or tonic-clonic activity. 
Diagnosis of epileptic seizures includes two steps: establish whether 
events animal are demonstrating are truly representative of epileptic seizures, 
and identifying the cause of the epilepticus seizure (De Risio et al. 2015). The 
first step is particularly difficult without observation of characteristic 
electroencephalographic (EEG) changes and physical manifestation of seizures. 
However, this is not practical in veterinary medicine and there is no standard 
protocol for acquiring EEG in dogs. Therefore, the current practice is to obtain a 
detailed and accurate history of events from pet owners, and completion of a 
standardized epilepsy questionnaire with video recording when available. The 
veterinarian must be able to distinguish epileptic seizures from other non-
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epileptic episodic paroxysmal events (e.g. syncope, narcolepsy, idiopathic head 
tremor).  
After the diagnosis of epileptic seizures, the next step is the determination 
of their cause which will have implications on the treatment and prognosis. 
Reactive seizures can result from intoxications (e.g. organophosphates, ethylene 
glycol) or from systemic metabolic disorders (e.g. electrolyte imbalance, 
hypoglycemia, hypothyroidism). Structural disorders resulting from infectious, 
inflammatory, traumatic, or neoplastic disease can result in epileptic seizures. 
Neurological examination if often abnormal and may present as asymmetric 
neurological deficits in dogs. Magnetic resonance imaging (MRI) of the brain and 
cerebrospinal fluid (CSF) analysis is recommended to rule out structural epilepsy. 
After exclusion of reactive seizures, MRI is CSF analysis is recommended in 
dogs with age of seizure onset <6 months or >6 years, status epilepticus or 
cluster seizure, interictal neurological abnormalities, or a previous presumptive 
diagnosis of idiopathic epilepsy and drug resistance with a single antiseizure 
drug titrated to the highest tolerable dose. The criteria for the diagnosis of 
idiopathic epilepsy is three-tiered: 1) a history of two or more unprovoked 
epileptic seizures occurring at least 24 hours apart, the age of seizure onset 
between 6 months and 6 years of age, unremarkable interictal physical and 
neurological examination, and no clinically significant abnormalities on blood 
tests and urinalysis; 2) unremarkable fasting and post-prandial bile acids, brain 
MRI, and CSF analysis; and 3) identification of ictal or interictal EEG 
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abnormalities characteristic for seizure disorders (criteria derived from human 
medicine). 
 
1.3.1.3 Management of Canine Epilepsy 
Antiseizure drugs (ASD) are the mainstay of therapy for idiopathic epilepsy 
(Bhatti et al. 2015; M. Podell et al. 2016; Marios Charalambous, Brodbelt, and 
Volk 2014) (Table 1.3.1-1). In contrast to the goal of ASD therapy in humans of 
seizure freedom, the goal of therapy in dogs is decrease seizure frequency, 
duration, or severity with limited/acceptable side effects to maximize the dog’s 
and owner’s quality of life. When the decision has been made to initiate ASD 
therapy, the selection of ASD is made by a veterinarian’s recommendation and 
depends on the dog (i.e. the seizure type, frequency, etiology), the drug (i.e. side 
effect profile, drug interactions, frequency of administration), and the owner (i.e. 
financial situation, lifestyle).  
Aside from ASD therapy, there are nonpharmacological interventions for 
the management of canine epilepsy. These include vagal nerve stimulation, 
medium chain triglyceride (MCT)-based diet, and acupuncture (Munana et al. 
2002; Hong Law et al. 2015; Goiz-Marquez et al. 2009; Klide, Farnbach, and 
Gallagher 1987). 
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Table 1.3.1-1 Antiseizure Drugs Used in the Management of Canine Epilepsy 
Antiseizure 
Drug 
Antiseizure Mechanism(s) of 
Action 
Place in Therapy 
Phenobarbital GABAA receptor agonist First-line; high recommendation for 
monotherapy and moderate 
recommendation for adjunctive 
therapy 
Imepitoin Partial GABAA receptor agonist First-line; high recommendation for 
monotherapy and low 
recommendation for adjunctive 
therapy 
Bromide Hyperpolarization of neuron via 
bromide influx 
Adjunctive to PB or monotherapy if 
hepatoxicity occurs with PB; 
moderate recommendation for 
monotherapy and adjunctive therapy 
Primidone GABAA receptor agonist 
(phenobarbital pro-drug) 
No advantage to using primidone 
over phenobarbital; not 
recommended for monotherapy or 
adjunctive therapy 
Felbamate NMDA receptor antagonist, 
inhibition of L-type calcium- and 
sodium-channels 
Adjunctive to PB; insufficient 
evidence to recommend its use 
Gabapentin Inhibition of L-type calcium 
channels 
Adjunctive to PB; insufficient 
evidence to recommend its use 
Pregabalin Inhibition of L-type calcium 
channels 
Adjunctive to PB; insufficient 
evidence to recommend its use 
Levetiracetam Inhibition of synaptic vesicle 
protein 2A 
Adjunctive to PB; low 
recommendation for monotherapy 
and moderate recommendation for 
adjunctive therapy 
Topiramate GABAA receptor agonist, 
AMPA/kainate receptor 
antagonist, inhibition of L-type 
calcium channels, inhibition of 
carbonic anhydrase (isozymes II 
and IV) 
Adjunctive to PB; insufficient 
evidence to recommend its use 
Zonisamide Inhibition of T-type calcium 
channels, inhibition of carbonic 
anhydrase 
Adjunctive to PB; low 
recommendation for monotherapy 
and moderate recommendation for 
adjunctive therapy 
GABA: -aminobutyric acid; NMDA: N-methyl-D-aspartate; AMPA: -amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid 
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1.3.2 Canine Status Epilepticus 
1.3.2.1 Prevalence and Etiology 
As in humans, SE in dogs is defined as continuous seizure activity lasting for at 
least five minutes or as two or more discrete seizures without complete recovery 
of consciousness in between (Blades Golubovic and Rossmeisl 2017a). 
Epidemiologic studies on SE in dogs report a prevalence ranging 2.5-59% in 
dogs admitted into a teaching hospital for seizures (Zimmermann et al. 2009; 
Saito et al. 2001; Bateman and Parent 1999) and 0.44-0.7% in the all dogs 
admitted into a teaching hospital (Zimmermann et al. 2009; Bateman and Parent 
1999). Although a rare condition in the general dog population, SE occurs more 
often in dogs without idiopathic epilepsy. A retrospective case-control study done 
in 50 dogs that exhibited generalized convulsive tonic-clonic (GCTC) SE 
compared with 50 dogs that exhibited non-SE GCTC seizures found that dogs in 
the non-SE group were more than twice as likely to have idiopathic epilepsy than 
symptomatic/reactive epileptic seizures (Platt and Haag 2002). Similarly, 
Zimmerman et al found that dogs with reactive seizures had a 1.87 relative risk of 
developing SE compared to all other dogs (Zimmermann et al. 2009). 
 
1.3.2.2 Canine Status Epilepticus Subtypes and Clinical Diagnosis 
Similar to human SE, canine SE is classified into convulsive and nonconvulsive 
SE. However, contrary to human SE, canine SE does not yet have 
subclassifications of early, established, refractory, and super-refractory SE. The 
  
35 
majority of animals that develop SE will present with a phenotype consistent with 
convulsive GCTC SE. Although it has been recognized by veterinary medicine, 
nonconvulsive SE has not been frequently documented, likely due to the 
underutilization of EEG in the diagnosis of epileptic seizures. A retrospective 
case series recently reported that 20% and 12% of 104 dogs and cats with any 
type of EEG procedure performed had electrographic seizures or electrographic 
SE, and were associated with a 48% and 50% in-hospital mortality rates, 
respectively (Granum et al. 2019). In addition, 81% of these animal patients with 
electrographic seizures had no or only subtle signs of seizure activity, 
emphasizing the need for future standardizing EEG procedures to detect 
electrographic seizure activity.  
 The diagnostic algorithm for SE for dogs consists of physical diagnostics 
(i.e. physical exam, neurological exam), point of care tests (e.g. blood glucose, 
electrolytes, electrocardiogram, complete blood count), and patient-specific 
diagnostics (e.g. evidence of toxic or metabolic encephalopathy, brain MRI, CSF 
analysis, serum ASD concentration) (Blades Golubovic and Rossmeisl 2017a). 
Pet owners should be questioned about the patient’s history of seizures or 
neurological disease, history of metabolic disease, potential exposure to toxins, 
and possibility of trauma.  
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1.3.2.3 Management and Prognosis of Canine Status Epilepticus 
The goals of treatment of canine SE is similar to that of the treatment of human 
SE and include seizure termination and prevention of further seizures while 
managing systemic complications of SE and, if possible, the underlying cause 
(Glauser et al. 2016; Blades Golubovic and Rossmeisl 2017b). The first step of 
treating SE is stabilization of the canine patient by assess airway, breathing, and 
circulation (Figure 1.3.2.3-1). An intravenous line should be established for 
pretreatment blood sampling, drug delivery, and intravenous fluids. Blood 
glucose, electrolytes, complete blood count, toxicology screen (if exposure is 
known or suspected), and ASD concentrations should be measured at this time.  
 The recommended first-line agent is a benzodiazepine (i.e. diazepam 0.5-
2 mg/kg IV/IN/PR, lorazepam 0.1-0.2 mg/kg IV, or midazolam 0.1-0.3 mg/kg 
 
Figure 1.3.2-1 Management of Status Epilepticus in Dogs and Cats 
Reproduced with permission from Blades Golubovic and Rossmeisl 2017b 
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IV/IN/IM) with or without a manual vagal maneuver. Benzodiazepines rapidly 
distribute into the central nervous system (CNS) and redistributes into fat and 
muscle quickly. Therefore, repeat dosing can cause accumulation in the CNS 
and unexpected CNS depression. For this reason, after two to three doses, a 
constant rate infusion (CRI) of another ASD should be initiated. Of note, 
diazepam and lorazepam are solubilized with the addition of propylene glycol. 
With rapid IV administration, propylene glycol can cause hypotension and 
phlebitis. Alternatively, instead of a second or third dose of a BZD bolus, a 
diazepam CRI 0.1-0.5 mg/kg/hr can be administered followed by second-line 
parenteral dosing of LEV 30-60 mg/kg IV/SC or PB 2-6 mg/kg IV (Patterson 
2014b). 
 If seizures terminate after the initial BZD dose, the canine patient will 
receive second-line parenteral dosing of a maintenance ASD (potentially more 
than once) before initiation of oral maintenance ASD (PB 2-3 mg/kg by mouth 
every 12 hours or LEV 20-30 mg/kg by mouth every 8 hours). However, if 
seizures fail to terminate within 20 minutes after several doses of BZD and 
parenteral maintenance ASD bolus, third-line parenteral treatments used for 
refractory SE (propofol 2-6 mg/kg IV bolus + 0.1-0.5 mg/kg/min IV CRI, ketamine 
3-5 mg/kg IV bolus + 0.1-0.5 mg/kg/hr CRI, or fosphenytoin 15 mg/kg [phenytoin 
equivalent] IV bolus). Finally, if seizures continue after third-line agents, 
isoflurane 1-2% minimum alveolar concentration should be used to induce 
seizure suppression. 
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 The mortality rates of canine patients with SE have been reported to range 
between 25-45%, with death occurring in 2.1-8% and mostly from euthanasia 
(Zimmermann et al. 2009; Bateman and Parent 1999; Saito et al. 2001). Dogs 
with structural epilepsy were found to have lower survival probably following SE 
than dogs with idiopathic epilepsy (HR 0.11 [95% CI 0.03;0.37]) and dogs with 
reactive seizures (HR 0.16 [95% CI 0.05;0.58]) (Zimmermann et al. 2009).  
 
1.3.2.4 Canine Status Epilepticus Clinical Trials 
In general, there is a lack of extensive published clinical trial evidence for canine 
SE. Much of the treatment recommendations are based on human clinical trial 
experience. Dosing for ASDs recommended in the treatment of canine SE largely 
stems from targeting the serum drug levels within the range considered 
therapeutic for people. To date, there are a handful of case series and controlled 
clinical trials for the treatment of early and refractory canine SE.  
Aside from one published case series on the use of rectal diazepam (PR 
DZP) for canine cluster seizures, there is one open-labeled, randomized, parallel 
group clinical trial comparing the effectiveness of an atomized intranasal 
midazolam (IN MDZ) to PR DZP for the first-line management of canine SE in 
client-owned animals (Michael Podell 1995; M. Charalambous et al. 2017). 
Success was defined as seizure termination within 5 minutes without recurrence 
of seizures within 10 minutes. IN MDZ (n=20) and PR DZP (n=15) terminated SE 
in 70- and 20-% of cases, respectively, and all dogs showed sedation and ataxia. 
Median time to seizure cessation was 47 seconds (range, 6-280) in the IN MDZ 
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group, whereas it was 214 seconds (range, 204-290) in the PR DZP group. 
Twenty-one percent of successful IN MDZ cases did not have a relapse of 
seizures, while all of the successful PR DZP cases relapsed (median time to 
relapse was 904 and 645 seconds in the IN MDZ and PR DZP groups, 
respectively). IN MDZ was more effective in terminating SE, with a higher rate of 
seizure termination, faster onset of action, and lower rate of seizure relapse. 
For refractory canine SE, one case series and two single case reports 
described success using rectal LEV, IV ketamine, and controlled hypothermia, 
respectively (Cagnotti et al. 2018; Serrano, Hughes, and Chandler 2006; Hayes 
2009). Two randomized, double-masked, placebo-controlled trials evaluated the 
clinical efficacy of IV LEV and IV fosphenytoin (FOS) in addition to IV DZP for the 
treatment of canine SE or acute repetitive seizures (Hardy et al. 2012; Patterson 
et al. 2015). In the IV LEV study, a responder was defined as a dog that had no 
additional seizures after study drug administration for the following 24 hours. Of 
the 19 cases (n=9 IV LEV, n=10 placebo), 56% in the IV LEV group responded to 
treatment compared to 10% in the placebo group (p=0.06). There was no 
difference in the mortality rates in either group (p=0.6), and no dogs required 
pentobarbital or propofol treatment. IV LEV was safe and potentially effective for 
the treatment of SE in addition to IV DZP. In contrast, a responder in the IV FOS 
study was defined as a dog that no additional seizures after drug administration 
for the following 2- and 12-hours. Of the 32 dogs (n=22 IV FOS, n=9 IV placebo), 
64% of IV FOS cases were responders compared to 22.2% of placebo cases 
(p=0.043). There was also a significant difference in the 2-hour responder rate, 
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with 95.4% responders in IV FOS group vs 55.5% in the placebo group (p=0.02). 
There were no significant differences in any adverse effects or in-hospital 
mortality rates between the two groups (p=0.63). IV FOS is safe and effective for 
the treatment of SE following IV DZP. 
 
1.3.3 Translatability of Therapeutic Research between Human and Canine 
Status Epilepticus 
Historically, animal models of epilepsy, typically induced chemically or by 
electrical stimulation, are used for the screening of potential antiseizure drugs. 
Although these have proven useful for the development of many first- and 
second-generation ASDs, they are not representative of human epilepsy or 
natural epileptogenesis. Rodent models of chronic epilepsy exhibit a low level of 
complexity regarding interindividual differences in cellular and molecular changes 
as well as genetic involvement (Potschka et al. 2013). Furthermore, these animal 
models are not able to predict for the approximate 30% of patients who develop 
pharmacoresistant epilepsy (Leppik 1992). Traditional animal models of epilepsy 
do not take into account the progression of epilepsy, or the development of drug 
resistance (Loscher et al. 1985). As a result, the current strategies for ASD 
development use models that are known to respond to presently marketed drugs, 
which may hamper the development of drugs with different mechanisms of 
actions that may be useful in treating pharmacoresistant seizures. There is a 
need for better animal models in the preclinical screening and assessment of 
ASD candidates (Potschka et al. 2013).  
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The ideal animal model of epilepsy has the following: development of 
spontaneously occurring recurrent seizures, a type of seizure similar in its clinical 
presentation to those occurring in human epilepsy, clinical seizures should be 
associated with epileptic-like activity in the electroencephalogram, 
pharmacokinetics of ASDs similar to those in people allowing for maintenance of 
effective drug concentrations, and effective plasma ASD concentrations similar to 
those reported for human epilepsy (Loscher 1984). As stated best by the British 
statistician George Box, “all models are wrong, some are useful.” It is likely that 
no model can meet all these criteria, but canine epilepsy may serve as a useful 
one for human epilepsy and has been compared to the human condition for 
decades (Barker 1973; Loscher et al. 1985; Patterson 2014a).  
When evaluating animal models for their usefulness, one should consider 
whether the cause of disease is mirroring clinical etiology (i.e. etiological validity), 
whether their symptoms and pathology mimic those in people (i.e. face validity), 
and whether their response to therapy is similar to those in humans (i.e. 
predictive validity) (Potschka et al. 2013). As described, dogs have naturally-
occurring epilepsy and SE with etiologies and pathology that closely mimic the 
human condition and are the only genetic animal model of epilepsy where 
interindividual variability exists that allows for the ability to select between 
animals that develop pharmacoresistant epilepsy and those that remain sensitive 
to currently marketed ASDs (Wolfgang Löscher 1997). In addition to breeds with 
suggested inherited idiopathic epilepsies, canine genetic studies have revealed 
genes found in canine progressive myoclonic epilepsies that are orthologous to 
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those causing human epilepsy syndromes (Ekenstedt, Patterson, and Mickelson 
2012). For instance, the LGI2 gene (an ortholog of the human epilepsy gene 
LGI1) in the Lagotto Romagnolo breed was found to cause recessive benign 
familial juvenile epilepsy (Jokinen et al. 2007; Seppälä et al. 2011) and the EPM2 
gene (an ortholog of human genes EPM2A or EPM2B) was discovered to cause 
Lafora disease in Miniature Wirehaired Dachshunds (Lohi et al. 2005). Similarly, 
causes for reactive seizures in dogs are comparable to those in humans, 
including but not limited to hypoglycemia, electrolyte disturbances, hyperthermia, 
and ethylene glycol poisoning (Brauer, Jambroszyk, and Tipold 2011; Levy 1994; 
Hutchinson et al. 2012; Bruchim et al. 2006; Keller and Goddard 2012). Finally, 
structural seizures in dogs, as they do in humans, occur following traumatic brain 
injury, inflammatory disease, neoplasia (Fredsø et al. 2017; Steinmetz, Tipold, 
and Löscher 2013). 
The types of seizures and clinical presentation of seizures and SE in dogs 
are comparable to those observed in people, so much so that the terms used to 
describe canine seizures are adapted from human seizure terminology. As noted 
previously, seizures in dogs are categorized into three: focal, generalized and 
focal epileptic seizure evolving to become generalized. These are analogous to 
the focal, generalized, and focal to bilateral tonic-clonic seizures. Similarly, dogs 
present most often with generalized convulsive SE, but nonconvulsive SE has 
been observed when EEG is available. The largest difference in categorization is 
that awareness may be more difficult to assess in the canine patient. As a result, 
veterinary categorization of seizure types do not include impaired awareness 
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focal onset seizures, nor cognitive focal onset seizures (Berendt et al. 2015; 
Fisher et al. 2017). Furthermore, EEG presentation of seizures have been shown 
to be similar between dogs and people (Holliday, Cunningham, and Gutnick 
1970; M. Berendt et al. 1999; Davis et al. 2011). In fact, seizure forecasting 
algorithms have been built and demonstrated 0.84 area under the classification 
curve using open access chronic ambulatory intracranial EEG from five dogs with 
naturally-occurring epilepsy and two humans undergoing prolonged intracranial 
EEG monitoring (Brinkmann et al. 2016). Finally, recent studies have reported 
blood-brain barrier (BBB) dysfunction in dogs with idiopathic epilepsy, along with 
evidence of altered neurogenesis, neuroinflammation, increased expression of P-
glycoprotein, and hippocampal atrophy (Borschensky et al. 2012; Patterson 
2013; Dirrig and Lamb 2016; Hanael et al. 2019; Pekcec et al. 2009; Kuwabara 
et al. 2010; Czerwik et al. 2018), pathology paralleling observations in epileptic 
foci of patients (Thom et al. 2005; Zhong, Ren, and Tang 2016; Marchi and 
Lerner-Natoli 2013; Feldmann et al. 2013; Blümcke et al. 2013).  
Clinical studies conducted in canine SE have also shown to be useful in 
mirroring human responder rates. For the treatment of SE, studies comparing the 
effectiveness of IN MDZ and PR DZP have been conducted mostly in children 
(Bhattacharyya, Kalra, and Gulati 2006; Holsti et al. 2010, 2007; Fisgin et al. 
2002; De Haan et al. 2010). In general, these studies considered a success as 
seizure termination within 10-15 minutes of drug administration and found that IN 
MDZ was at least as effective, if not superior, as PR DZP. In one pediatric study, 
effectiveness to stop prolonged seizure activity before emergency department 
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arrival without recurrence was compared between IN MDZ (using a Mucosal 
Atomization Device [MAD]) administered by paramedics and PR DZP historical 
controls (Holsti et al. 2007). Seizures recurred in the ED in 38% and 72% of 
patients in the IN MDZ and PR DZP groups, respectively. These results are 
similar to those seen in the IN MDZ (MAD) and PR DZP study in dogs in which 
the primary endpoint was seizure termination within 5 minutes without recurrence 
in 10 minutes in an emergency department setting (M. Charalambous et al. 
2017). Seventy percent and 20% of cases had success, respectively, with a 
recurrence rate of 79% and 100%. For studies in established SE, IV FOS 
compared to placebo had a 64% 12-hr responder rate, and was similar to the 
56%-69% success rate reported in the literature in people (Patterson et al. 2015; 
Treiman et al. 1998; Gujjar et al. 2017; Chakravarthi et al. 2015; Mundlamuri et 
al. 2015). Furthermore, Patterson et al demonstrated that this response rate was 
achieved at the same unbound plasma FOS concentration range that had been 
demonstrated to be therapeutic in humans. These results further supported the 
observation that dogs have similar responses to ASDs as humans, and the 
translation of therapeutic and mechanistic research between canine and human 
epilepsy.  
 
1.3.3.1 Advantages of Using Canine SE as a model of Human SE 
There are several advantages to using canine SE as a translational platform for 
therapeutic and mechanistic research between preclinical rodent models and 
human SE. First, they are large enough to evaluate behavioral responses and to 
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accommodate human devices (Potschka et al. 2013). Second, as noted in the 
previous sections, there are many similarities in clinical and neurophysiological 
presentation of SE in dogs and people (Patterson 2014a). The presence of 
nonconvulsive and convulsive SE, and the subdivision of nonmotor and motor 
focal seizures is astonishing, as are the similarities in epileptiform and epileptic 
activity in EEG (Davis et al. 2011). Next, their response rate to therapies 
approved to treat human SE syndromes are comparable, and as a result, many 
of the drugs used to treat canine SE are also used to treat human SE, including 
using BZDs as a first-line agent in SE treatment guidelines (Glauser et al. 2016; 
Blades Golubovic and Rossmeisl 2017b).  
 
1.3.3.2 Limitations of Using Canine SE as a model of Human SE 
One important limitation of using canine SE as a model for human SE is we 
cannot interview canine patients and are restricted to pet owner recounts of 
description and frequency SE episodes (Mette Berendt et al. 2015). Second, 
although NCSE is often diagnosed using EEG in people, scalp EEG is not routine 
nor practical in canine patients, because animals are often moving excessively, 
and only way to get a good reading is to sedate them which leaves an EEG 
artifact on its own. Furthermore, canine skulls are surrounded by a layer of 
muscle, which could also leave electrical artifacts (Potschka et al. 2013). Another 
key limitation is that some owners decline diagnostic investigation of SE due to 
financial concerns (Mette Berendt et al. 2015), which may contribute to 
inaccurate diagnosis and epidemiological findings of canine SE. A few 
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consequences of the natural occurrence of seizures and SE in canines is that the 
investigators are unable to elicit seizures and SE to screen potential therapeutic 
agents, it is much more difficult to recruit for canine clinical trials than it would be 
to screen ASDs in rodent models. In addition, it is much more costly in time and 
money and not pragmatic to select for and breed epileptic sublines of dogs to 
have enough subjects for experimental study (Loscher and Meldrum 1984).  
Finally, dogs metabolize drugs differently than people do. In general, drugs are 
metabolized at a faster rate in dogs compared to humans, and different 
pharmacokinetics would have to be considered for potential therapies (Frey and 
Löscher 1985). However, this can be overcome by targeting therapeutic drug 
concentrations rather than doses. Dogs may also have different metabolite 
profiles, which may prohibit them from using specific drugs and limit translation to 
humans (Dalgaard 2015; Martignoni, Groothuis, and de Kanter 2006; Yoshida et 
al. 2018). 
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CHAPTER 2  
 
DEVELOPMENT OF ALLOPREGNANOLONE FOR THE EARLY TREATMENT 
OF STATUS EPILEPTICUS  
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2.1 Introduction 
In this chapter, I will discuss the development of intravenous and intramuscular 
allopregnanolone for early treatment of convulsive SE. The central hypothesis is 
that ALLO would be beneficial in the early treatment of SE based on its novel 
mechanisms of action and ability to rapidly diffuse into the brain. The specific aim 
of my study was to characterize the pharmacokinetics (PK), pharmacodynamics 
(PD) and safety/tolerability following IV and IM ALLO in dogs. The objectives of 
these studies were to 1) develop PK models that describe concentration-time 
profiles following single ascending doses of IV and IM ALLO, 2) sequentially build 
a PK-PD model to describe the plasma concentration-intracranial EEG data, and 
3) assess the safety and tolerability of IV and IM ALLO. First, I will provide a brief 
review of ALLO and a rationale for the development ALLO for the treatment of 
SE, followed by a summary of the studies conducted in the following order: IV 
ALLO PK and safety, IM ALLO PK and safety, and PK-PD modeling. The last 
section describes the design of a clinical trial of IV ALLO for the treatment of 
CSE. 
 
2.2 Review of Allopregnanolone 
2.2.1 Endogenous Allopregnanolone 
Allopregnanolone is a progesterone derivative that is produced in the brain, 
adrenals, and gonads (Reddy and Rogawski 2012; Corpéchot et al. 1981). In 
men and women, the steady-state plasma ALLO concentration is less than 2 
ng/mL (Pierucci-Lagha et al. 2006; Girdler et al. 2001; Ottander et al. 2005; 
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Droogleever Fortuyn et al. 2004). However, plasma ALLO concentrations have 
been shown to increase in response to stress, menstruation, and throughout 
each trimester of pregnancy (Purdy et al. 1991; Droogleever Fortuyn et al. 2004; 
Reddy 2009; Herzog 2015; Luisi et al. 2000). It functions as an endogenous 
anxiolytic and uterine myorelaxant via GABAA modulation (Bali and Jaggi 2014; 
Putnam et al. 1991). In healthy, pregnant women, ALLO levels have been 
reported to reach as high as 150 nM in the third trimester (Luisi et al. 2000).  
 
2.2.2 Physicochemical Properties 
Allopregnanolone (molecular formula C21H34O2) has a molecular weight of 318.5 
g/mol and a topological polar surface area of 37.3 A2 (National Center for 
Biotechnology Information 2019a). With a logP of 4.9, it is insoluble in water, 
slightly soluble in methanol, soluble in 2-methyl-tetrahydrofuran, and freely 
soluble in tetrahydrofuran (National Center for Biotechnology Information 2019a; 
FDA CDER Other Review(s) 2019). The low molecular weight, small polar 
surface area and lipophilicity suggests it would easily cross biological 
membranes, namely the blood-brain barrier. These are ideal characteristics for a 
drug intending to treat seizure emergencies. Its generic name, provided by the 
United States Adopted Names Council, is brexanolone and will be used 
interchangeably with allopregnanolone throughout this chapter. 
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2.2.3 Known Mechanisms of Action 
 Allopregnanolone is a positive allosteric modulator of GABAA receptors, and 
binds on the -subunit and in the interface between - and -subunits, enabling 
potency at synaptic and extrasynaptic GABAA receptors (Hosie et al. 2006). At 
nanomolar concentrations (300 nM), ALLO potentiates GABA currents and 
requires GABA for chloride channel activation, while at micromolar (1 M) 
concentrations, it functions as a direct agonist of the channel (Majewska et al. 
1986). ALLO has also been shown to have neuroprotective effects in traumatic 
brain injury, ischemia, and neurodegenerative diseases models (He et al. 2004; 
He, Hoffman, and Stein 2004; Irwin, Solinsky, and Brinton 2014; Irwin et al. 2015; 
Djebaili, Hoffman, and Stein 2004; Moralí et al. 2011; Napoli et al. 2019; Mellon, 
Gong, and Schonemann 2008). In addition, the neurosteroid has been shown to 
increase superoxide dismutase 2 enzyme (decreases neuronal death as a result 
of reactive oxygen species production) following pilocarpine-induced SE in mice 
and increase phosphorylation and membrane insertion of extrasynaptic GABAA 
receptors via protein kinase C (Cho et al. 2018; Lejri et al. 2017; Abramian et al. 
2014; Modgil et al. 2017). 
 
2.2.4 Clinical Pharmacokinetics 
Brexanolone has low oral bioavailability of <5% (FDA CDER 2019). Its volume of 
distribution is approximately 3 L/kg and is highly plasma protein bound (>99%) 
(ZULRESSO [package insert] 2019). With an estimated total clearance of 1 
L/h/kg, its terminal half-life is approximately 9 hours(ZULRESSO [package 
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insert] 2019). Brexanolone is extensively metabolized by non-cytochrome P540 
(CYP) pathways, including aldo-keto-reduction, glucuronidation, and sulfation 
(FDA CDER 2019). The three major metabolites in humans are sulfated or 
glucuronidated conjugates of the C20-reduced form of brexanolone, and are not 
pharmacologically active (FDA CDER 2019). Less than 1% of brexanolone is 
excreted via urine or feces unchanged (FDA CDER 2019). Due to its extensive 
metabolism via multiple pathways, the sponsor claims that brexanolone is less 
susceptible to metabolic drug-drug interactions (FDA CDER 2019). In vitro 
studies suggested that brexanolone showed potential to inhibit CYP2C9. 
However, co-administration with phenytoin, a CYP2C9 substrate, did not result in 
clinically significant changes in phenytoin pharmacokinetics (ZULRESSO 
[package insert] 2019). 
In dogs, brexanolone is rapidly and extensively metabolized to produce 48 
quantifiable compounds (FDA CDER 2019). Oxidation was the exclusive 
biotransformation mechanism identified in dogs (FDA CDER 2019). Only a 
minimal amount of the parent compound was excreted in the bile, urine, and 
feces (FDA CDER 2019).  
 
2.2.5 FDA-Approved Indications and Marketed Formulations 
Brexanolone is indicated for the treatment of moderate-to-severe post-partum 
depression (ZULRESSO [package insert] 2019). It is marketed as a clear, 
colorless, and preservative-free injectable solution. One milliliter of ZULRESSO 
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contains 5 mg brexanolone, 250 mg of betadex sulfobutyl ether sodium, 0.265 
citric acid monohydrate, 2.57 mg sodium citrate dihydrate, and water.  
 
2.2.6 Present State of Knowledge of Allopregnanolone in Status Epilepticus 
Allopregnanolone has been shown to be effective in terminating seizures in 
several SE rodent models, including pilocarpine, kainate, perforant path 
stimulation, and tetramethylenedisulfotetramine (Rogawski et al. 2013; Kokate et 
al. 1996; C A Frye 1995; Cheryl A Frye and Scalise 2000; Zolkowska, Wu, and 
Rogawski 2018). Clinically, ALLO has only been studied in super-refractory SE 
(Vaitkevicius et al. 2017; Broomall et al. 2014; Rosenthal et al. 2017; Sage 
Therapeutics 2015). An open-label Phase I/II study in adult and pediatric (2 
years) patients with SRSE was conducted using a brexanolone loading dose 
(286.6 g/kg for 1 hour), followed by a four-day maintenance infusion (standard: 
86 g/kg/hr or high-dose: 156 g/kg/hr) and one-day taper period (Rosenthal et 
al. 2017). The inclusion criteria included patients who failed to respond to at least 
one first-line agent, one second-line agent, and who were unable to be weaned 
off of third-line agents (TLAs) after 24 hours or had breakthrough seizures after 
6 hours of initiation of burst-suppression from third-line therapies. The standard 
maintenance infusion rate was chosen to attain a steady-state concentration of 
150 nM (approximately 50 ng/mL), which is the physiological maximum plasma 
ALLO concentration observed in healthy pregnant women (Luisi et al. 2000; 
Broomall et al. 2014; Vaitkevicius et al. 2017). Responders were defined as 
patients who were successfully weaned from TLAs without reinitiation of other 
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TLAs during administration of brexanolone. Brexanolone administration was well-
tolerated, with response rate of 77% (n=17/22, 13 standard dose, 4 high-dose) 
and improved overall functional status measured at follow-up day 29.  
This success was followed by a failed Phase III placebo-controlled trial of 
brexanolone for SRSE in 132 adult and pediatric (2 years) patients (Sage 
Therapeutics 2015). Similar to the Phase I/II trial, brexanolone was administered 
as a 300 g/kg loading dose in the first hour, followed by a constant rate infusion 
at 90 g/kg/hr, followed by a slow taper off brexanolone in the last 24 hours. In 
contrast to the Phase I/II study, the brexanolone infusion was designed to last 
one additional day, the inclusion criteria required patients to fail a qualifying wean 
(even if they had failed at least one wean prior to screening), there was an open-
label high-dose arm (150 g/kg/hr for 119 hours) if the patient failed the primary 
endpoint, and the response was defined with more strict criteria (i.e. no 
reinitiation of TLAs within 24 hours following study drug infusion). Brexanolone 
was no different than placebo in meeting the primary endpoint (43.9% vs 42.4%, 
respectively). The investigators found that during the screening of the Phase III 
study, 52% (144/276) of patients were able to successfully wean off of their 
TLAs. It is possible given the differences in study design and inclusion criteria 
that the patients in the Phase III study were harder to treat than those included in 
the Phase I/II study. Further, the lack of control arm made it difficult to estimate 
the placebo response. In addition, nearly 40% of the study population (27 in 
placebo arm, 24 in brexanolone arm) opted into the open-label high-dose arm. It 
is possible that clinicians may have been tempted to declare an early failure in 
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order for their patient to receive “active” drug. Finally, the targeted steady-state 
concentration was based off of the highest observed concentration healthy, 
pregnant women, which may be safe but not sufficient for treating SE. 
Nonetheless, the results of this Phase III trial provides a number of 
considerations and lessons for future development, including whether the SRSE 
population is where brexanolone use could be most beneficial. 
 One reason why brexanolone would not be an ideal choice to treat SRSE 
is that its main mechanism of action is equivalent to those used by TLAs to 
induce burst/seizure suppressions, i.e. via GABAA receptor potentiation. In the 
Phase III study, SRSE was defined when patient experienced breakthrough 
seizures during the induction of burst/seizure suppression or when a patient had 
breakthrough seizures while attempting a wean from TLAs. Since an anesthetic 
agent will inevitably induce seizure suppression if the dose is high enough 
(Shorvon and Ferlisi 2012), the more common diagnosis of SRSE was likely due 
to the latter reasoning (per personal communication with Dr. M. A. Rogawski, 
August 2019). Physical dependence is a physiological phenomenon that occurs 
with CNS-acting drugs, including those that act via GABAA receptors (e.g. 
ethanol, benzodiazepines, barbiturates) (Boisse et al. 1990; Okamoto, Hinman, 
and Aaronson 1981; Rosenberg and Chiu 1985; Miranda and Pinardi 1998; 
Cicero et al. 1971). Following chronic administration and subsequent abrupt 
withdrawal of GABAA-potentiating drugs, rebound conditions of the symptoms 
treated originally with the drug (such as seizures or anxiety) occur. Therefore, 
one could hypothesize that following chronic seizure suppression with a TLA 
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following by the administration of brexanolone, patients would have a high risk of 
rebound seizures. A monotherapy or combination of therapies with at least one 
different mechanism of action (i.e. not via GABAA receptor potentiation) may 
have a higher likelihood of success for the treatment of SRSE. 
  
2.2.7 Rationale for Developing Allopregnanolone for Early Treatment of SE 
In addition to having activity at synaptic GABAA receptors, like the current first-
line therapies, ALLO has exhibited additional mechanisms of action that would be 
beneficial in terminating SE, including activity at extrasynaptic GABAA receptors 
which mediate tonic inhibition, and insertion of additional extrasynaptic GABAA 
receptors (Hosie et al. 2006; Abramian et al. 2014; Modgil et al. 2017). Similar to 
benzodiazepines, ALLO has ideal physicochemical properties (low molecular 
weight and high logP) that enable its rapid distribution into the brain (Irwin et al. 
2015). The rapid brain penetration also manifests as a fast onset of action of 
sedative (within 5 minutes following IM injection and 30 seconds following IV 
injection) and antiseizure effects (within 1 minute of intraperitoneal injection) in 
rodent models (Irwin et al. 2015; Rogawski et al. 2013). ALLO, at 2- and 3-mg/kg 
given intraperitoneal and intramuscularly, respectively, has shown preclinical 
efficacy in seizure termination following drug-induced SE in early and 
benzodiazepine-refractory stages (Rogawski et al. 2013; Zolkowska, Wu, and 
Rogawski 2018). 
The development of ALLO for treatment of SE is currently limited by its 
failure in SRSE. Evaluating the safety and effectiveness of drugs in the SRSE 
  
56 
patient population is particularly difficult and ethically complex given that these 
patients 1) are the smallest subset of patients experiencing SE, 2) are critically-ill 
and have the highest morbidity and mortality risk (and consequently, a higher 
futility risk), and 3) there are no widely-accepted standards of practice to 
compare to active drug arm or even standard practices between clinical sites. 
Therefore, developing ALLO for early termination of SE would have the 
advantage of inclusion of active, standardized comparators, larger patient 
population, and a lower risk of confounding medical complications. Moreover, 
due to the desire to quickly attain peak brain concentrations and/or the ability to 
treat SE in the pre-hospital setting with relative ease, pursuing the IV and IM 
routes of administration would be ideal. 
 
2.3 Pharmacokinetics and Safety of Intravenous Allopregnanolone for Early 
Treatment of Status Epilepticus in Dogs 
2.3.1 Introduction 
The central hypothesis is that ALLO possesses the requisite pharmacologic, 
physicochemical, and pharmacokinetic (PK) properties to serve as an early 
treatment for SE, either in combination with BZDs or as a replacement. One 
approach to testing this hypothesis is the use of dogs with naturally-occurring 
epilepsy, which is similar to human disorder in its electroencephalographic 
presentation and response to therapy (Chapter 1.3). Although IV ALLO 
pharmacokinetics has been characterized in rodents and humans (Irwin et al. 
2015; Luisi et al. 2000), there is a lack of PK data in dogs.  
  
57 
My working hypotheses are 1) ALLO exhibits linear pharmacokinetics with 
respect to dose, and 2) ALLO is safe to administer IV. The specific aim of this 
study is to characterize IV ALLO PK and safety following single ascending doses. 
The primary objectives were to develop a PK model to describe the 
concentration-time data, evaluate its safety and tolerability, and simulate dosing 
regimens that can be used to inform dosing recommendations for a clinical study 
of CSE. 
 
2.3.2 Methods 
2.3.2.1 Study Animals and Safety Monitoring 
Five dogs with (n=2) and without (n=3) a history of seizures were used. One of 
the dogs with a history of seizures had recurrent seizures despite being on 
phenobarbital (PB) maintenance regimen, while the other dog had not had 
seizures in the last 7 years and was not on an ASD. Approval to conduct the 
study was obtained through the Institutional Animal Care and Use Committee of 
the University of Minnesota. The dogs were housed at the University of 
Minnesota’s College of Veterinary Medicine. The dog on PB was previously 
implanted with a device which wirelessly transmits continuous iEEG recordings 
(Kremen et al. 2018). On study days, each dog participating in the study was 
removed from their kennel to have a central-line catheter inserted an hour prior to 
study start. On days where IV ALLO was administered, a peripheral-line catheter 
was also inserted. Drug administration took place in a procedure room away from 
the dog’s kennel.  
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2.3.2.2 Study Drug 
ALLO concentrate was provided by the Rogawski laboratory at the University of 
California, Davis. The concentrate consists of 6% allopregnanolone in 24% 
sulfobutyl ether β-cyclodextrin (Dexolve) in a 0.9% sodium chloride solution 
(normal saline). The concentrate was prepared using chemically pure, laboratory 
grade ALLO using Good Manufacturing Practices and shipped frozen to the 
University of Minnesota. Frozen ALLO was thawed and diluted with normal saline 
(1 part ALLO: 1-3 parts normal saline, as directed by the manufacturing 
laboratory) prior to IV administration for a final ALLO concentration of 1.5-3 
mg/mL.  
 Dexolve (CycloLab) is a solubilizing agent comprised of a ring of a 
hydrophilic exterior and lipophilic interior environment and is considered a 
“generic” of the cyclodextrin Captisol (Ligand). Both are cyclic 
oligosaccharrides with a sodium sulfonate salt separated from the ring structure 
by a butyl ether group (Captisol). The cyclodextrin is able to dissolve the poorly 
water-soluble compounds via noncovalent interactios within the lipophilic cavity 
(Loftsson and Brewster 1996; Varan et al. 2017). Captisol is exclusively renally 
eliminated and has been shown to be safe in humans. The technology has 
received FDA approval for its use in parenteral formulations of carbamazepine, 
amiodarone, and voriconazole. 
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2.3.2.3 Starting Dose Rationale 
Basal levels of ALLO in healthy, pregnant women have been reported to reach 
as high as 50 ng/mL (Luisi et al. 2000). Using allometric scaling of preclinical and 
clinical data reported in the literature (Tables 2.3.2-1 and 2.3.2-2), PK 
parameters for dogs were determined. These parameter estimates were used to 
simulate concentration-time profiles and determine doses and dose regimens 
predicted to attain plasma concentrations in the 50 ng/mL range for 
approximately an hour following infusion (Figure 2.3.2-1). A 1 mg/kg dose infused 
over 5 minutes was chosen based on my simulations. 
Table 2.3.2-2 PK parameter values reported in the literature 
Species Wt 
(kg) 
Dose 
(mg/kg) 
Cmax 
(ng/mL) 
AUCinf 
(hr*ng/mL) 
kel 
(hr-1) 
t1/2 
(hr) 
Vd 
(L/kg) 
Cl 
(mL/hr/kg) 
Mouse1 0.03 1.5 214.6 155.6 0.174 4 55.4 9640.1 
Rabbit1 3.6-
4.5 
3 1176 625.1 0.209 3.3 23 4799.2 
Human 
(female)2 
70 Cumulative 
0.09 mg/kg 
 47.15 0.156 4.35 12.5 1956 
1Irwin et al 2015, 2Timby et al 2006 
Table 2.3.2-1 Estimated and Calculated Three-compartment Model PK Parameter Values.  
 Volume of distribution (mL/kg) Clearance (mL/(kg*min) 
Species V V2 V3 CL CL2 CL3 
Rat 0.15 1527 1944 101.2 3275 72.94 
Dog 0.06 598.3 761.8 38.09 1233 27.47 
Rat data provided by the Rogawski Lab. Dog PK parameters calculated by allometric scaling 
using preclinical and clinical data in Table 2.3.2-1. 
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2.3.2.4 Study Design 
Three healthy dogs and one dog with a history of seizures were given single IV 
doses of ALLO ranging from 1-4 mg/kg as a 5-minute infusion via a catheterized 
peripheral vein (Table 2.3.2-3). One to two dogs were studied at each dose. Whole 
blood samples (~2 to 5 mL) were collected via a catheterized central vein at pre-
dose and at approximately 3, 5, 15, 30, and 45 minutes, 1, 2, 4, and 6 hours post-
infusion. There was a washout period of at least 1 week. 
After completion of the IV dose escalation study, two healthy dogs were 
given a standard PB dose (2 mg/kg) until steady state was reached (at least 15 
days). Once at steady state, the ALLO PK study was repeated in these dogs and 
Table 2.3.2-3 Number of Animals per IV Study Dose 
Route IV 
Dose (mg/kg)  1 2 3 4 
Number of Dogs (total) 4 4 2 2 
Number of Dogs on PB 2 2 0 0 
Number of Dogs with EEG 1 1 0 0 
 
 
Figure 2.3.2-1 Dosing Simulations for Initial IV ALLO Dose in Dogs 
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one dog with a history of seizures on chronic PB (1-2 mg/kg). PB was 
discontinued in both healthy dogs immediately after IV study completion.  
 
2.3.2.5 Allopregnanolone Assay 
Whole blood was collected in EDTA-containing purple-top vacutainer tubes, and 
centrifuged for plasma separation. The red blood cells and plasma were 
immediately frozen (−80°C) until analysis. An ultra high-performance liquid 
chromatography-mass spectrometry (UPLC-MS/MS) method developed and 
validated at the UC Davis laboratory was used to measure total plasma ALLO 
concentrations (Zolkowska, Wu, and Rogawski 2018).  
 
2.3.2.6 Pharmacokinetic Analysis 
2.3.2.6.1 Non-compartmental Analysis 
ALLO concentration–time data were analyzed using non-compartmental analysis 
(Phoenix 64, Build 8.0.0.3176, Certara L.P., Princeton, NJ, USA). Data was 
uniformly weighted. Pharmacokinetic parameters determined included first 
observed concentration (C1), terminal rate constant (k), and terminal half-life 
(t1/2). k was calculated using WinNonlin default setting, including estimating k 
using a regression with the largest adjusted R2 value with the largest number of 
concentration-time points used. Each individual concentration-time profile was 
visually checked to make sure the concentration-time data points were adequate 
and sufficient concentration-time points to characterize k. If not, user-defined 
concentration-time points were used. t1/2 was calculated as 0.693/k. The area 
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under the time–concentration curve from time 0 to infinity (AUC) was calculated 
using the linear up log down method and equation (1), where Cp is the plasma 
ALLO concentration, tlast is the time at which the last plasma sample was 
measured, Cplast is the last measured plasma ALLO concentration, and kel is the 
terminal rate constant. Clearance (CL) and volume of distribution (Vd) were 
calculated using equations (2) and (3), respectively, where the bioavailability (F) 
is assumed to be 100% for an IV dose. Dose proportionality was determined by 
comparing log-normalized AUC across all doses using a one-way ANOVA test. 
Concentration–time profiles were created using the GraphPad Prism 7 (Version 
7.0a, GraphPad Software, Inc., La Jolla, CA, USA). 
Equations: 
(1) 
(2) 
(3) 
 
2.3.2.6.2 Compartmental Analysis 
PK parameters estimates were also determined using compartmental analysis 
(Phoenix Non-Linear Mixed Effects 8.0). PK parameter values were estimated 
from individual concentration-time profiles using a first-order conditional 
estimation extended least squares method. Additive, multiplicative, and 
combined error models for residual unexplained variability were evaluated. The 
best fit model was determined using visual inspection, goodness of fit plots (e.g. 
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conditional weighted residual plots and individual observed versus predicted), 
and precision of model parameters. Arithmetic and geometric means and 
standard deviation of parameter values were calculated using Phoenix 
Descriptive Statistics function. 
A population approach was used to determine PK parameter “typical 
values.” An exponential error model for between-subject variability was used. 
Additive, multiplicative, and combined error models for residual unexplained 
variability were evaluated. The best fit model was determined as stated above, 
with the addition of evaluating objective function value (OFV, as determined by 
the log-likelihood function) and Akaike’s Information Criterion.  
 Normalized weight with fixed allometric exponents of 0.75 and 1 was 
added as a covariate on clearance and volume, respectively. Weight was 
normalized to median weight. The relationship of the covariate and PK parameter 
was modeled by the equation 𝑃𝐾 = (
𝑊𝑇
19.2
)0.75 𝑜𝑟 1 ∗  𝑡𝑣𝑃𝐾 ∗ 𝑒𝜂𝑃𝐾, where PK is the 
PK parameter, tvPK is the typical value of that parameter from the population, 
dPK is the estimated value of the covariate effect, and PK is the between-
subject variability of that parameter.  
 Pharmacokinetic parameter estimates from the population model were 
used to simulate concentration-time profiles from a “typical dog” with a weight of 
19.2 kg (median weight of dogs in my study) receiving a single 5-minute infusion 
of 1-4 mg/kg ALLO. 
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2.3.2.7 Safety and Behavioral Response Evaluations 
A modified Glasgow coma scale (mGCS) was used to quantitate degree of 
sedation pre-dose and at scheduled blood sampling times (Table 2.3.2-4). 
Cardiorespiratory activity (blood pressure, heart rate, and respiratory rate) was 
assessed at blood sampling times up to 30 minutes. In addition to sedation and 
vitals, the dogs were monitored for vomiting, diarrhea, and lethargy prior to and 
for 60 minutes after drug administration, and at each blood sampling time. 
Behavioral and iEEG activity were monitored by veterinary staff for seizure 
activity. As doses were escalated, the maximal tolerated toxicity, as determined 
by the supervising veterinarian, was 20 minutes of sedation with stable 
cardiorespiratory activity (respiratory rate greater than 6 or less than 60 bpm, 
systolic blood pressure greater than 60 mmHg, heart rate greater than 50 but 
less than 160 bpm). 
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Table 2.3.2-4 Modified Glasgow Coma Scale. Reproduced with permission from Platt et al 
2001. 
 Score 
Motor activity 
Normal gait, normal spinal reflexes 6 
Hemiparesis, tetraparesis, or decerebrate activity 5 
Recumbent, intermittent extensor rigidity 4 
Recumbent, constant extensor rigidity 3 
Recumbent, constant extensor rigidity with opisthotonus 2 
Recumbent, hypotonia of muscles, depressed or absent spinal reflexes 1 
Brain stem reflexes 
Normal pupillary light reflexes and oculocephalic reflexes 6 
Slow pupillary light reflexes and normal to reduced oculocephalic reflexes 5 
Bilateral unresponsive miosis with normal to reduced oculocephalic 
reflexes 
4 
Pinpoint pupils with reduced to absent oculocephalic reflexes 3 
Unilateral, unresponsive mydriasis with reduced to absent oculocephalic 
reflexes 
2 
Bilateral, unresponsive mydriasis with reduced to absent oculocephalic 
reflexes 
1 
Level of consciousness 
Occasional periods of alertness and responsive to environment 6 
Depression or delirium, capable of responding but response may be 
inappropriate 
5 
Semicomatose, responsive to visual stimuli 4 
Semicomatose, responsive to auditory stimuli 3 
Semicomatose, responsive only to repeated noxious stimuli 2 
Comatose, unresponsive to repeated noxious stimuli 1 
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2.3.3 Results 
The demographics of the dogs are listed in Table 2.3.3-1. 
  
Table 2.3.3-1 Animal Demographics  
ID Age 
(years) 
Gender Weight 
(kg) 
Breed Seizure 
Type 
Seizure 
Frequency 
Co-
medications 
3 9 Male, 
neutered 
16 Beagle History of 
one 
witnessed 
seizure 
None None 
6 13 Male, 
neutered 
16 Keeshound 
Mix 
Focal, with 
generalized 
seizures 
Focal 
cluster 
seizures 
every 14-
60 days. 
With 
secondarily 
generalized 
seizures 
every 1-2 
months. 
Phenobarbital 
(PB) 
7 1 Female, 
intact 
17 Coonhound 
Mix 
(healthy) None None 
8 1 Female, 
intact 
22 Coonhound 
Mix 
(healthy) None None 
9 1 Male, 
intact 
22 Coonhound 
Mix 
(healthy) None None 
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2.3.3.1 Non-compartmental PK Analysis 
The concentration-time profiles of IV are shown in Figures 2.3.3-1. 
Pharmacokinetic parameter estimates using noncompartmental analysis are 
summarized in Table 2.3.3-2. Following IV dosing, clearance ranged from 3.4-
20.1 L/hr/kg, while volume of distribution ranged from 1.9-6.0 L/kg. The terminal 
half-life ranged between 7-33 minutes.  
 
Figure 2.3.3-1 Plasma ALLO Concentration-Time Profile Following IV Administration on a log-
scale. cPB: Chronic PB 
cPB: Chronic PB 
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Table 2.3.3-2 Non-compartmental PK Parameter Estimates 
Dose 
(mg/kg) 
n z  
(hr-1) 
t1/2  
(hr) 
Cmax 
(ng/mL) 
CL  
(L/hr/kg) 
V  
(L/kg) 
AUC∞/Dose 
(ng/mL*hr/(ng/kg)) 
x 10-5 
1 2 
(1) 
7.2-
8.1 
(3.6) 
0.09-
0.10 
(0.2) 
425-
1340 
12.1-14.2 
(5.6) 
1.5-2.0 
(1.7) 
7.0-8.2 
(16.9) 
2 3 
(1) 
1.2-
4.0 
(1.8) 
0.17-
0.56 
(0.4) 
1654-
5287 
6.2-9.5 
(3.2) 
2.0-5.0 
(1.8) 
10.4-12.0 
(31.1) 
3 2 2.1-
2.3 
0.31-
0.33 
2440-
4661 
6.2-7.9 2.9-3.4 12.6-16.1 
4 2 1.4-
1.7 
0.40-
0.50 
3660-
5172 
5.9-8.2 4.0-4.6 12.2-17.9 
Estimates are presented as a range. Values in parentheses are from one dog on chronic PB. 
z: terminal phase slope; t1/2: terminal half-life; Cmax: observed peak plasma concentration; CL: 
clearance; V: volume of distribution; AUC/Dose: dose-normalized area under the 
concentration-time curve from time 0 extrapolated to infinity 
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As shown in Figures 2.3.3-2 and 2.3.3-3, dose-normalized AUC0-INF and 
observed Cmax across doses were similar.  
 
Figure 2.3.3-3 Dose-proportionality: Dose-normalized observed Cmax  
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Figure 2.3.3-2 Dose-proportionality: Dose-normalized AUC0-INF  
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2.3.3.2 Individual Compartmental PK Analysis Following IV Administration 
A two-compartment model with first-order elimination and a combined error 
model best fit all ALLO concentration data following IV administration (goodness 
of fit plots included in Figure 2.3.3-4). The model was unable to estimate PK 
parameter values with precision for one animal, 6J. This may be due to the small 
number of concentration-time data above the lower limit of quantitation available 
for that animal. However, goodness of fit plots do not show gross signs of model 
misspecification. Individual and averaged parameter estimates are summarized 
in Table 2.3.3-3.  
 
 
Figure 2.3.3-4 Goodness of fit plots for a two-compartment model. IWRES: individual 
weighted residual; TAD: time after dose; IPRED: individual predicted concentration 
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2.3.3.3 Population Compartmental PK Analysis Following IV Administration 
A population approach was also used to fit the IV concentration-time data. A two-
compartment model with first-order elimination with proportional error model best 
Table 2.3.3-3 Individual Compartmental PK Parameter Estimates 
ID CL 
(L/hr) 
Q 
(L/hr) 
V 
(L) 
V2  
(L) 
Proportional 
Error (%) 
Additive 
Error 
(ng/mL) 
3G 122.3 
(5.5%) 
19.3 
(11.6%) 
7.7 
(10.3%) 
7.5 
(14.1%) 
8.0 
(31.8%) 
1.4 
(100%) 
6J 6.3 
(294%) 
0.1 
(586%) 
0.2 
(348%) 
0.1 
(582%) 
11.1 
(45%) 
3.4 
(69.5%) 
7D 180.8 
(6.7%) 
33.8 
(14.1%) 
12.9 
(13.3%) 
15.9 
(21.8%) 
12.8 
(21.7%) 
0.002 
(---) 
8N 155.2 
(13.9%) 
29.8 
(28.6%) 
13.0 
(24.9%) 
18.9 
(29.5%) 
20.5 
(20.4%) 
0.002 
(---) 
9B 171.7 
(0.2%) 
32.6 
(1.8%) 
13.5 
(0.8%) 
11.5 
(2.5%) 
--- 0.8 
(31.6%) 
Mean 
(SD) 
127.3 
(71.2) 
23.1 
(14.1) 
9.4 
(5.7) 
10.7 
(7.4) 
10.5 
(7.5) 
1.1 
(1.4) 
Geometric 
Mean (SD) 
81.9 
(0.3) 
9.1 
(0.8) 
4.9 
(0.01) 
4.2 
(0.01) 
--- --- 
Values are shown with coefficient of variation (%). CL: clearance from central compartment; 
Q: intercompartment clearance; V: volume of distribution from central compartment; V2: 
volume of distribution from peripheral compartment. 
 
 
 
Figure 2.3.3-5 Goodness of fit plots for a population two-compartment Model. IPRED 
(red open circle): individual predicted concentration; PRED (blue open circle): 
population predicted concentration; CWRES: conditional weighted residual; TAD: time 
after dose 
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described all of the IV data (Figure 2.3.3-5). Goodness of fit plots do not show 
signs of model misspecification. PK parameter estimates and individualized PK 
parameter estimates (post-hoc) are summarized in Tables 2.3.3-4 and 2.3.3-5. 
Between-subject variability on CL was estimated to have a variance of 0.011. I 
was unable to estimate between-subject variability of volume without high eta 
shrinkage. For that reason, it was excluded from the final model. Allometric 
scaling on CL and V centered on the median weight improved the fit of the model 
(decrease in OFV of 8.0597) and were included in the final model. A proportional 
error model was used to describe the residual unexplained variability. 
Table 2.3.3-4 Population Compartmental PK Parameter Estimates 
MODEL PARAMETER ESTIMATE STD. 
ERROR 
CV% 
 
FIXED EFFECT V (L) 11.40 0.22 1.94 
 
V2 (L) 16.15 2.17 13.4 
 
CL (L/hr) 145.16 6.86 4.72 
 
Q (L/hr) 28.74 2.58 8.97 
 
Weight on CL 0.75 --- --- 
 
Weight on V 1 --- --- 
 
RANDOM 
EFFECT 
 
Estimate Std. 
Error 
RSE% Shrinkage% 
BSV
CL
 0.011 0.008 7.23 4.32 
RESIDUAL 
UNEXPLAINED 
VARIABILITY 
 
Estimate Std. 
Error 
CV% 
 
Proportional 
error (%) 
18.18 1.65 9.08 
 
PK parameter values estimated by pooling together all data. V: typical value of volume of 
distribution from central compartment; V2: typical value of volume of distribution from 
peripheral compartment; CL: typical value of clearance from central compartment; Q: typical 
value of intercompartment flow; BSV: between-subject variability; Stderr: standard error; 
CV%: coefficient of variation; RSE%: relative standard error. 
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To determine a target plasma ALLO concentration range, I evaluated data 
from a TETS-induced benzodiazepine-refractory SE mouse model (Zolkowska, 
Wu, and Rogawski 2018). In this model, ALLO given intramuscularly successfully 
terminated SE in 92% of animals. The range of maximum plasma ALLO 
concentrations was between 400-900 ng/mL during the time of SE termination 
(Zolkowska, Wu, and Rogawski 2018). For those reasons, target plasma ALLO 
concentrations was determined to be 500-1000 ng/mL. Based on my simulations 
(Figure 2.3.3-6), an IV infusion of at least 2 mg/kg would be necessary in order to 
attain target plasma ALLO concentrations associated with seizure termination 
rapidly (i.e. within 2 minutes) and remain above this concentration for 
approximately 10 minutes.  
 
Table 2.3.3-5 Individualized PK Parameter Estimates from a Population Approach 
ID Weight 
(kg) 
CL V (L) V2 (L) CL (L/hr) Q (L/hr) 
3G 16 0.08 9.70 
16.15 
139.70 
28.74 
6J 16 
-0.16 
9.70 109.31 
6J 15.7 9.52 107.77 
7D 17 
0.13 
10.31 153.71 
7D 19.2 11.64 168.40 
7D 20.2 12.25 174.93 
8N 21.3 
-0.03 
12.92 154.50 
8N 20.8 12.61 151.77 
8N 21.4 12.98 155.04 
9B 24.5 -0.02 14.86 173.63 
Individualized PK parameter values from population PK analysis. Weight on CL and V were 
included in the final model and between-subject variability was estimated on CL. V2 and Q 
are population typical values. CL: between-subject variability on clearance; V: volume of 
distribution from central compartment; V2: volume of distribution from peripheral 
compartment; CL: clearance from central compartment; Q: intercompartment flow 
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2.3.3.4 Safety and Tolerability 
As shown in Table 2.3.3-6, IV ALLO 1-3 mg/kg infused over 5 minutes was 
shown to be safe and tolerable in dogs. There was a dose-dependent increase in 
ataxia and sedation. At 4 mg/kg IV, dogs were immobile and briefly unarousable 
even with pain stimulation for 1-3 minutes with stable vital signs. Ataxia occurred 
within 1.5-3 minutes following the start of infusion for a duration of 10-18.5 
minutes. In healthy dogs, the onset of sedation occurred at 3.5-5 minutes 
following the start of infusion and lasted up to 6 minutes at doses greater than 2 
mg/kg. The dog on chronic PB had greater sedation at 2 mg/kg, which was 
Table 2.3.3-6 Behavioral Response Following IV Administration 
Dose 
(mg/kg) 
n 
Cmax 
(ng/mL) 
Ataxia Sedation 
Ataxia 
Onset 
(min 
post-
injection) 
Ataxia 
Duration 
(min) 
Sedation 
Onset 
(min 
post-
injection) 
Sedation 
Duration 
(min) 
1 3 
425-
1340 
33% 0% 
3 6   
2 4 
1654-
5287 
100% 25% 
1.5-2 10-16 3.5 10 
3 2 
2440-
4661 
100% 50% 
1.5-3 13-13.5 3.5 4.5 
4 2 
3660-
5172 
100% 100% 
1.5 15.5-
18.5 
4.5-5 5-6 
Data are shown was percentage of animals within each dose. 
 
Figure 2.3.3-6 Simulation of Plasma ALLO Concentration-Time Profiles Following IV Dosing. 
Dashed line: highest peak plasma concentration (900 ng/mL) associated with seizure 
termination in TETS SE mouse model; Dot-dashed line: lowest peak plasma concentration 
(400 ng/mL) associated with seizure termination in TETS SE mouse model. 
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associated with higher plasma ALLO concentrations. There were no infusion site 
reactions observed. 
 
2.3.4 Discussion 
Intravenous ALLO is a compound with a short elimination half-life and a 
moderately large volume of distribution in dogs. Across the doses studied, IV 
ALLO exhibited linear pharmacokinetics with respect to dose. This information 
will be useful for instances where a manipulation of ALLO exposure (e.g. 
doubling the dose to double the exposure, up to 4 mg/kg) may be necessary 
during clinical trials. This is in agreement Zulresso PK, as it has been shown to 
exhibit dose-proportional increases in exposure within the dose range of 0.72-
6.48 mg/kg/day (FDA CDER 2019).   
Despite including an allometric exponent of weight on clearance and 
volume to explain some of the residual variability, there remains large 
interindividual variability that I am unable to explain given the small number of 
animals and experiments in the present study. The inability to estimate the 
between-subject variability on volume of distribution without high eta shrinkage 
may be due to the small number of observations in several animals (Xu et al. 
2012). It should also be noted that in the animals such as 6J in whom there were 
as few as three concentration-time data points available, the PK parameter 
estimates may be biased since the data points were not sampled at optimized 
time points and because the weight of each data point is much more significant 
when there are only a few. With a larger sample size and optimized sampling 
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times, I may be able to estimate the interindividual variability of 
intercompartmental clearance and volumes of distribution (central and peripheral) 
in addition to evaluating covariate effects such as sex or PB.  
While the simulations suggested a dose of at least 2 mg/kg would be 
necessary to attain target plasma concentrations, the safety data provided insight 
into plasma concentrations associated with heavy sedation (i.e. >2440 ng/mL). 
Ideally, a dose that can attain high enough plasma concentrations without 
eliciting deep sedation would be desirable. Therefore, a 2 mg/kg dose infused IV 
over 5 minutes would be an appropriate dose to test for efficacy in treating 
canine established SE given these criteria. This dose compares to 1.1 mg/kg in 
humans using the FDA conversion factor to determine a human equivalent dose 
and is predicted to attain plasma ALLO concentrations above the target 
concentration of 1000 ng/mL rapidly without causing sedation in most animals.  
 
2.3.5 Conclusions 
This study demonstrates IV ALLO exhibits dose-proportional increases in 
exposure within 1-4 mg/kg. This would be valuable information to know when 
designing a clinical trial in canine SE in order to easily calculate the appropriate 
dose to attain specific target plasma concentrations. IV ALLO is safe and 
tolerable when administered at doses between 1-3 mg/kg. The onset of ataxia 
and sedation following IV infusion is rapid and transient, both desirable for the 
termination of and recovery from SE.  
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2.4 Pharmacokinetics, Safety, and Optimization of an Intramuscular 
Allopregnanolone Formulation 
2.4.1 Introduction 
Although IV administration is the best option to rapidly attain high ALLO 
concentrations in blood and the CNS, this route is limited by the need for trained 
personnel to establish an IV line and administer the drug. This often results in a 
delay in treatment. Ideally, the drug should be administered at the onset of SE, 
which most often occurs in a pre-hospital setting. Parenteral routes offer the 
advantage of bypassing the difficulty of oral administration in a seizing patient 
and avoiding first-pass metabolism. Of these alternative routes, IM administration 
is a route that requires little technical training or the need to remove much 
clothing (as compared to a rectal administration).   
 My working hypotheses are 1) IM ALLO will have relatively high 
bioavailability, 2) IM injection of ALLO is safe in dogs, and 3) formulation 
concentration and injection volume will affect bioavailability. The specific aim of 
this study was to characterize the PK and safety of IM ALLO. The primary 
objectives of this study were to develop a PK model that best fit concentration-
time data, estimate the PK parameter values specifically bioavailability at all 
doses, assess its safety and tolerability, and simulate dosing regimens that can 
be used to inform dosing recommendations for a clinical study of CSE. The 
results of this study will be used to advise further development of an IM 
formulation and dosing recommendations for a clinical study of CSE.  
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2.4.2 Methods 
2.4.2.1 Study Animals and Safety Monitoring 
Four dogs with (n=2) and without (n=2) a history of seizures were used. One of 
the dogs with a history of seizures had recurrent seizures despite being on 
phenobarbital (PB) maintenance regimen. Approval was obtained through the 
Institutional Animal Care and Use Committee of the University of Minnesota prior 
to the initiation of the study. The dogs were housed at the University of 
Minnesota’s Veterinary College. The dog on PB was previously implanted with a 
device which wirelessly transmits continuous iEEG recordings (Kremen et al. 
2018). On study days, each dog participating in the study was removed from their 
kennel to have a central-line catheter implanted an hour prior to study start. 
implanted. Drug administration took place in a procedure room away from the 
dog’s kennel. The dogs were fasted prior to and fed no sooner than 2 hours after 
drug administration. 
 
2.4.2.2 Study Drug 
ALLO concentrate was provided by the Rogawski laboratory at the University of 
California, Davis. The concentrate was prepared using chemically pure, 
laboratory grade ALLO and shipped frozen to the University of Minnesota. Three 
formulations were used:  
• 6% ALLO in 24% sulfobutyl ether β-cyclodextrin (Dexolve) in 0.9% 
sodium chloride solution (normal saline) diluted and undiluted prior to IM 
administration for a final concentration of 3-6 mg/mL 
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• 11% ALLO in 40% Dexolve in normal saline, not diluted prior to IM 
administration 
• 14% ALLO in 40% Dexolve in normal saline, not diluted prior to IM 
administration 
 
2.4.2.3 Starting Dose Rationale 
Assuming 100% IM bioavailability, a starting dose should be one with an 
acceptable safety profile following IV administration. In healthy dogs without a 
history of seizures (regardless of two weeks of PB therapy), 2 mg/kg IV ALLO 
showed no signs of ataxia or sedation. In one dog on chronic PB therapy, 2 
mg/kg IV caused ataxia and sedation. Therefore, the starting dose for IM 
administration was 2 mg/kg. 
 
2.4.2.4 Study Design 
PK studies were 
completed following IM 
administration in two 
healthy dogs and two dogs 
with a history of seizures (one on chronic PB) in a dose escalation manner, 
however, in addition to varying the doses, I also administered different injection 
volumes to test my hypothesis that a high formulation concentration 
(consequently, a lower injection volume) would increase bioavailability. After the 
first 2 mg/kg IM study, the bioavailability was approximately 50%. In order to 
Table 2.4.2-1 Number of Animals per IM Study Dose 
Dose (mg/kg)  1 2 6 
Formulation (mg/mL) 11 3 6 14 6 
Number of Dogs (total) 1 1 1 1 2 
Number of Dogs on PB 1 0 0 0 0 
Number of Dogs with EEG 1 0 0 0 0 
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attempt to attain concentrations comparable to the 3 mg/kg IV dose, the following 
two dogs were dosed at 6 mg/kg. In total, three doses (1-,2- and 6-mg/kg) across 
four ALLO concentrations (3-, 6-, 11-, and 14-mg/mL) were evaluated. Whole 
blood samples (~2 to 5 mL) were collected via a catheterized central vein at pre-
dose and at 1-, 3-, 5-, 15-, 30-, 45-minutes, 1-, 2-, 4-, and 6-hours post-injection. 
A washout period of at least 1 week was used. 
 
2.4.2.5 Allopregnanolone Assay 
Whole blood was collected in EDTA-containing purple-top vacutainer tubes and 
centrifuged for plasma separation as described in Chapter 2.3.2.5.  
 
2.4.2.6 Pharmacokinetic Analysis 
ALLO concentration–time data were analyzed using non-compartmental analysis 
(NCA) (Phoenix 64, Build 8.0.0.3176, Certara L.P., Princeton, NJ, USA). Data 
was uniformly weighted as described in Section 2.3.2.6.1, with the addition of 
determining the maximum concentration (Cmax), time at which maximum 
concentration is achieved (tmax), and bioavailability (F). Due to the large 
interindividual variability, IM bioavailability (F%) was calculated using equation 
(4), where the individual’s IV and IM AUC0-last’s were compared. AUC0-last 
estimates were used rather than AUC0-INF due to the large percent extrapolated 
AUC in 3G (>30%). 
Equation: 
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 (4) 
 PK parameters were also determined using individual compartmental 
modeling (Phoenix Non-Linear Mixed Effects 8.0). Due to the exploratory and “n 
of 1” nature of these IM studies, a population approach was not used. First-order 
conditional estimation extended least squares method was used as described in 
Section 2.3.2.6.2.  
 Individual PK parameter estimates from one dog in whom multiple doses 
(2- and 6-mg/kg) and formulations (3- and 6-mg/mL) were studied were used to 
simulate plasma ALLO concentration-time profiles of a “typical” dog given 1-8 
mg/kg of IM ALLO using a formulation concentration of 6 mg/mL. 
 
2.4.2.7 Deconvolution Analysis 
In addition to calculating bioavailability via the standard method of dividing drug 
exposure (AUC, determined by NCA) following two routes of administration, 
bioavailability can be calculated as the cumulative fraction absorbed using 
deconvolution. Deconvolution is based on the assumptions of the linear 
superposition principle (Rowland and Tozer 2011). Deconvolution can also be 
used to determine drug input rate into systemic circulation from varying drug 
formulations (e.g. oral immediate-release vs extended-release tablets, dermal 
patches, etc.).  
Deconvolution is based on the idea that the concentration-time data of an 
extravascular dose is a convolution of the input rate and drug disposition 
(Rowland and Tozer 2011). Therefore, with knowledge of two of these 
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components, one could calculate the third component. For example, once 
concentration-time data following IV and IM administration are known, the input 
rate into the compartment where concentration measurements are drawn (i.e. the 
central compartment, plasma) and the cumulative amount absorbed can be 
calculated.  
Phoenix WinNonlin deconvolution function was performed to determine 
the input rate following IM administration using individual PK parameters 
following IV administration as the exponential terms of the unit impulse function 
(Table 2.3.3-3). Concentration-time data from the IM administration were used as 
the response function. 
 
2.4.2.8 Safety and Behavioral Response Evaluations 
A modified Glasgow Coma Scale (mGCS) was used to quantitate degree of 
sedation pre-dose and at scheduled blood sampling times as described in 
Chapter 2.3.2.7, with the addition of inspecting the injection site for swelling, 
tenderness, and redness. A muscle biopsy was performed in the dog who 
received the formulation of highest concentration to assess for evidence of 
inflammation and/or tissue damage (3G, 14 mg/mL). 
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2.4.3 Results 
The demographics of the dogs are listed in Table 2.4.3-1. 
 
 
Table 2.4.3-1 Animal Demographics  
ID Age 
(years) 
Gender Weight 
(kg) 
Breed Seizure 
Type 
Seizure 
Frequency 
Co-
medications 
3 9 Male, 
neutered 
16 Beagle History of 
one 
witnessed 
seizure 
None None 
6 13 Male, 
neutered 
16 Keeshound 
Mix 
Focal, with 
generalized 
seizures 
Focal 
cluster 
seizures 
every 14-
60 days. 
With 
secondarily 
generalized 
seizures 
every 1-2 
months. 
PB 
7 1 Female, 
intact 
17 Coonhound 
Mix 
(healthy) None None 
8 1 Female, 
intact 
22 Coonhound 
Mix 
(healthy) None None 
 
  
83 
2.4.3.1 Non-compartmental Analysis 
The concentration-time profiles following IM administration are shown in Figure 
2.4.3-1. Pharmacokinetic parameters estimated by NCA are summarized in 
Table 2.4.3-2. Apparent clearance ranged from 6.0-12.2 L/hr/kg and apparent 
volume of distribution ranged from 4.9-44.7 L/kg. Dose-normalized Cmax following 
IM administration ranged between 4.7-20.5 x 10-5 ng/mL at 3-10 minutes, with a 
terminal phase half-life between 34-152 minutes. The IM bioavailability calculated 
by the NCA method was estimated to range between 51-112%. There was a 
 
Figure 2.4.3-1 Plasma ALLO Concentration-Time Profile Following IM Administration. 
cPB: Chronic PB. Blue: 1 mg/kg dose; Red: 2 mg/kg dose; Green: 6 mg/kg dose 
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Table 2.4.3-2 Non-compartmental PK Parameter Estimates 
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e
 
(m
g
/k
g
) 
n tmax  
(min) 
Cmax  
(ng/mL
) 
z  
(hr-1) 
t1/2  
(hr) 
CL/F 
(L/hr/
kg) 
V/F 
(L/kg) 
AUC0-
>∞/Dose 
(ng/mL*
hr/(ng/kg
)) x 10-5 
F  
(%) 
3 2 1 5 94 0.50 1.4 11.4 22.9 8.78 51 
6 2 1 3 328 1.23 0.56 10.1 8.2 9.86 62 
6 6 2 3-10 323-
877 
0.27-
0.60 
1.2-
2.5 
9.5-
12.2 
15.9-
44.7 
8.19-10.5 56-65 
11 1 1* 15 205 1.25 0.56 6.0 4.8 16.6 96 
14 2 1 10 53 0.32 2.13 5.1 15.8 19.5 112 
Estimates are presented as a range. (*) denotes dog on chronic PB. tmax: time at maximum 
concentration; Cmax: maximum observed plasma concentration; z: terminal phase slope; t1/2: 
elimination half-life; CL: clearance; Vd: volume of distribution; AUC: area under the 
concentration-time curve from time 0 extrapolated to infinity; F: bioavailability 
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formulation concentration-related increase in bioavailability with the 14 mg/mL 
formulation resulting in greater than 100% bioavailability (Figure 2.4.3-2). 
 
 
Figure 2.4.3-2 Bioavailability by Formulation Concentration 
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2.4.3.2 Individual Compartmental PK Analysis Following IM Administration 
A two-compartment model with first-order elimination with a proportional error 
model best fit the ALLO concentrations following IM administration (goodness of 
fit plots included in Figure 2.4.3-3). Individual parameter estimates are 
Table 2.4.3-3 Individual Compartmental PK Parameter Estimates 
ID Dose 
(mg/kg) 
Form. 
(mg/mL) 
ka 
(1/hr) 
CL/F 
(L/hr) 
Q/F 
(L/hr) 
V/F 
(L) 
V2/F 
(L) 
Proportional 
Error (%) 
8N 2 3 0.68 
(52%) 
--- 312.0 
(2286%) 
14.8 
(67%) 
940.1 
(5061%) 
15.3 
(28%) 
8N 2 6 2.87 
(28%) 
202.9 
(---) 
161.6 
(---) 
0.8 
(---) 
137.4 
(---) 
11.6 
(22%) 
8N 6 6 2.06 
(19%) 
193.3 
(5%) 
115.0 
(32%) 
7.7 
(46%) 
164.3 
(13%) 
14.3 
(23%) 
7D 6 6 2.60 
(33%) 
234.0 
(6%) 
671.9 
(35%) 
14.0 
(48%) 
642.2 
(11%) 
12.4 
(22%) 
6J 1 11 3.88 
(146%) 
100.7 
(11%) 
44.5 
(36%) 
28.0 
(162%) 
60.0 
(53%) 
30.9 
(23%) 
3G 2 14 0.39 
(281%) 
160.1 
(32%) 
91.6 
(754%) 
10.1 
(282%) 
151.1 
(725%) 
26.8 
(23%) 
Form.: ALLO formulation; ka: absorption rate constant; CL/F: apparent clearance from central 
compartment; Q/F: apparent intercompartment clearance; V/F: apparent volume of distribution 
from central compartment; V2/F: apparent volume of distribution from peripheral compartment. 
  
  
Figure 2.4.3-3 Goodness of fit plots for a two-compartment model. IWRES: individual 
weighted residual; TAD: time after dose; IPRED: individual predicted concentration 
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summarized in Table 2.4.3-3. With the exception of the 14 mg/mL formulation, 
the rate of absorption increased with formulation concentration.  
 
2.4.3.3 IM Absorption Rate and Bioavailability by Deconvolution Analysis 
Across all experiments, the calculated IM absorption rate is highest in the initial 
10-15 minutes following injection (Figure 2.4.3-4). Excluding the 14 mg/mL 
formulation, the higher absorption rates occurred at the combination of higher 
dose and higher concentration.  
Cumulative fraction absorbed over time is illustrated in Figure 2.4.3-5. The 
absorption follows a first-order rate, except in one dog (3G) administered 2 mg/kg 
at the highest formulation concentration tested (14 mg/mL). Absorption following 
this IM injection appears to follow a zero-order absorption rate, which raises 
concern for the possibility of agglomeration, crystallization, and/or precipitation of 
drug. However, the tissue biopsy completed in this animal yielded inconclusive 
 
Figure 2.4.3-4 IM ALLO Absorption Rate Over Time 
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results (no muscle tissue in sample). In one animal (8N) in whom multiple 
formulations and doses were studied, there appeared to be a formulation 
concentration-dependent increase in the cumulative fraction absorbed, which 
supports the observation of increasing absorption rate constant with higher 
formulation concentration noted in the individual PK analysis.  
 
 
Figure 2.4.3-5 IM ALLO Fraction Absorbed Over Time 
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The bioavailability estimated by the NCA approach was compared to the 
cumulative fraction absorbed estimated by deconvolution. The results are shown 
in Figure 2.4.3-6 and Table 2.4.3-4.  
Based on our simulations of a “typical dog” using a 6 mg/mL ALLO 
formulation (Table 2.4.3-5), an IM dose of 8 mg/kg would be required to attain the 
target plasma ALLO concentration of 900 ng/mL and maintain above this 
concentration for about 5 minutes.  
 
 
Figure 2.4.3-6 Bioavailability Estimated by NCA vs Deconvolution 
Methods. A: NCA; B: deconvolution 
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Table 2.4.3-4 Bioavailability Calculated by NCA and Deconvolution Methods 
Animal 8N  8N 8N 7D 6J 3G 
Dose (mg/kg) 2 2 6 6 1 2 
Formulation 
(mg/mL) 
3 6 6 6 11 14 
Calculation Method 
NCA 0.51 0.62 0.65 0.56 0.96 1.12 
Deconvolution 0.57 0.73 0.78 0.65 1.17 0.76 
 
Table 2.4.3-5 PK Parameter Estimates Used for IM Simulations 
ka (min-1) CL/F (L/hr) Q (L/hr) V/F (L) V2/F (L) 
0.034 193.31 114.96 7.65 164.32 
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2.4.3.4 Safety and Tolerability 
The onset of ataxia without sedation occurred 3-5 minutes following the 6 mg/kg 
dose and lasted for 17-19 minutes (Table 2.4.3-5). Pain associated with injection 
volume was observed only at the 6 mg/kg IM dose, and is likely associated with 
the large injection volume (~20 mL).  
 
2.4.4 Discussion 
The development of IM ALLO for treatment of SE is limited by the slow 
absorption rate of ALLO from the IM injection site. When comparing the 
concentration-time profiles following IV and IM administration (Figures 2.3.3-1 
 
Figure 2.4.3-7 Simulation of Plasma ALLO Concentration-Time Profiles Following IM 
Administration. Dashed line: highest peak plasma concentration (900 ng/mL) associated with 
seizure termination in TETS SE mouse model; Dot-dashed line: lowest peak plasma 
concentration (400 ng/mL) associated with seizure termination in TETS SE mouse model. 
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Table 2.4.3-6 Behavioral Response Following IM Administration 
Dose 
(mg/kg) 
n 
Cmax 
(ng/mL) 
Ataxia Sedation 
Ataxia Onset (min 
post injection) 
Ataxia Duration 
(min) 
1 1 205 0% 0%   
2 3 53-328 0% 0%   
6 2 322-876 100% 0% 3-5 17-19 
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and 2.4.3-1), one can notice the loss of the biexponential decay in the IM 
concentration-time profiles. This apparent monoexponential decay in plasma 
ALLO concentration is likely due to an absorption rate constant much slower than 
the elimination rate constant or “flip-flop” kinetics. This is also seen by the 
difference in z estimated following IV (Chapter 2.3.3.1) and IM dosing (ranges: 
1.2-8.1 versus 0.27-1.23, respectively). The terminal rate constant has become 
limited by the slower absorption rate constant (i.e. the body can only eliminate 
drug as fast as it is being absorbed). The longer half-life with IM dosing may 
provide an advantage of maintaining plasma ALLO concentrations above a 
specific concentration for a longer duration. Due to the exploratory nature of 
these experiments (“n of 1”), there is large variability that I am unable to explain. 
Simulations suggest an 8 mg/kg IM dose would be necessary to achieve target 
plasma concentration window of 500-1000 ng/mL using a 6 mg/mL formulation, 
however this would result in a large injection volume (~27 mL for a 20 kg dog) 
which would limit the absorption rate and cause pain upon injection similar in 
severity to what was observed at the 6 mg/kg dose.  
By evaluating the PK across different doses and formulation strengths, I 
found that a higher formulation concentration (and most importantly, a lower 
injection volume) was associated with a faster absorption rate. It has been noted 
that injection volume does have an inverse relationship with absorption rate for 
IM injections regardless of the water solubility of the drug (Pfeffer and Van 
Harken 1981; Hirano, Ichihashi, and Yamada 1981). Other factors that may affect 
the absorption rate constant include the particle size, cohesiveness of the 
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dissolved particles, initial injection concentration, injection speed and pressure, 
and the physiological state of the injection site (Hirano, Ichihashi, and Yamada 
1981). I also found that at the highest formulation concentration of 14 mg/mL, the 
estimated absorption rate constant was not as high as I expected based on the 
formulation-absorption trend observed at previous doses. This suggests that 14 
mg/mL may be too high of an initial injection concentration and has negatively 
affected the absorption rate. It is tempting to conclude that the ideal IM 
formulation concentration must be between 11- and 14 mg/mL. However, one 
caveat to consider is that the 11- and 14-mg/mL formulations were studied in one 
dog each. It is difficult to determine whether these changes in absorption rate are 
due to formulation alone or the individual animal. A crossover study would be 
necessary to answer this question. 
The results of the deconvolution analysis were comparable to those of the 
NCA approach. The advantage of performing a deconvolution analysis is the 
ability to calculate the absorption profile of each IM injection, which may reveal 
complex absorption patterns. Although the individual PK analysis was able to 
estimate a first-order absorption rate, it is unable to capture any absorptive 
activity following the initial peak. In the present study, there was large 
interindividual and inter-formulation variability in absorption profiles. However, 
due to the small number of animals and number of IM studies per animal, it is 
difficult to attribute the large variability to drug disposition kinetics alone. A 
second peak was seen in all dogs (except for one occasion at 2 mg/kg [6 
mg/mL]) at 20-45 minutes post-injection, and in one dog, a third peak was 
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observed at 50 minutes post-injection. These secondary peaks in absorption rate 
suggest a delayed absorption, which may be explained by increased blood flow 
to the injection site (e.g. walking, playing, or receiving pets from veterinary 
technicians) and/or a depot effect. In addition, small differences in the estimated 
bioavailability may be due to the sensitivity of the deconvolution method to errors 
in the unit impulse function (based on exponential terms provided by individual 
PK parameter values following IV administration).  
 
2.4.5 Conclusions 
This study demonstrates that ALLO is safe and tolerable when administered IM 
at doses up to 2 mg/kg and at injection volumes less than 10 mL per injection 
site. Following the 6 mg/kg dose, the onset of ataxia occurred within 5 minutes of 
IM injection and lasted for almost 20 minutes, which suggests relatively quick 
brain penetration and moderate residence time. However, at the 6 mg/mL 
formulation, my simulations suggest an 8 mg/kg IM dose would be necessary to 
achieve target plasma concentration range of 500-1000 ng/mL, which would 
result in an injection volume (~27 mL in a 20 kg dog) large enough to limit the 
absorption rate and cause pain with injection. Therefore, based on absorption 
rate limitations, the development of IM ALLO would require alternative 
approaches to be feasible.  
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2.5 Pharmacodynamics of Intravenous and Intramuscular Allopregnanolone in 
Dog 
2.5.1 Introduction 
Allopregnanolone has been shown to effectively terminate seizures in several 
acute seizure and SE rodent models (Rogawski et al. 2013; Kokate et al. 1996; 
Cheryl A Frye and Scalise 2000; Zolkowska, Wu, and Rogawski 2018). It has 
also been reported to affect electroencephalograph parameters in a fashion 
similar to benzodiazepines (BZDs) in rats, causing increases in higher-frequency 
(beta) activity (Lancel et al. 1997; Slawecki, Purdy, and Ehlers 2005). Based on 
behavioral observation of our study animals alone, ALLO appears to have a fast 
onset of action, inducing ataxia as early as 90 seconds and sedation just 3.5 
minutes following the start of IV infusion. However, it remains unknown whether 
ALLO can affect electrical brain activity in a manner that could stop and/or 
prevent further seizures in dogs.  
For these studies, I hypothesized that 1) ALLO has a quick onset of effect 
on intracranial electroencephalograph (iEEG) activity in dogs, and 2) based on its 
potentiation of GABAA currents, its effect on iEEG is similar to that of 
benzodiazepines (i.e. increase in beta activity) (Mandema, Kuck, and Danhof 
1992; Mandema and Danhof 1992). Alternative hypotheses include 1) ALLO has 
a moderate or slow onset of effect on iEEG, and 2) its effect on iEEG can be 
differentiated from those due to benzodiazepine administration. The specific aim 
of this study is to develop a PK-PD model relating plasma ALLO concentrations 
to iEEG response in one dog. The primary objectives of this study were to 
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estimate the concentration that produces 50% of the maximum response (EC50) 
and the effect compartment rate constant (ke0) of IV and IM ALLO. The results of 
this study will be used to inform the target therapeutic concentration and dosing 
recommendations for a clinical study in CSE. 
 
2.5.2 Methods 
2.5.2.1 Study Design 
One dog with a history of seizures was used. Despite being on a PB antiseizure 
maintenance regimen, he occasionally had breakthrough seizures. Approval was 
obtained through the Institutional Animal Care and Use Committee of the 
University of Minnesota prior to the initiation of the study. The dog was housed at 
the University of Minnesota’s Veterinary College. This dog was previously 
implanted with a device which wirelessly transmits continuous iEEG recordings 
(Kremen et al. 2018). On study days, the dog was removed from his kennel to 
have a central-line catheter emplaced an hour prior to study start. On days where 
IV ALLO was administered, a peripheral-line catheter was also emplaced. Drug 
administration took place in a procedure room away from the dog’s kennel. The 
dogs were fasted prior to and fed no sooner than 2 hours after drug 
administration. 
iEEG data were collected in the dog during two IV studies (1-2 mg/kg) and 
one IM study (1 mg/kg). Each collection period started the day before and 
finished the day after IV injection to determine baseline data. iEEG data were 
recorded continuously at a sampling rate of 250 Hz. 
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2.5.2.2 Intracranial Electroencephalographic (iEEG) Analysis  
iEEG data were analyzed using custom algorithms (Matlab, version 2018b) for 
characterizing iEEG power in bands of interest and its temporal dynamics (Delta  
(1 -3  Hz), Theta (>3 – 7 Hz), Alpha (>7 - 12 Hz), Beta (>12 – 25 Hz), High Beta 
(>20 -25 Hz)) as described previously (Kremen et al. 2017). Absolute and relative 
power densities across frequency bands were used as the pharmacodynamic 
response. Absolute power density refers to the absolute power (voltage) of the 
patient’s iEGG, while relative power density refers to the percentage of power a 
frequency band (such as beta) compared to the sum of all frequency bands 
(delta, theta, alpha, and beta).  
 
2.5.2.3 Pharmacokinetic-Pharmacodynamic (PK-PD) Modeling 
Individualized PK parameters were estimated using a population approach as 
described in Section 2.3.2.6.2 (Table 2.3.3-5), fixed, then indirect-link Emax/Imax 
PD models were explored. An indirect-link was used due to the hysteresis that 
was observed. The best fit model was determined using visual inspection and 
precision of model parameters. 
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2.5.3 Results 
2.5.3.1 Intracranial Electroencephalographic Analysis 
2.5.3.1.1 Absolute power density  
Across all iEEG frequency bands, absolute power density increased during and 
transiently after IV ALLO (Figure 2.5.3-1). The beta frequency band (purple) 
appears to occur at the lowest plasma ALLO concentrations. As the dose 
increased, the amplitude and duration of these iEEG changes also increased. 
Following IM injection, plasma ALLO concentrations did not reach high enough 
concentrations to produce iEEG changes comparable to the IV infusion at the 
same dose and changes were more spread out over time. However, changes in 
absolute power densities at all doses were statistically significantly different 
 
 
Figure 2.5.3-1 Absolute Power Density and Plasma ALLO Concentration-Time Profiles 
Following IV and IM ALLO Administration in One Dog on Chronic PB. 
Colored solid lines: iEEG, separated into four frequency bands; dashed black line: plasma 
ALLO concentration 
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compared to pre-dose and non-study day baselines irrespective of route of 
administration.  
2.5.3.1.2 Relative power density  
High beta frequency band (20-25 Hz) relative power density decreased, while 
alpha frequency band (7-12 Hz) relative power density increased during and 
transiently after IV infusion (Figure 2.5.3-2). These changes occurred for a longer 
duration but not to a larger extent at the higher dose. As with absolute power 
density, relative power density changes following IM injection were not as drastic 
as changes seen following IV infusion.  
 
 
 
Figure 2.5.3-2 Relative Power Density and Plasma ALLO Concentration-Time Profiles 
Following IV and IM ALLO Administration in One Dog on Chronic PB. 
Purple solid line: Relative beta power density; green solid line: relative alpha power density; 
dashed black line: plasma ALLO concentration 
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2.5.3.2 Pharmacokinetic-Pharmacodynamic Analysis 
For all frequency bands, changes in absolute power density in response to 
plasma ALLO concentrations were best described by an indirect-link sigmoidal 
Emax model (Table 2.5.3-1 and Figure 2.5.3-3). There was an overall increase in 
brain activity following ALLO administration, especially via the IV route. Following 
IV administration, the delay equilibrium half-life ranged from 8-32 seconds, 
suggesting the time required to reach the full response in the brain is less than 3 
minutes. The delay equilibration rate constant could not be calculated with 
precision for most frequency bands following IM injection, likely due to a lack of 
significant change in absolute power density. The beta frequency band 
(comprised of the low and high beta frequency range) had the lowest EC50 (270 
Table 2.5.3-1 PKPD Parameter Estimates (iEEG Absolute Power Density) 
Frequency 
Band 
ke0 (1/min) 
EC50 
(ng/mL) 
E0 (106) Emax (106) 
Route IV IV IV IV 
Dose 1 2 1 2 1 2 1 2 
Delta  
(1-3 Hz) 
2.93 
(18.2) 
1.42 
(24.4) 
652 
(2.0) 
700 
(20.3) 
2.6 
(9.9) 
0.1 
(>500) 
9.1 
(6.6) 
37.1 
(23.2) 
Theta  
(3-7 Hz) 
3.75 
(29.6) 
1.32 
(27.8) 
666 
(2.6) 
538 
(6.1) 
2.9 
(38.2) 
9.4 
(36.4) 
32.3 
(8.6) 
68.5 
(6.9) 
Alpha  
(7-12 Hz) 
5.05 
(35.4) 
1.32 
(13.7) 
681 
(2.3) 
499 
(4.1) 
2.3 
(86.8) 
8.8 
(81.0) 
67.7 
(7.8) 
92.3 
(9.2) 
Beta  
(12-25 Hz) 
2.00 
(22.4) 
1.60 
(26.3) 
276 
(6.7) 
270 
(25.9) 
4.5 
(55.3) 
13.0 
(39.6) 
27.7 
(10.7) 
32.5 
(16.5) 
Values are presented with coefficient of variation (%). ke0: delay equilibrium rate constant; 
EC50: concentration in the effect compartment required to elicit half of the maximum response; 
E0: baseline response; Emax: maximum response 
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ng/mL) compared to the other frequency bands, suggesting it could be a 
surrogate marker useful in clinical studies as a signal for CNS penetration. This 
would approximate 400 ng/mL in the plasma. 
 
 
Figure 2.5.3-3 iEEG (absolute power density) effect-concentration profiles following 1-2 mg/kg 
infused IV over 5 minutes (red and blue, respectively) and 1 mg/kg injected IM as a bolus 
(orange) in 1 dog on cPB. 
Effect compartment concentrations are predicted using an indirect-link between PK and 
sigmoidal Emax PD models. Colored circles are observed data; solid lines represent predicted 
data. IPRED: predicted effect; DV: observed effect. 
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Concentration-iEEG data using relative power densities were also 
examined. Only alpha and high beta frequency bands had consistent changes in 
relative power density with an increasing IV dose. In contrast to changes 
observed in absolute power density, relative power density of high beta 
decreased after administering ALLO, while relative power density of the alpha 
band increased. In other words, relative to all the increasing brain activity, the 
input higher beta frequency band is decreasing in response to ALLO. The relative 
power density changes and concentration-time data for high beta and alpha 
frequency bands were best fit by an indirect-link sigmoidal Imax and Emax 
models, respectively (Table 2.5.3-2 and Figure 2.5.3-4). Similar to absolute 
power density changes, relative power densities had a larger change and for a 
longer duration at the higher IV dose, no significant changes following IM dosing, 
and changes occurred at lower concentrations in the high beta frequency band 
compared to alpha frequency band. The EC50 in the theoretical effect 
compartment to produce changes in the high beta frequency band is 
approximately 720 ng/mL in the plasma. 
Table 2.5.3-2 PKPD Parameter Estimates (iEEG Relative Power Density) 
Frequency 
Band 
ke0 (1/min) 
EC50 
(ng/mL) 
E0 (106) 
Emax /Imax 
(106) 
Route IV IV IV IV 
Dose 1 2 1 2 1 2 1 2 
Alpha  
(7-12 Hz) 
2.35 
(25.0) 
1.20 
(10.6) 
759 
(14) 
455 
(4.2) 
0.09 
(19.6) 
0.10 
(25.4) 
0.57 
(36.6) 
0.32 
(8.8) 
High Beta  
(20-25 Hz) 
2.27 
(26.5) 
0.92 
(5.1) 
635 
(10) 
329 
(3.0) 
0.43 
(4.7) 
0.52 
(3.3) 
0.47 
(22.4) 
0.45 
(4.2) 
 
Values are presented with coefficient of variation (%). ke0: delay equilibrium rate constant; 
EC50/IC50: concentration in the effect compartment required to elicit half of the maximum 
(inhibitory) response; E0: baseline response; Emax/Imax: maximum (inhibitory) response 
  
101 
 
 
2.5.4 Discussion 
Overall, I observed higher absolute power in all bands after administering the 
drug, suggesting that ALLO increases brain activity. Following increases in IV 
dose, the extent and duration of iEEG changes also increased. With the higher 
dose of ALLO, the iEEG changes were greater, the onset of duration was faster, 
and occurred for a longer period of time. In contrast, following IM dosing, there 
were statistically significant but minimal changes to iEEG, likely due to the 
attainment of lower plasma ALLO concentrations. The peak plasma 
concentration following IM dosing (205 ng/mL) was just below the lowest plasma 
EC50 for absolute and relative power density changes estimated from the IV 
infusions (~400- and 720-ng/mL for beta frequency).  
In contrast, increases in absolute and relative power density of the beta 
frequency band in response to benzodiazepine intervention have been widely 
cited (Mandema and Danhof 1992; Mandema, Kuck, and Danhof 1992; 
 
Figure 2.5.3-4 iEEG (relative power density) effect-concentration profiles following 1-2 mg/kg 
infused IV over 5 minutes (red and blue, respectively) and 1 mg/kg injected IM as a bolus 
(orange) in 1 dog on cPB. 
Effect compartment concentrations are predicted using an indirect-link between PK and 
sigmoidal Emax/Imax PD models. Colored circles are observed data; solid lines represent 
predicted data. IPRED: predicted effect; DV: observed effect. 
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Greenblatt et al. 1989; Van Lier et al. 2004; Friedman et al. 1992). In contrast to 
what I observed following IV ALLO, Van Lier et al reported that diazepam elicits 
increases in relative power density of high beta (defined as 21-30 Hz) while 
decreasing alpha (defined as 9-10 Hz) in rats (Van Lier et al. 2004). This 
suggests that although ALLO and BZDs potentiate GABAA receptors, they induce 
differential effects on EEG activity. This may be due to ALLO’s activity at synaptic 
and extrasynaptic GABAA receptors while BZDs have activity at only synaptic 
GABAA receptors. 
The frequency band that appears to have highest sensitivity for plasma 
ALLO concentrations is beta (15-25 Hz). For absolute and relative power density 
changes, beta frequency changes occur at EC50/IC50 lower than other frequency 
bands. Interestingly, the estimated EC50 for beta changes following IV ALLO are 
comparable to what has been observed following a clinically-relevant IV 
diazepam dose (0.15 mg/kg) for percent change over baseline beta activity in 
healthy human volunteers (400 ng/mL vs. 270 ng/mL, respectively) (Greenblatt et 
al. 1989).  
Another PD model that could have been used to describe the iEEG data is 
an indirect-response model, using either stimulation of the “rate in” or inhibition of 
the “rate out” (Gabrielsson and Hjorth 2016). However, many of the previous 
exposure-response models developed with benzodiazepines used Emax models 
(Mandema and Danhof 1992; Mandema, Kuck, and Danhof 1992; Greenblatt et 
al. 1989; Van Lier et al. 2004; Friedman et al. 1992). Furthermore, using an 
indirect-response model would require the estimation of more parameters, which 
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may be difficult given the limited data that I have. Therefore, in order to generate 
comparable results, especially with respect to the beta frequency band, a 
sigmoidal Emax model was used.  
It is important to note that this animal (6J) had higher concentrations at the 
doses administered compared to the other animals who have been administered 
the same dose. This should be taken into consideration when designing a clinical 
trial for canine SE, knowing that many of dogs that present in a veterinary 
emergency department with canine SE are on PB chronically to maintain seizure 
control. 
Zolkowska’s work demonstrated that IM ALLO has great potential to be 
useful as a first-line treatment for SE, but the current formulations do not meet 
the ideal criteria for a first-line SE treatment (Zolkowska, Wu, and Rogawski 
2018). The largest limitation of the IM route of administration is the inability to 
attain high enough plasma concentrations to elicit iEEG changes. Strategies to 
increase plasma concentration using clinically-relevant volumes include but are 
not limited to: 1) increasing its water solubility by synthesizing a pro-drug or using 
alternative delivery systems; 2) using different administration strategies like 
multiple injections of changing the needle gauge and/or length; or 3) optimizing 
the formulation by using multiple solvents. 
 
2.5.5 Conclusion 
The onset of effect of IV ALLO, as seen from iEEG changes and behavioral 
response, was rapid and transient, both desirable for the termination of and 
recovery from SE. Only apparent following IV infusion, I observed a dose-related 
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increase in extent and duration of absolute and relative power densities. Because 
change in absolute and relative power densities for the beta frequency band 
occurred at the lowest EC50 compared to other frequencies, it may be useful as a 
surrogate marker of drug brain penetration. Although IM ALLO would be ideal for 
pre-hospital settings, at the IM formulations studied, plasma ALLO 
concentrations following IM administration are not high enough to induce 
changes in iEEG activity comparable to those seen following IV infusion due to 
low absorption rates.  
 Compiling all of the PKPD and safety data from this project and what has 
been reported by my collaborators at UC Davis (Figures 2.5.5-1 and 2.5.5-2), I 
propose that a 2 mg/kg dose infused over 5 minutes is an appropriate starting 
dose to test as a first-line agent to treat canine SE, as this dose is predicted to 
attain the target concentrations (500-1000 ng/mL) without causing heavy 
sedation. Although a 1 mg/kg dose would also attain plasma concentrations that 
fall within the range between the EC50 and those associated with heavy sedation, 
 
Figure 2.5.5-1 Determination of the Target Plasma ALLO 
Concentration 
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only the 2 mg/kg dose is predicted to attain the peak concentration observed in 
the TETS SE mouse study (900 ng/mL) and as early as 3 minutes into the start 
of infusion. 
 
2.6 Design of a Safety and Effectiveness Clinical Trial of Intravenous 
Allopregnanolone for the Treatment of Canine Status Epilepticus 
In spite of having established guidelines for the management of convulsive SE, 
upwards of 40% of patients are clinically non-responsive to benzodiazepines 
(BZDs) and there remains a critical need to identify a treatment for SE that is 
efficacious for all patients. Without such a therapeutic agent or regimen, 31-40% 
SE cases are at risk for untimely death due to prolonged seizure episodes 
(Hocker et al. 2013; Leitinger et al. 2019). My long-term goal is to find a more 
effective first-line drug for SE treatment that has the potential of replacing or 
being used in conjunction with BZDs. IV ALLO is an ideal agent to treat this 
 
Figure 2.5.5-2 Determination of IV ALLO Dose for a Clinical Trial in Canine SE 
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emergent condition based on its mechanisms of action and its ability to rapidly 
diffuse into the CNS.  
The development path for potential approval of IV ALLO for the treatment 
of seizure emergencies requires conducting clinical trials that safety and 
effectiveness. Because IV ALLO has been approved for another indication, much 
of the toxicity and safety studies may not be required. A unique pathway to 
encourage development of IV ALLO for SE in people is first establishing safety 
and efficacy in canine patients prior to human use. Although this approach would 
not replace the need for safety and effectiveness trials in people, the results 
would inform the design of a clinical trial in human SE. The following proposed 
study have a primary objective of characterizing the safety and effectiveness of 
ALLO for the treatment of SE in dogs. Evaluating potential therapies for SE in 
dogs with naturally-occurring epilepsy and SE have the added advantage of 
developing life-changing treatments for dogs and people.   
 
2.6.1 Study Objective 
The primary objective for this study is to demonstrate that the effectiveness and 
safety of IV ALLO as an agent for early CSE is as effective as IV DZP. 
 
2.6.2 Study Population 
Dogs (5-40 kg in body weight) admitted into an emergency/urgent veterinary 
medical clinic with a clinical diagnosis of convulsive status epilepticus and have 
received at least one adequate dose of a BZD will be enrolled.  CSE is defined 
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as continuous convulsions lasting >5 min, or 2 or more recurrent convulsions 
without regaining consciousness between seizures within the last 12 hours and 
seizures are continuing to occur or likely to reoccur without recovery in between.  
Canine patients may be excluded from the study for the following reasons: owner 
not wishing to participate, anoxic cause for status epilepticus, or metabolic cause 
for status epilepticus (i.e. must have normal blood glucose, calcium, bilirubin, etc. 
on admission bloodwork). 
 
2.6.3 Study Design 
This will be a double-blinded, randomized, multicenter non-inferiority study in 
canine patients with SE who have failed first-round or second round 
benzodiazepines study (Figure 5.2.2-1). This study design will be modeled after a 
prospective, multicenter, randomized parallel-group study comparing the 
 
Figure 2.6.3-1 IV ALLO Study Schematic 
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effectiveness of intranasal midazolam and rectal DZP in terminating CSE within 5 
minutes without seizure recurrence in 10 minutes (M. Charalambous et al. 2017). 
Although I am interested in developing IV ALLO as first-line treatment, it would 
be unethical to test its effectiveness without giving the canine patient a known 
effective treatment first.   
 
2.6.4 Endpoints 
2.6.4.1 Primary Endpoint 
Termination of seizure within 5 minutes of infusion without recurrence of seizures 
within 10 minutes of dosing. Clinical cessation of SE consists of absence of 
clinical seizures and improving responsiveness. Absence of apparent seizures 
will be determined clinically. Responsiveness will be determined by patient’s 
response to verbal command or noxious stimuli.  
2.6.4.2 Secondary Endpoints 
Secondary endpoints include: Safety/tolerability (degree and duration of ataxia 
and sedation, heart rate, blood pressure, EKG monitoring, SpO2 measurement, 
need for intubation within 60 minutes of start of study drug infusion, seizure 
cessation at 60 minutes after drug administration, need for rescue therapy, time 
to next seizure, 12-hour responder rate, discharge status, and presence of subtle 
CSE via EEG monitoring (when available).  
2.6.4.3 Blinding/Unblinding and Randomization 
Patients, veterinary emergency department study team members, PIs, and 
clinical coordinating centers will be blinded to the treatment assignment. 
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Emergency unblinding may be required if the treating team feels that a patient’s 
care requires knowledge of what study drug was given. Emergency unblinding 
will not be performed within 60 minutes of the start of study drug infusion with the 
exception of veterinarian judgment that it is necessary for the safety or care of 
the patient or because of unanticipated situations accommodated by study 
procedures. The PK study PIs and laboratory scientists will know the assay 
results but will remain blinded to response until the completion of the study. Drug 
concentration data will not be disseminated until the completion of study. 
Randomization for this study will be 1:1 between 2 mg/kg IV ALLO and a 
second-/third-round BZD (0.5 mg/kg IV DZP).  
 
2.6.5 Sample Size 
The primary objective of this study is to demonstrate that the number of patients 
whose seizures terminate within 5 minutes of study drug infusion without seizure 
recurrence in the IV ALLO group is not inferior to that in the IV DZP group by 
more than a noninferiority margin of 10%. The null hypothesis of inferiority will be 
tested using a one-sided test with an 80% power and a significance of 5% (one-
sided probability of a type I error of 0.05). The estimate of IV BZD success rate of 
55% is from a prospective, double-masked, randomized parallel-group study of 
IV benzodiazepine (BZD, lorazepam or DZP) + saline infusion and IV BZD + IV 
fosphenytoin (FOS) for the treatment of CSE (Patterson et al. 2015). In this 
study, once a seizure occurred in the emergency department, canine patients 
were given an IV BZD followed immediately by either IV FOS or normal saline, 
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and success was defined as seizure termination without recurrence within 2 
hours. Therefore, the sample size required is 342 per treatment arm (a total of 
684 canine patients), which takes into account a 10% inflation to account for loss 
of follow up, protocol deviation (inclusion/exclusion criteria violation), and/or 
repeat enrollment of the same subject. This conservative approach of assuming 
ALLO has an efficacy rate of 55% is to ensure the study has a large enough 
sample size and sufficient power. 
 
2.6.6 Study Drug 
IV ALLO (6 mg/mL in 24% Dexolve, manufactured by University of California 
Davis) and IV DZP (commercially supplied as 5 mg/mL injectable solution) will be 
used for this study. 
2.6.6.1 Dose Rationale 
Based on the population pharmacokinetic model presented in Chapter 2.3.3.3, 2 
mg/kg IV ALLO infused over 5 minutes is predicted to attain the target plasma 
concentration within 2 minutes of the start of infusion and maintain 
concentrations above this target for approximately 5 minutes without causing 
heavy sedation. The corresponding dose for DZP is 0.5 mg/kg, representing the 
standard of care dose for treatment of SE in canines. The concentrations were 
chosen so that volumes of the two study drugs would be identical based on 
weight. A Dosing Chart will be provided to enable veterinary clinicians to 
administer the same volume of either drug based on kg bodyweight. For 
example, a 5 kg dog will be given 2 mL, while a 40 kg dog will be given 16 mL. 
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2.6.7 Study Protocol 
Dogs arriving at the study centers for emergency treatment of seizures will be 
considered for enrollment. If they meet the inclusion criteria, and informed 
consent is obtained, dogs will be entered into the study and assigned a 
randomized, blinded treatment. The dog may have received 1-2 previous doses 
of BZDs en route to the study center or upon presentation at the study center. 
The standard of care for dogs is to initially treat up to 3 times with IV BZDs as 
they have a shorter half-life in dogs than in humans. If a dog presents to the 
study veterinary clinic in a continuous seizure, an IV BZD will be given, and then 
consent for the study offered. A central-line catheter will be placed, and dogs will 
be admitted to the veterinary ICU for monitoring for 5 hours consisting of: 1) 
continuous seizure watch; and 2) hourly checks for alertness, vomiting, diarrhea, 
or salivation; temperature, pulse, and respirations. If the subject recovers fully, 
the subject will be discharged from the study and $500 of the bill will be covered 
by the study. If the seizure continues or another seizure occurs within 5 hours or 
a seizure is continuing after consent is obtained, the canine study patient will 
receive the randomized treatment: either 0.5 mg/kg DZP IV or 2 mg/kg ALLO IV 
as a slow bolus over 5 minutes. An aggressive rescue treatment plan, based on 
the standardized treatment protocol in place at each institution, will be initiated if 
the canine patient’s convulsions do not diminish 10 min after the completion of 
the infusion or completely stop by 15 min or if motor seizure activity re-occurs 
within 12 hours. All subjects entered into the randomization phase will be 
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observed for at least 12 hours after treatment with the study drug and the owners 
will receive $1500 towards their veterinary care. Appropriate tests will be 
performed to diagnose the cause of the CSE. If a dog does not survive, a post-
mortem exam will be requested. 
 
2.6.8 Data Analysis Plan 
All canine patients who receive study medication will be included in the analyses. 
Continuous demographic and baseline variables such as sex, age, weight, 
laboratory values (complete blood count, serum chemistry, and bile acids), 
number of previous BZDs prior to study treatment, and duration of SE and/or 
number of seizures prior to arrival, will be tested between treatment groups using 
a two-sample t-test; categorical variables such as sex, neuter status, breed (if 
known), history of epilepsy diagnosis, seizure etiology, and seizure type (if 
history of epilepsy) will be tested using a Chi-square test. If any of the subgroups 
are expected to be less than 5 in count, Fisher’s exact test will be used.  
The primary endpoint will be compared between BZD and ALLO groups 
using the Chi-square test. 
Secondary endpoints including the time to next seizure and duration of 
ataxia and sedation will be compared between groups using a log rank test. 
Seizure cessation at 60 minutes after drug administration, need for rescue 
therapy, need for intubation within 60 minutes of start of study drug infusion, 
presence of EKG abnormalities, 12-hour responder rate, discharge status, and 
presence of subtle CSE via EEG monitoring will be compared between groups 
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using a Chi-square test. Continuous variables such as heart rate, blood pressure, 
SpO2 measurement, Ranked/scored endpoints such as degree of ataxia and 
sedation will be compared between groups using a Mann-Whitney test. In 
addition, binary secondary endpoints will be compared across clinic sites using 
the Cochran-Mantel-Haenszel test. If there are statistically significant differences 
in demographic covariates and/or factors, an exploratory logistic regression 
analysis can be performed evaluate the influence of these covariates/factors on 
the probability of treatment outcome. 
 
2.6.9 Challenges and Limitations 
One major challenge of this study design is the large sample size required, which 
may be difficult to recruit for given the low prevalence of CSE (Chapter 1.3.1.1). 
To overcome this, involving more veterinary medicine centers and extending the 
study internationally may help with recruitment. However, this approach would 
also require more time for study set up and staff training. Alternative approaches 
are discussed in the following section that would require a smaller sample size. 
Because this study will be done in emergency departments, complete adherence 
to all aspects of the protocol may be difficult. Deviations can be expected. 
Collecting blood within the pre-defined collection windows within the emergency 
department environment may be a challenge. Incomplete data collection will be 
monitored, and additional training will be implemented where and when needed. 
The number of patients arriving with CSE varies from time to time, and 
enrollment may be slower than estimated. To offset this, we can increase the 
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number of clinic sites. Finally, subjects may be enrolled than later are found to 
not have met the entry criteria due to the cause of the CSE not having been 
accurately diagnosed initially. In our study, there will be little need for unblinding, 
as the study drug administered will not affect the subsequent standard of care, if 
necessary. 
 
2.6.10 Expected Results and Alternative Approaches 
I anticipate that IV ALLO will prove to achieve seizure cessation within 5 min of 
dosing without seizure recurrence within 60 min as frequently as IV DZP, and 
that it will be as safe as IV DZP. This will lead to consideration of IV ALLO as a 
treatment for CSE and will encourage human clinical trials.  
If IV ALLO does not exhibit a noninferior effect compared with IV DZP, it is 
possible that our dose selection based on studies in mice was not appropriate. 
An alternative approach I can consider is an adaptive dose-escalation study, as 
Hardy et al had designed when evaluating the effectiveness of IV LEV for CSE 
(Hardy et al. 2012). Applying this approach, if the 2 mg/kg dose does not cause 
adverse effects in the first cohort of animals, the following cohort would receive a 
higher dose that has been shown to be well-tolerated in dogs (e.g. 3 mg/mL).  
Another alternative approach would be to conduct an adaptive Bayesian 
study design where the study can be stopped earlier if it has been determined 
that ALLO is much more superior or inferior compared to IV DZP. This approach 
may allow a smaller number of required canine patients, however it would require 
information on the expected efficacy of IV ALLO in the treatment of CSE. Since 
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the efficacy in CSE is unknown, I may use the efficacy rate of 92% from a mouse 
model of BZD-refractory SE while making large assumptions or conduct a 
smaller pilot study to better estimate the effectiveness on CSE (Zolkowska, Wu, 
and Rogawski 2018). 
Rather than compare IV ALLO to IV DZP directly, I could compare the 
effectiveness of IV DZP + normal saline with IV DZP + IV ALLO. This design 
would be considered a placebo-controlled trial, however, given that both study 
drugs potentiate GABAA current, it is possible they will exhibit a synergistic effect 
and increase the risk for severe sedation (Ying-Qing and Rong 2001; Gunter et 
al. 2016). Furthermore, a placebo-controlled trial typically test for superiority 
rather than noninferiority, which may require a larger sample size. 
If animals exhibit toxicity (i.e., strong sedation) but superior seizure 
protection is not obtained, I will conclude that it is unlikely that the treatment 
represents an improved approach to treat SE and human subjects will be spared 
from expensive clinical trials that may subject them to risk.  
  
  
116 
 
 
 
 
CHAPTER 3  
 
EVALUATING THE SAFETY OF INTRAVENOUS LACOSAMIDE FOR THE 
TREATMENT OF ACUTE SEIZURES  
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3.1 Introduction 
In this chapter, I will discuss the cardiac safety concerns associated with the use 
of intravenous lacosamide (IV LCM) in patients under critical care. The central 
hypothesis is that IV LCM administration increases the likelihood for PR 
prolongation, which is considered an event unlikely to occur due to chance alone 
in healthy volunteers and ambulatory patients with epilepsy (Nada et al. 2013; 
Mason et al. 2007). The specific aims were to investigate the relationship 
between PR prolongation and IV LCM administration in this vulnerable and 
medically-complex patient population. The objectives of this study were to 1) 
estimate the proportion of patients who shift from a normal to prolonged PR 
interval and whose PR interval increase >20% of their baseline PR interval within 
24 hours of the first IV LCM administration, and 2) determine clinical covariates 
that may help explain the variability in PR prolongation event occurrence. First, I 
will provide a brief review of LCM and a rationale for the development IV LCM for 
the treatment of seizure emergencies, including acute seizures and SE, followed 
by a manuscript.  
 
3.2 Lacosamide 
3.2.1 Physicochemical Properties 
Lacosamide (molecular formula C13H18N2O3) is a functionalized amino acid 
compound with a molecular weight of 250.3 g/mol and a topological polar surface 
area of 67.4 A2 (National Center for Biotechnology Information 2019b). With a 
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logP of 0.3, its predicted water solubility is 0.465 mg/mL (The Governors of the 
University of Alberta 2019), and is slightly soluble in acetonitrile and ethanol.  
 
3.2.2 Known Mechanisms of Action 
Although its precise antiseizure mechanisms are unknown, in vitro studies have 
shown that LCM selectively enhances the slow inactivation of voltage-gated 
sodium channels (VIMPAT® [package insert] 2019; Errington et al. 2008). 
Lacosamide has also been shown have neuroprotective properties. In vitro and in 
silico studies have shown that LCM inhibits collapsin response mediator protein 
2, which decreases tubulin polymerization and neurite outgrowth (Zhang and 
Koch 2017; Wilson et al. 2012; Wilson and Khanna 2015; Y. Wang et al. 2010). 
As a result, LCM has been shown to prevent axon sprouting and decrease 
neuron loss following trauma and status epilepticus (Wilson et al. 2012; X. Wang 
et al. 2018; Licko et al. 2013).  
 
3.2.3 FDA-Approved Indications and Marketed Formulations 
Lacosamide is indicated for the management of focal onset seizures in patients 
at least 4 years of age (VIMPAT® [package insert] 2019). The safety of the 
injectable formulation has not been tested in pediatrics and is only indicated for 
treatment of focal onset seizures in patients who are at least 17 years old. Its 
marketed formulations include tablets, oral solution, and injection. 
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3.2.4 Clinical Pharmacokinetics 
Lacosamide is completely absorbed following oral administration (approximately 
100% bioavailability) (VIMPAT® [package insert] 2019). An average peak plasma 
concentration of 8.5 g/mL occurs approximately 1-4 hours (VIMPAT® [package 
insert] 2019). Its volume of distribution is 0.6 L/kg, approximating the volume of 
total body water, and has low plasma protein binding (<15%) (VIMPAT® 
[package insert] 2019). The elimination half-life is approximately 13 hours 
(VIMPAT® [package insert] 2019). Approximately 40% of the dose is excreted in 
the urine unchanged and 30% as its major O-desmethyl metabolite (VIMPAT® 
[package insert] 2019). CYP3A4, 2C9, and 2C19 are responsible for the 
formation of its O-desmethyl metabolite, which has no known pharmacological 
activity (VIMPAT® [package insert] 2019). VIMPAT demonstrated no clinically 
significant changes on the pharmacokinetics of co-administered antiseizure 
drugs in patients with epilepsy, including valproic acid, carbamazepine, 
levetiracetam, lamotrigine, topiramate, oxcarbazepine, phenytoin, phenobarbital, 
gabapentin, clonazepam, and zonisamide (VIMPAT® [package insert] 2019). In 
patients with partial-onset seizures, small reductions in lacosamide 
concentrations occurred when co-administered with carbamazepine, 
phenobarbital, or phenytoin (VIMPAT® [package insert] 2019).   
 
3.2.5 Present State of Knowledge of Lacosamide in Status Epilepticus 
Most studies and case reports on the use of LCM for SE have been with the 
intravenous formulation with promising results in convulsive and nonconvulsive 
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SE (Bauer et al. 2017; Adam Strzelczyk et al. 2017; Paquette et al. 2015; 
Sebastián Ortiz De La Rosa et al. 2018). Much of the evidence is from 
retrospective and prospective observational open-label cohort studies or case 
reports. One systematic review of the evidence reports an overall efficacy of 57% 
(out of 522 episodes) in treating SE, with comparable efficacy in convulsive and 
nonconvulsive SE, and decreasing efficacy with later use of LCM in the 
management of SE (Adam Strzelczyk et al. 2017). In the retrospective pediatrics 
studies, 45-100% of refractory SE cases were successfully treated when used as 
a third- or fourth-line agent (Arkilo, Gustafson, and Ritter 2016; Grosso et al. 
2014; Shiloh-Malawsky et al. 2011; Jain and Harvey 2012; Poddar, Sharma 
Mbbs, and Ng 2016). There is no paucity of retrospective open-label studies in 
adult refractory SE. Of the few larger studies, IV LCM was successful in 
terminating 33-88% of refractory SE cases and was well-tolerated (C. 
Kellinghaus et al. 2011; C Kellinghaus et al. 2014; Sutter et al. 2013; Höfler et al. 
2011; Santamarina et al. 2018; Newey et al. 2017; Garcés et al. 2014). In 
addition, 36-80% of prospective open-label refractory adult SE cases were 
successfully treated when IV LCM was used as a third- or fourth-line agent 
(Legros et al. 2014; Miró et al. 2013; D’orsi et al. 2016). To date, only one 
prospective, randomized, open-label, comparative cohort study has been 
published evaluating the effectiveness of IV LCM compared to IV valproate 
(VPA) in lorazepam-resistant SE (U. K. Misra, Dubey, and Kalita 2017). Seizure 
termination within one hour was no different between the two groups (63.6% 
LCM, 69.7% VPA), but the LCM group had a statistically insignificant lower 
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proportion of cases with 24-hour seizure freedom (45.5% LCM, 60.6% VPA). 
These results suggest that LCM is as effective as VPA in lorazepam-resistant SE 
and warrants the development of LCM as a treatment for established SE. 
 
3.2.6 Rationale for Developing Intravenous Lacosamide for Treatment of SE 
The unique mechanisms of action of LCM, neuroprotective properties, lack of 
significant drug-drug interactions, low protein binding, availability of intravenous 
and oral formulations, and lower risk for systemic complications make LCM an 
ideal agent for the treatment of seizure emergencies like SE and/or in medically-
complex patients. Considering the systemic complications SE alone, employing a 
therapy that does not increase risk for hypotension (like phenytoin), hepatoxicity 
(like VPA), or respiratory depression (like barbiturates) would be highly desirable 
(Hawkes and Hocker 2018). Although IV LCM has shown great promise, its use 
is somewhat limited by its potential to cause PR prolongation and other cardiac 
dysrhythmias (Rudd et al. 2015; Nizam et al. 2011). 
 
3.3 Intravenous Lacosamide Use and PR Interval Prolongation in the 
Critically-Ill Patient 
3.3.1 Introduction 
Seizures are a common occurrence in critically-ill patients. The prevalence of 
seizures in this population has been estimated to range between 16-27% (Koppel 
et al. 2001; Brandon Westover et al. 2015; Herman et al. 2015). Moreover, the 
presence of electrolyte abnormalities, hepatic and/or renal impairment, 
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requirement of mechanical ventilation, and polypharmacy (enzyme 
inducers/inhibitors, central nervous system depressants, and drugs that 
affect/maintain cardiovascular function, etc) further complicate the hemodynamic 
and metabolic status of critically-ill patients. Although there are a number of 
antiseizure drugs (ASDs) available to treat seizures in the inpatient setting, many 
of these drugs have a high risk for drug-drug interactions and can cause 
systemic complications, including hypotension, Stevens-Johnson Syndrome, and 
respiratory depression. Therefore, an ideal ASD for this population should be 
available as an intravenous (IV) formulation, have a rapid onset of action, not be 
highly protein bound, not induce/inhibit enzymes, and have a low risk for serious 
adverse effects.  
Among the ASDs with available IV formulations, lacosamide (LCM) is 
appealing for use in critically-ill patients due to its novel mechanisms of action 
and low potential for drug-drug interactions. However, LCM has been associated 
with cardiac conduction abnormalities in the form of PR interval prolongation. In a 
study of 944 patients with partial-onset seizures across four oral dose groups 
(placebo, 200-, 400-, and 600-mg), dose-related mean increases in PR interval 
length were observed. Of those patients, 0.4% developed asymptomatic first-
degree atrioventricular block (PR segment prolongation >0.2 msec) (Rudd et al. 
2015). In addition to PR interval prolongation, LCM has been associated with 
serious cardiac arrhythmias including atrial fibrillation, bradyarrhythmia, and 
ventricular tachycardia (Shaibani et al. 2009; Krauss et al. 2010; Berei, Lillyblad, 
and Almquist 2018). These concerns for PR interval prolongation or other 
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potential cardiac issues limits the use of IV LCM in patients at high-risk for 
developing cardiac arrhythmias or conduction abnormalities.  
Although there is information on the overall efficacy and safety of IV LCM 
in the critically-ill, there is a lack of detailed information on PR interval changes in 
this patient population (Sutter et al. 2013; Ramsay et al. 2015; Newey et al. 
2017). These papers capture PR intervals before and after IV LCM 
administration, however details on when PR intervals were recorded are limited, 
or the times at which PR intervals were collected do not permit determination of 
association between PR interval prolongation with IV LCM exposure.  
We performed a retrospective chart review to investigate the relationship 
between IV LCM use and PR interval prolongation in patients in an intensive-care 
unit (ICU) setting. Our primary objectives were to 1) estimate the proportion of 
critically-ill patients whose PR interval shifts from normal (200 msec) to 
prolonged (>200 msec) after receiving at least one dose of IV LCM, and 2) 
estimate the proportion of critically-ill patients who have a PR interval increase of 
>20% from baseline after receiving at least one dose of IV LCM. Our secondary 
objective was to evaluate clinical factors that may help explain the variability in 
PR prolongation event occurrence. 
 
3.3.2 Methods 
3.3.2.1 Study Design 
We performed a retrospective chart review of all patients (aged 18-89 years) 
admitted into either a cardiac, medical, or neurological ICU following admission 
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at Abbott Northwestern Hospital who received at least one dose of IV LCM 
between October 2008 and June 2017. The study was approved by the Allina 
Health and University of Minnesota institutional review boards. 
 
3.3.2.2 Inclusion Criteria 
Patients must have also had at least one PR interval reading within 24 hours 
before and after IV LCM administration. We used the longest pre-dose and post-
dose PR intervals for statistical analyses. 
 
3.3.2.3 Determination of PR Interval Prolongation 
We defined PR interval prolongation as a shift from normal (200 millisecond 
[ms]) to prolonged (>200 ms) PR interval or an increase of >20% in PR interval 
from pre-dose PR interval. Although an increase of >20% in PR interval is not a 
known surrogate marker of PR interval prolongation or cardiac arrhythmias, this 
cutoff was based on the observation from descriptive electrocardiographic 
studies of ambulatory healthy volunteers across several clinical trials that the 
occurrence of either event in PR interval would be considered rare and unlikely to 
occur by chance alone (Nada et al. 2013; Mason et al. 2007). Percent change 
from baseline PR interval was calculated by subtracting the pre-dose PR interval 
from the post-dose interval and dividing by the pre-dose interval. Proportions of 
PR interval prolongation and their respective 95% confidence intervals (CI) were 
calculated using R (Version 3.4.3). 
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3.3.2.4 Evaluation of Clinical Variables 
A covariate analysis was performed in order to identify clinical factors that help 
predict PR prolongation. Variables of interest included: age upon admission, sex, 
race, weight, body mass index (BMI), length of stay (LOS), condition on 
discharge (alive/expired), serum creatinine (Scr), glomerular filtration rate (GFR), 
blood urea nitrogen, glucose, smoking status (never, current, former), serum 
electrolytes (potassium, sodium, chloride, calcium, phosphorus, magnesium, 
bicarbonate), anion gap, dose, total daily dose (TDD), pre-dose PR interval, post-
dose PR interval, new cardiac arrhythmias, and concomitant medications (drugs 
known to cause PR interval prolongation or cardiac disturbances, strong and 
moderate CYP2C9 inhibitors, and strong and moderate CYP3A4 inhibitors). The 
distribution of all predictors were examined visually; those that were heavily 
skewed were log-normalized, while all others were normalized to the median 
value. Missing values for continuous predictors were imputed with the median 
value. Missing values for factors were left blank. Logistic regression analysis (
 where  is the probability of an event 
occurrence,  is the odds of an event occurrence, 0 is an intercept, i is the 
coefficient of the predictor) was used, with PR interval prolongation coded as “1”. 
Forwards and backwards stepwise covariate inclusion were used. A p-value < 
0.01 was considered statistically significant. Selection criteria during the model 
development process were based on changes in Akaike’s Information Criterion, 
residual unexplained variability (deviance), and parameter estimates and their 
standard errors. 
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3.3.3 Results 
3.3.3.1 Study Demographics  
Of the 162 patients screened, 34 were excluded due to lack of recorded pre- or 
post-dose PR intervals, sixteen had a pacemaker, and one was older than 90 
years. Our final analysis included 111 patients. Sixty-three patients were male, 
53 had epilepsy-related primary diagnoses, 87 were Caucasian, eleven were 
African American, fourteen expired prior to discharge, and twelve patients were 
on a co-medication of interest. The median pre- and post-dose PR intervals of 
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180 msec and 180 msec, respectively (ranges: pre-dose: 118-260 [standard 
devation (sd): 30] msec; post-dose: 131-320 [sd: 28] msec) (Table 3.3.3-1).  
 
3.3.3.2 Prevalence of PR Prolongation 
Eight percent (n = 7/88, 95% confidence interval (CI): 2.3,13.6) of our patients 
had a shift from normal to prolonged PR interval, and 13% (n = 15/111, 95% CI: 
7,20) of our patients had a >20% increase in PR interval after their first dose of IV 
LCM (Figure 3.3.3-1). 
Table 3.3.3-1 Patient Demographics 
Variable Min 
25th 
percentile 
Median 
75th 
percentile 
Max Mean 
St. 
Dev. 
Dose (mg) 50 100 200 200 400 179.27 80.19 
Total Daily Dose 
(mg) 
100 300 400 600 1200 440.09 209.20 
Pre-dose PR 
Interval (msec) 
118 160 180 200 260 182.04 30.46 
Post-dose PR 
Interval (msec) 
131 170 180 200 320 186.29 27.94 
Change from Pre-
dose PR Interval 
(msec) 
-60 -10 6 20 90 4.25 26.55 
Age upon 
admission (years) 
18.18 39.46 57.23 69.84 86.37 54.20 19.28 
Length of stay 
(days) 
1.70 4.29 8.51 16.13 50.65 12.19 10.40 
Serum Creatinine 
(mg/dL) 
0.42 0.67 0.79 1.00 7.61 1.11 1.09 
Estimated 
Glomerular 
Filtration Rate 
(mL/min) 
6.95 70.78 92.74 112.64 223.35 91.68 40.45 
Serum Potassium 
(mEq/L) 
2.10 3.60 3.90 4.30 5.10 3.92 0.50 
Serum Total 
Calcium (mg/dL) 
6.60 8.20 8.70 9.00 10.20 8.62 0.65 
Serum 
Magnesium 
(mg/L) 
0.90 1.70 2.00 2.20 4.70 2.04 0.56 
Anion Gap 
(mEq/L) 
3 8 9 11 17 9.40 2.47 
BMI 17.27 22.52 26.87 31.75 48.86 27.63 6.18 
Weight (lbs) 96.00 154.40 177.50 202.15 329.87 181.36 42.87 
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3.3.3.3 Logistic Regression Analysis 
Based on a statistical significance cut-off of <0.01, age, total daily LCM dose 
(TDD), and serum potassium levels were associated with PR prolongation based 
on trending significance (Table 3.3.3-2). After adjusting for all other covariates, 
as a patient increases in age by 10 years, the odds of PR prolongation increase 
by e0.07*10 = 2-fold; as the TDD increases by 100 mg, the odds increase e0.01*100 = 
2.27-fold (or 127%); as the serum potassium (normalized to the median serum 
potassium of 3.9 mEq/L) increases by 0.25 units (equivalent to an increase in 
serum potassium of 0.98 to 4.88 mEq/L), the odds increase e7.62*0.25 = 6.72-fold. 
Figure 3.3.3-2 is an illustration of the relationships between these covariates and 
 
Figure 3.3.3-1 Dotplot of Primary Outcomes. Each circle represents a patient. 
Blue circles denote patients who experienced a PR prolongation within 24 
hours following IV LCM administration. 
 
Table 3.3.3-2 Logistic Regression Results for PR Prolongation 
Coefficients Estimate Standard Error z-value p-value 
Intercept -17.51 5.58 -3.14 <0.01 
Age 0.07 0.03 2.28 <0.05 
Total Daily Dose 0.01 0.002 2.05 <0.05 
Normalized Serum Potassium 7.62 3.86 1.98 <0.05 
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PR interval prolongation. The cases (blue circles) tended to be either on or above 
the median TDD, on or above the median serum potassium, and older in age. 
 
 On the other hand, a shorter baseline PR interval and current/former 
smoking status are associated with a baseline-adjusted increase in PR interval 
>20% following IV LCM (Table 3.3.3-3). After adjusting for all other covariates,  
as pre-dose PR interval increases by ten ms, the odds of having a >20% 
increase from baseline PR interval increases by a factor of e-0.07*10 = 0.5 (or 
decrease by 50%); if patient is a current or former smoker, the odds increases by 
Table 3.3.3-3 Logistic Regression Results for PR Increase >20% 
Coefficients Estimate Standard Error z-value P-value 
Intercept 8.19 2.98 2.75 <0.01 
Pre-dose PR Interval -0.07 0.02 -3.48 <0.001 
Current/Former Smoker 2.50 1.06 2.36 <0.05 
 
 
Figure 3.3.3-2 Relationships between Age, Total Daily Dose (TDD) of LCM, Median-Normalized 
Serum Potassium, and PR Prolongation. 
The size and color of the circles denote the age (i.e. larger circle, older age) and PR 
prolongation (i.e. blue = shift from normal to prolonged PR interval), respectively. 
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a factor of e2.50 = 12.2. Figure 3.3.3-3 depicts the binomial regression of the event 
of a >20% increase from pre-dose PR interval on its two covariates. The 
regression is less steep for current/former smokers, which suggests that the odds 
of a >20% baseline-adjusted increase stays relatively high for current/former 
smokers compared to a patient who has never smoked. For example, at the 
same baseline PR interval of 150 msec, the odds of an event occurrence are 
approximately 0.4, whereas for a nonsmoker, they close to 0. 
 
3.3.4 Discussion 
Intravenous LCM is known to be an effective and well-tolerated treatment for 
seizures in hospitalized adult and pediatric patients (Christoph Kellinghaus, 
Berning, and Besselmann 2009; Luk et al. 2012; Arkilo, Gustafson, and Ritter 
2016; Ngampoopun et al. 2018; Welsh et al. 2017). While several studies have 
suggested that LCM is a relatively safe ASD, there are a growing number of 
reports describing its adverse effects on cardiac conduction. A recent (November 
 
Figure 3.3.3-3 Pre-Dose PR Interval on Event Occurrence and the Effect of 
Smoking Status 
 
 
 
  
131 
2018) FDA alert described new prescribing information for LCM which now 
contains additional serious warnings about cardiac arrhythmias, including 
ventricular arrythmias. Few studies have systematically evaluated LCM effect on 
cardiac function in the critical care setting. Our study sought to evaluate the 
relationship between IV LCM use and PR interval prolongation in patients in the 
ICU. An important finding in our study is that IV LCM use did not cause 
significant change in median PR interval when comparing pre- and post-drug 
exposure within the first 24 hours of administration. However, we observed that 
8% patients had prolonged PR interval and 13% patients had PR interval 
increases >20% of baseline PR interval following IV LCM administration. The 8% 
of patients who experienced PR prolongation is greater than the previously 
reported prevalence of 0.4% in ambulatory patients (Rudd et al. 2015).  
One of our goals was to determine if there was a specific subpopulation of 
patients who were more likely to experience significant increases in PR interval. 
Our logistic regression analyses revealed that older age, higher TDD, and higher 
serum potassium levels are weakly associated with PR prolongation. Many of 
these covariates are expected. Older age has long been associated with longer 
PR intervals, and there is increasing awareness of its increased risk for atrial 
fibrillation (Mason et al. 2007; Magnani et al. 2013; Cheng et al. 2015; 
Macfarlane et al. 2011). There may be confounding variables that may explain 
the relationship between older age and PR prolongation, including heart rate 
(Soliman and Rautaharju 2012). In addition, oral and IV LCM has been reported 
to increase PR interval in a dose-dependent manner and cause first-degree 
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atrioventricular block in a small number of cases (Rudd et al. 2015; Shaibani et 
al. 2009; Krauss et al. 2010; Ramsay et al. 2015; Nizam et al. 2011). 
Interestingly, higher serum potassium levels are typically associated with a lower 
PR interval (Noordam et al. 2019). Therefore, it would seem counterintuitive that 
these patients would be more likely to experience PR prolongation. However, we 
did not find a correlation between serum potassium levels and pre-dose PR 
intervals in our study sample. Therefore, at least in our sample, serum potassium 
levels were associated with PR prolongation independent from baseline PR 
interval.  
With a p-value cut-off of <0.01, only pre-dose PR interval was a strong 
predictor of a >20% increase in PR interval following IV LCM administration. This 
seems rather intuitive, since a lower baseline would require a smaller increase to 
be considered a case. In contrast, the relationship between smoking status and 
PR interval increase was unexpected. The association between smoking status 
and a higher odds of PR interval increase >20% of baseline may be due to the 
effect of nicotine on cardiac conduction. Nicotine increases AV conduction and 
decreases the refractory period of the AV node, and is a risk factor for atrial 
fibrillation (Haass and Kiibler 1996; Watanabe 2018). In fact, several  
prospective, longitudinal cohort studies (including the Health, Aging, and Body 
Composition Study) also found that smoking status was a useful factor in 
predicting incident cardiovascular disease with increases in PR intervals (Cheng 
et al. 2015; Magnani et al. 2013). There may also be confounding variables that 
we were unable to tease out given the small sample size, such as the presence 
  
133 
of cardiovascular or respiratory condition, age, and sex. It would have also been 
of interest to assess whether these patients were had concomitant use of 
varenicline, bupropion, or other smoking cessation drugs. 
This study is one of the largest reported series of IV LCM use in critically ill 
patients to date and used a systematic protocol to assess PR intervals. The 
limitations of our study included the retrospective design, lack of control group, 
and small sample size. Furthermore, we lacked information on arrhythmias in our 
sample. We were able to obtain new arrhythmia data in the electronic medical 
record in 2 out of 7 patients who had PR prolongation and 9 out of 15 patients 
who had a PR interval increase >20% from baseline. Of those patients, only 2 
had a new cardiac arrhythmia diagnosis (atrial fibrillation, cardiac arrest, 
paroxysmal ventricular tachycardia, supraventricular tachycardia, unspecified 
atrial fibrillation, or other specified cardiac dysrhythmias). It is unclear whether 
these event occurrences are important predictors for cardiac dysrhythmia at this 
time. Finally, the absence of a control group prohibited our ability to determine 
whether the higher event occurrence is attributable to the drug effect, the 
circumstances that lead to ICU admission, and/or the complex interaction of co-
morbidities in this patient population.  
 
3.3.5 Conclusions 
The prevalence of PR interval prolongation and of PR interval increase of >20% 
of baseline following IV LCM administration in the critically-ill patient population 
are 8% and 13%, respectively. These event occurrences are higher than what 
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has been reported in the literature for ambulatory patients taking LCM oral tablets 
and more common than expected in healthy volunteer Phase I clinical trials. 
Larger, controlled, prospective studies are needed to confirm the prevalence of 
these events and impact of clinical variables on PR interval changes.  
 
3.4 Design of a Prospective Observational Study of PR Prolongation in 
Critically-Ill Patients on Intravenous Antiseizure Therapy: Focus on 
Intravenous Lacosamide 
Despite the available evidence-based recommendations for management of 
established SE, 12-50% of cases are resistant to current therapies (Malamiri et 
al. 2012; Agarwal et al. 2007; W. B. Chen et al. 2011; U. Misra, Kalita, and 
Maurya 2012; Lyttle et al. 2019; Dalziel et al. 2019; Gujjar et al. 2017; 
Mundlamuri et al. 2015; Nene et al. 2019). My long-term goal is to find a safe 
drug for the treatment of established SE. Fortunately, since the its FDA approval, 
IV LCM has shown promise in the acute treatment of seizures and refractory SE. 
Its neuroprotective properties, lack of significant drug-drug interactions and lower 
risk for systemic complications make it a particularly attractive agent for the 
treatment of seizure emergencies and use in critically-ill patients.  
The development path for potential approval of IV LCM for the treatment 
of seizure emergencies includes conducting clinical trials demonstrating its safety 
and effectiveness. However, its use in established SE is limited by the lack of 
strong evidence (i.e. prospective, blinded, randomized comparative or 
noninferiority trials) and the concerns for its safety in patients with cardiac 
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dysfunction. Therefore, there remains a need to further evaluate the safety of IV 
LCM, with particular focus on cardiac rhythmicity. The following proposed study 
has a primary objective of comparing the prevalence of PR prolongation following 
IV LCM administration in critically-ill patients to matched controls. The results of 
this study will help address concerns for its use in the critically ill population 
and/or seizure emergencies. 
 
3.4.1.1 Study Rationale 
The retrospective study revealed that patients in critical-care who have received 
at least one dose of IV LCM are more likely to experience PR interval 
prolongation compared to healthy individuals and ambulatory patients with 
epilepsy who have taken oral LCM. The major limitations from my retrospective 
study is the lack of a control group and missing data in the medical charts. 
Without a control group, I was unable determine whether the increased 
prevalence of PR interval prolongation was due to IV LCM use alone or to the 
circumstances of the critically-ill population (e.g. co-morbidities or reason for ICU 
admission). Without data on new arrhythmia diagnoses, I was unable to 
determine the clinical significance of PR prolongation following IV LCM 
administration. Thus, a prospective observational study can be conducted to 
address these issues. 
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3.4.1.2 Study Objective 
The primary objective of this study is to compare the proportion of critically-ill 
patients who develop PR prolongation within 24 hours immediately following IV 
LCM administration to the proportion of critically-ill patients matched by 
admission date, ICU, age, and sex who were administered an IV antiseizure drug 
(excluding LCM). 
 
3.4.1.3 Study Population 
All patients (aged 18-89 years) admitted into either a cardiac, medical, or 
neurological ICU following admission at a tertiary care hospital will be screened 
over a ten year period. Consent and enrollment will occur if it is likely that a 
patient will require an IV antiseizure drug (i.e. fosphenytoin, phenytoin, valproic 
acid, levetiracetam, brivaracetam, LCM, or lamotrigine) or if the patient received 
one 24 hours prior to enrollment (e.g. if drug needed to be administered quickly 
in an emergent situation). Patients must have at least one PR interval reading 
within 24 hours before and after initial antiseizure drug (and/or IV LCM) 
administration. 
 
3.4.1.4 Study Design 
A prospective observational study will be performed. Control patients will be 
matched to IV LCM patients by admission date, ICU, age (+/- 5 years), and sex 
to a ratio of 3:1 (control patients to IV LCM patients). Control patients are defined 
as patients who required at least one IV antiseizure drug and did not receive IV 
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LCM during the studied hospital admission. Oftentimes, a patient may have had 
at least one IV antiseizure drug before and/or after requiring the use of IV LCM. 
For those patients, antiseizure drugs used within 24 hours prior to and after IV 
LCM administration will be recorded for covariate testing. Control patients will be 
matched on the number of antiseizure drugs prior to IV LCM administration. For 
example, if a patient received IV LCM after trying two other IV antiseizure drugs, 
three control patients of the same sex and age, from the same admission date, in 
the same type of ICU, who have also received three antiseizure drugs will be 
matched. The PR intervals prior to and after the use of the third antiseizure drug 
will be recorded and used for statistical analyses. After the study period, a data 
extraction team will be utilized to pull data of interest from electronic medical 
records. 
 
3.4.1.5 Sample Collection 
All of the following will be extracted from the electronic medical records: age 
upon admission, sex, race, weight, body mass index (BMI), length of stay (LOS), 
condition on discharge (alive/expired), serum creatinine (Scr), glomerular 
filtration rate (GFR), blood urea nitrogen, glucose, smoking status (never, 
current, former), serum electrolytes (potassium, sodium, chloride, calcium, 
phosphorus, magnesium, bicarbonate), anion gap, dose, total daily dose (TDD), 
pre-dose PR interval, post-dose PR interval, new cardiac arrhythmias, 
concomitant medications (drugs known to cause PR interval prolongation or 
cardiac disturbances, strong and moderate CYP2C9 inhibitors, strong and 
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moderate CYP3A4 inhibitors, and smoking cessation drugs), and antiseizure 
drugs used within 24 hours prior to and following the first dose of IV LCM (or 
antiseizure drug in the equivalent sequence of IV LCM in matched patient). 
 
3.4.1.6 Data Analysis Plan 
The longest PR interval before and after IV antiseizure drug and/or IV LCM 
administration will be used for statistical analyses. PR interval prolongation will 
be defined as a shift from a normal (200 millisecond [ms]) to prolonged (>200 
ms) PR interval. Proportions of PR interval prolongation and their respective 95% 
confidence intervals (CI) will be calculated using R (Version 3.4.3). Continuous 
demographic and baseline variables such as sex, age, weight, laboratory values 
(i.e. basic metabolic panel), and number of previous antiseizure drugs within 24 
hours prior to IV LCM treatment will be tested between treatment groups using a 
two-sample t-test or Mann-Whitney test; categorical variables such as sex, race, 
primary diagnosis, and smoking status will be tested using a Chi-square test. If 
any of the subgroups are expected to be less than 5 in count, Fisher’s exact test 
will be used. 
The distribution of all predictors will be examined visually; those that are 
heavily skewed will be log-normalized, while all others will be normalized to the 
median value. Missing values for continuous predictors will be imputed with the 
median value. Missing values for factors will be left blank. Logistic regression 
analysis (  where  is the probability of an event 
occurrence,  is the odds of an event occurrence, 0 is an intercept, I is the 
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coefficient of the predictor) will be used, with PR interval prolongation coded as 
“1”. Stepwise covariate method will be used to determine significant covariates 
with a forward-inclusion criterion of p<0.05 and a backwards-inclusion criterion of 
p<0.01. Selection criteria during the model development process will be based on 
changes in Akaike’s Information Criterion, residual unexplained variability 
(deviance), and parameter estimates and their standard errors. 
 
3.4.1.7 Challenges and Limitations 
One of the biggest challenges noted from the initial retrospective study is the 
small number events (PR interval prolongation). This affected my ability to search 
for significant predictors. To offset this, I can lengthen the time over which patient 
data will be collection period and recruit more tertiary hospital centers within the 
same health system (to minimize system-wide differences in practice). Another 
challenge is missing data in the electronic medical record. It was found to be 
relatively common for screened patients to be missing either a pre- or post-dose 
PR interval, laboratory values, and/or new diagnoses of arrhythmias. It was also 
difficult to determine whether these data are missing data completely at random, 
missing at random, and missing not at random. For example, are patients with 
missing arrhythmia diagnosis data arrhythmia-free (missing not at random), or 
was the arrhythmia not charted correctly (missing at random or missing 
completely at random), or were neither of possibilities listed above not true but 
data are somehow missing (missing completely at random). To minimize this 
limitation, ICU staff can be trained to collect all data of interest for all patients 
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who receive IV antiseizure drugs, especially PR intervals and arrhythmia 
diagnosis data.  
 
3.4.1.8 Expected Results and Alternative Approaches 
I expect that the proportion of critically-ill patients who experience PR 
prolongation following IV LCM administration will not be statistically different from 
those who do not receive IV LCM. It is possible that the co-morbidities and 
complications that lead a patient to intensive care may contribute cardiovascular 
and autonomic stress, resulting in a longer PR interval. This is reflected in the 
observed high average PR interval at baseline in my retrospective study and that 
which was reported by Luk et al (Luk et al. 2012). Given these assumptions, I 
expect that the proportions of PR prolongation in critically-ill patients will be 
statistically different (and greater) than those from healthy volunteers or 
ambulatory patients with epilepsy. An alternative approach to answering the 
same question would be to conduct larger retrospective study and include 
matched controls as mentioned above. However, the challenge with retrospective 
studies is that one would have less control over what data will be available in the 
medical records. Finally, given the medically-complex circumstances, ethical 
considerations limit the study of IV LCM in critically-ill patients who have 
conditions for which IV LCM is not indicated, in those who do not need an IV 
antiseizure drug, and in those whose hospitalists would not use IV LCM as first 
choice therapies in.  
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CHAPTER 4  
 
DEVELOPMENT OF AN INVESTIGATIONAL INTRAVENOUS 
FORMULATION OF TOPIRAMATE FOR THE TREATMENT OF 
REFRACTORY STATUS EPILEPTICUS  
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4.1 Introduction 
Topiramate is a drug used for focal onset or generalized tonic-clonic seizures 
and for adjunctive treatment for seizures associated with Lennox-Gastaut 
Syndrome for patients at least 2 years of age (Chapter 1.2.1.3). An intravenous 
formulation in the development phase and could be beneficial as an adjunctive 
treatment for SE based on its multiple mechanisms of action and low potential for 
drug-drug interactions as described in more detail below. The objective of my 
work presented here was to characterize the pharmacokinetics and 
pharmacodynamics of IV TPM in dogs. The specific aims were to 1) characterize 
the pharmacokinetics of IV and oral TPM, 2) describe changes in iEEG activity, 
and 3) simulate dosing regimens that would have the highest likelihood of 
achieving plasma concentrations associated with SE response to inform the 
design of a clinical trial in canine SE. In this chapter, I will provide a brief review 
of topiramate and a rationale for the development IV TPM for the treatment of 
SE, followed by published manuscript which describes my research. 
 
4.2 Topiramate  
4.2.1 Physicochemical Properties 
Topiramate (molecular formula C12H21NO8S) is a sulfamate-substituted fructose 
analog with a molecular weight of 339.36 g/mol and a topological polar surface 
area of 124 A2 (National Center for Biotechnology Information 2019c). With a 
logP of -0.8, its water solubility is 9.8 mg/mL, and is soluble in most alkaline 
solutions (pH 9-10) containing sodium hydroxide/phosphate and freely soluble in 
acetone, dimethylsulfoxide, and ethanol. Its saturated solution has a pH of 6.3. 
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Taken together, these properties suggest TPM is highly soluble in neither water 
nor lipids, and transport across biological membranes is likely not by passive 
diffusion. 
 
4.2.2 Known Mechanisms of Action 
Although its precise antiseizure and migraine prophylaxis mechanisms are 
unknown, preclinical studies suggest that at pharmacologically relevant 
concentrations, topiramate inhibits voltage-gated sodium channels, enhances 
activity at GABAA receptors subtypes, blocks AMPA/kainate glutamate receptors, 
and antagonizes carbonic anhydrase isozymes II and IV (TOPAMAX [package 
insert] 2019). Furthermore, there is evidence of neuroprotective properties in 
animal models of limbic SE, methylphenidate-induced toxicity, hypoxia-ischemia, 
and stroke (Niebauer and Gruenthal 1999; Motaghinejad et al. 2017; Schubert et 
al. 2005; Liu et al. 2004; Cha et al. 2002). More specifically, these studies 
illustrated that TPM reduced neuronal cell death in the area of the brain most 
susceptible to seizures and improved cognitive function. The multiple 
mechanisms of action and neuroprotective properties of TPM make it an 
attractive agent for treating SE. 
 
4.2.3 FDA-Approved Indications and Marketed Formulations 
Topiramate is indicated for monotherapy and adjunctive therapy in patients at 
least 2 years of age with partial onset or primary generalized tonic-clonic 
seizures, for patients at least 2 years of age with seizures associated with 
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Lennox-Gastaut syndrome, and for migraine prophylaxis in patients 12 years of 
age or older (TOPAMAX [package insert] 2019). Its marketed formulations are 
limited to tablets, immediate-release sprinkle capsules, and extended-release 
capsules. Extemporaneous compounding of an oral suspension using the 
immediate-release tablets can be made using a mixture of Ora-Sweet and Ora-
Plus (Allen 2017). 
 
4.2.4 Clinical Pharmacokinetics 
Topiramate is well-absorbed after oral administration (TOPAMAX [package 
insert] 2019). An average peak plasma concentration of 27 g/mL occurs 
approximately 2 hours following 400 mg multiple oral dose administration every 
12 hours (FDA CDER 2004). Clinically relevant plasma concentration range of up 
to 33 g/mL (FDA CDER 2004). TPM is 15-41% plasma protein bound, and its 
mean elimination half-life is approximately 21 hours (TOPAMAX [package insert] 
2019). TPM exhibits dose-proportional PK over 100-400 mg dose range (FDA 
CDER 2004). In 19 studies of human PK and PD submitted by the sponsor, TPM 
was found not to be extensively metabolized (FDA CDER 2004). The major route 
of elimination is by renal excretion, with 80% excreted unchanged in 24 hours 
(FDA CDER 2004). However, when changed from PHT or CBZ + TPM therapy to 
TPM monotherapy, TPM oral clearance was reduced by 50% (Bourgeois 2007; 
R. Sachdeo et al. 2002; R. C. Sachdeo et al. 1996). As a result, two-fold lower 
plasma TPM concentrations have been observed (Contin et al. 2013; Yamamoto 
et al. 2017). Although the enzymes responsible for its metabolism have not been 
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fully characterized, it is possible that the increase in oral clearance may be due to 
increased expression of intestinal efflux transporters like P-glycoprotein (Wang-
Tilz et al. 2006; Atasayar et al. 2016). 
 
In dogs, 90% of TPM is excreted unchanged over 96 hours (Caldwell 2005). 
However, TPM is metabolized more extensively in dogs compared to people. The 
most dominant metabolic pathway was found to be hydrolysis at the 2,3-O-p-
isopropylidene group.    
 
4.2.5 Present State of Knowledge of Topiramate in Status Epilepticus 
Cases reported in the literature have suggested that TPM was well-tolerated and 
effective in stopping more than 50% of cases with different types of SE (Shorvon 
and Ferlisi 2012; Wasterlain and Chen 2008). The first case reports of enteral 
TPM used in adult refractory and super-refractory SE were published in 2002 and 
2003 (Reuber, Evans, and Bamford 2002; Towne et al. 2003; Bensalem and 
Fakhoury 2003). After these reports, much of the literature on TPM use in 
refractory and super-refractory SE were from use in pediatrics, which showed  
termination of SE in 77% (17/22) of cases (Kahriman et al. 2003; Perry, Holt, and 
Sladky 2006; Blumkin et al. 2005; Akyıldız and Kumandaş 2011). Since then, a 
few retrospective chart analyses have been published and one prospective open-
label non-randomized clinical trial (Stojanova and Rossetti 2012; W. Kim et al. 
2011; Synowiec et al. 2011; Hottinger et al. 2012; Asadi-Pooya et al. 2015). In 
total, the retrospective studies reported success in terminating refractory SE in 
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70% cases (61/87). However, there are a number of confounders, including the 
number of other ASDs administered, the place in SE management where TPM 
was used (e.g. administration as the third ASD versus sixth ASD), or the effect of 
the combination of medications rather than TPM alone (Hottinger et al. 2012; 
Synowiec et al. 2011). In addition, in many of these studies, TPM tablets were 
crushed to a powder and mixed with water (Towne et al. 2003; Synowiec et al. 
2011). Given that TPM is not highly soluble in water, it is possible that the lack of 
clinical response may be due to limited bioavailability of this “formulation.” In the 
prospective study, TPM was administered as an adjunctive therapy via 
nasogastric tube 30 mins after administration of second-line therapy (phenytoin) 
(Asadi-Pooya et al. 2015). Five of the twenty (25%) patients successfully 
responded (SE termination within 24 hours following TPM introduction without 
modification of concomitant ASDs). Although prospective, this study lacks a 
control, and it is difficult to distinguish whether seizures stopped due to the 
addition of phenytoin, topiramate, or both. Although there is a lack of 
randomized, double-blinded, controlled trials evaluating TPM safety and 
effectiveness for either refractory or super-refractory SE, the enteral TPM 
appears to show promise in the treatment of SE. 
 
4.2.6 Rationale for Developing Intravenous Topiramate for Treatment of SE 
The multiple mechanisms of action of TPM, especially the potentiation of GABA-
ergic inhibition via a benzodiazepine-insensitive pathway and antagonization of 
glutaminergic AMPA/kainate receptors (White et al. 2000), would be particularly 
  
147 
useful when considering SE pathophysiology. That is, TPM has the potential to 
be effective after the internalization of benzodiazepine-sensitive GABAA 
receptors and increased externalization of AMPA/NMDA receptors in the 
synaptic cleft.  
Considering all of its potential benefits, the use of TPM for acute seizure 
emergencies like SE is limited by its route of administration. Despite an oral 
absolute bioavailability of approximately 100%, peak plasma concentrations are 
achieved at approximately two hours following a solid oral dose (Clark, Kriel, 
Leppik, White, et al. 2013a; Clark, Kriel, Leppik, Marino, et al. 2013; Cipla USA 
2017). Although the time to peak concentration following the typical TPM 
preparation comprised of crushed TPM tablets in water is unknown, the earliest 
time to SE termination following enteral TPM was twelve hours (Towne et al. 
2003; Stojanova and Rossetti 2012), with the highest cumulative response rate at 
72 hours (Hottinger et al. 2012; Stojanova and Rossetti 2012; Synowiec et al. 
2011; W. Kim et al. 2011; Bensalem and Fakhoury 2003). Further, these results 
are likely confounded by the various factors, including inconsistent doses and 
titration schedules, lack of controls, and possible disrupted gastrointestinal 
motility due to SE or other acute co-morbidities (Deane et al. 2019). Therefore, 
an intravenous formulation would enable a more rapid loading of TPM that would 
bypass the need for enteral movement and the variability in gastrointestinal 
absorption. This would allow for attainment of higher peak concentrations in a 
shorter length of time compared to the same dose given enterally in this patient 
population. Furthermore, an intravenous route of administration would remove 
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the need for an enteral feeding tube (e.g. nasogastric or gastrostomy tubes), and 
enable TPM use earlier on in the management of SE and prior to the need for 
mechanical ventilation (i.e. third-line therapy).  
4.3 Intravenous Topiramate: Pharmacokinetics and Effect on 
Electroencephalograph Activity in Dogs with Naturally-Occurring Epilepsy1 
4.3.1 Introduction 
Status epilepticus (SE) is defined as a condition characterized by abnormally 
prolonged seizures that can lead to long-term consequences, including 
permanent neuronal injury (Trinka et al. 2015). SE has been reported to have an 
incidence between 2.5-59% in dogs with idiopathic epilepsy, and 32% in dogs 
with secondary epilepsy (Saito et al. 2001; Platt and Haag 2002; Monteiro et al. 
2012). In dogs that have had at least one episode of SE, overall mortality rates 
(primarily from euthanasia) were 32%-38% (Saito et al. 2001; Zimmermann et al. 
2009). In humans, SE occurs with an incidence between 0.04-0.06% in the 
United States, and its complications result in an overall mortality rate of 22% 
(DeLorenzo et al. 1995). While benzodiazepines are the standard first line of care 
for SE in both dogs and humans (Michael Podell 1995; Brophy et al. 2012), 
approximately one third fail to respond to first line therapy (Hocker et al. 2013). 
There remains a need for safe alternatives for early and rapid first- and/or 
second-line therapy of SE to reduce the probability of recurring seizures, 
 
1 This chapter has been published by Frontiers Media SA as: Intravenous Topiramate: 
Pharmacokinetics and Effect on Electroencephalograph Activity in Dogs with Naturally-Occurring 
Epilepsy, Frontiers in Veterinary Science, (2016) 3:107. doi: 10.3389/fvets.2016.00107. 
Reproduction rights for this dissertation were not required by this publisher.  
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minimize associated complications, and improve patient outcomes.  
 One of the barriers to developing new treatments for SE is the 
experimental model used to find and evaluate investigational therapies. 
Oftentimes in rodent models, epilepsy is induced by chemical or electrical insult 
and may not be truly representative of epilepsy pathophysiology (Pitkänen and 
Mcintosh 2006). Dogs with naturally-occurring epilepsy have been proposed as 
appropriate models to examine new antiepileptic therapies prior to human trials 
(Coles et al. 2015). Canine epilepsy is strikingly similar to the human condition in 
both disease presentation and response to treatment. Holliday et al. 
demonstrated that intracranial electroencephalograms (EEGs) of dogs and 
humans during focal onset seizure are indistinguishable (Holliday, Cunningham, 
and Gutnick 1970). Moreover, studies of antiseizure drugs (ASDs), such as 
fosphenytoin and levetiracetam, have shown comparable efficacy in both dogs 
and humans for SE (Coles et al. 2015; Hardy et al. 2012).Given these 
similarities, assessing new therapies for SE in dogs will facilitate drug 
development and increase the chance of successful translation for both canine 
and human SE.  
               Among the newer ASDs with injectable formulations, topiramate (TPM) 
is an attractive candidate for evaluation in the treatment of SE. TPM is a second-
generation, broad-spectrum ASD that inhibits of voltage-gated sodium channels 
and enhances gamma-aminobutyrate (GABA) activity at specific GABAA receptor 
subtypes (Topiramate [package insert] Cipla 2017). TPM also has mechanisms 
of action that differ from those exhibited by current therapies, including 
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antagonizing AMPA/kainate glutamate receptors, and inhibiting specific carbonic 
anhydrase isozymes.  
              Our group has studied the pharmacokinetics (PK) of a novel intravenous 
(IV) TPM formulation in humans. However, the pharmacokinetics of IV TPM and 
its effect on EEG has not been characterized in dogs. This study evaluated TPM 
in dogs with naturally occurring epilepsy to characterize its PK and effect on EEG 
activity. The aims of this study were to 1) characterize TPM PK following an IV 
and oral dose of TPM, 2) evaluate effect of TPM on intracranial EEG (iEEG) 
features, and 3) simulate doses to attain target concentrations of 20-30 µg/mL. 
 
4.3.2 Methods 
4.3.2.1 Study Animals and Safety Monitoring 
Five dogs with naturally-occurring epilepsy were used in this study. Three of the 
dogs have uncontrolled seizures despite being on antiseizure maintenance 
regimens. Approval was obtained through the Institutional Animal Care and Use 
Committee of the University of Minnesota prior to the initiation of the study. The 
dogs were housed at the University of Minnesota’s Veterinary College. Each dog 
was previously implanted with a device which wirelessly transmits iEEG 
recordings (Davis et al. 2011; Coles et al. 2013). Dogs were monitored 
continuously via iEEG and video for five to ten days to obtain baseline data, and 
throughout the study for vomiting, diarrhea, and lethargy prior to and for 90 
minutes after drug administration, and at each blood sampling time. In the event 
of a seizure emergency (seizure lasting >5 minutes) or repetitive seizures (2+ 
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seizures within 1 hour, or 3+ seizures within 4 hours), the on-call veterinarian 
received an automated text message and confirmed the seizure activity using 
remote video monitoring. The rescue therapy protocol consisted of midazolam 12 
mg administered as a single IM dose. 
 
4.3.2.2 Study Drug 
For this study, a stable-isotope labeled TPM compound containing six 13C, 
resulting in a mass 6 units greater than the unlabeled molecule was used for the 
IV formulation (10 mg/mL in 10% Captisol®). This formulation was manufactured 
by the University of Iowa under Good Manufacturing Practices and has been 
licensed to Ligand/CuRx Pharmaceuticals. Unlabeled TPM tablets (25 mg) 
purchased from the University of Minnesota Veterinary Pharmacy (Cipla USA 
Inc) were used for the oral treatment arm. Using a labeled IV formulation and 
non-labeled oral tablets allowed us to simultaneously administer both 
formulations and characterize TPM pharmacokinetics by each route. This 
approach also reduces inter-occasion variability caused by dosing on different 
days and/or times (Marino et al. 2012). 
 
4.3.2.3 Dose Rationale 
Based on reports of doses associated with efficacy in human SE, we estimated 
corresponding target plasma TPM concentrations of 20-30 µg/mL. A previous 
single IV dose study in one dog reported TPM concentrations from which we 
calculated an apparent volume of distribution (Vd) of 0.6 L/kg (Streeter et al. 
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1995). Using this Vd, we estimated that IV doses of 10 and 20 mg/kg would 
produce initial concentrations (C0) of approximately 16 and 32 μg/mL, 
respectively. 
 
4.3.2.4 Study Design 
Low dose IV/oral TPM study: Four dogs were used in this study (ID 1-4, Table 1). 
Two of the four dogs were on ASD maintenance regimen including phenobarbital 
(PB). Each dog was fasted overnight prior to receiving a 10 mg/kg dose of stable-
labeled IV TPM infused over 5 minutes. One hour following the IV bolus, each 
dog also received a 5 mg/kg dose of unlabeled oral TPM. This delay in oral 
administration was by design to allow evaluation of the IV dose on iEEG for one 
hour after dosing. Blood samples were collected from an indwelling catheter prior 
to dosing and at 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 9 hours 
following the IV bolus.  
 
High dose IV TPM study: Three dogs were used in this study (ID 3-5, Table 1). 
One dog was on PB maintenance therapy. Each dog was fasted overnight prior 
to receiving a 20 mg/kg dose of stable-labeled IV TPM infused over 5 minutes. 
Blood samples were collected from an indwelling catheter prior to dosing and at 
0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 9 hours following the IV bolus.  
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Diazepam (DZP) positive control: IV diazepam (0.5 mg/kg) was administered to 
two dogs who were having uncontrolled seizures (ID 1 & 2) during an interictal 
period as a positive control as it has been shown to elicit iEEG change. 
 
4.3.2.5 Plasma TPM Measurements 
A 250 µL sample of whole blood was aliquoted for TPM analysis. The remaining 
blood was placed on ice and plasma was separated. All samples were 
immediately frozen (-20 C) until analysis. Each dog was fed no sooner than 2 
hours after the oral dose. A high-performance liquid chromatography-mass 
spectrometry (HPLC-MS) method developed and validated at the Center for 
Orphan Drug Research was used to measure TPM concentrations in dog 
plasma. Seven calibration standards (run in triplicate) and nine quality control 
standards (low, medium, high run in triplicates) were prepared in plasma. Study, 
calibration, and quality control samples were extracted using methyl tert-butyl 
ether. TPM and stable-labeled TPM were analyzed using the Hewlett Packard 
Agilent 1100 Model G1946 liquid chromatography mass spectrometry detection 
system and Agilent ChemStation software. The analytes were separated using a 
Zorbax C18 column (150 mm x 3.0 mm, 3 µm) and the mobile phase consisted of 
an ammonium acetate buffer and methanol.  The quantization was performed 
using the selective ion monitoring in the negative mode, with deuterated TPM 
(d10) as the internal standard. The mass-to-charge ratios were 338 m/z and 244 
m/z for TPM and stable-labeled TPM, respectively. The calibration curves were 
linear (r 2 = 0.998) in the concentration range of 0.05–50 µg/mL for TPM and 
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0.05-10 µg/mL for stable-labeled TPM in plasma.  The limit of detection and 
quantitation were 0.05 ng/mL and 0.05 µg/mL, respectively.  The precision for 
both TPM and stable-labeled TPM ranged from 3-6%, and accuracy values were 
between 95-114% and 86-105%, respectively. 
 
4.3.2.6 Pharmacokinetic Analysis 
Topiramate concentration-time data were analyzed using non-compartmental 
analysis (Phoenix WinNonLin, version 6.4, Pharsight Corporation, Mountain 
View, CA, USA). Pharmacokinetic parameter values included maximum 
concentration (Cmax), time at which maximum concentration is achieved (tmax), 
elimination rate half-life (t1/2), and the area under the time-concentration curve 
(AUCINF) calculated using the equation 𝐴𝑈𝐶 =  ∫ 𝐶𝑝 ∗ 𝑑𝑡
𝑡=∞
𝑡=0
 (where Cp is the 
plasma TPM concentration) and a linear-log trapezoidal method. Oral 
bioavailability (F%) was calculated using the equation F (%) =
AUC(oral)∗Dose(IV)
AUC(IV)∗Dose(oral)
x 100. Clearance (CL) and Vd were calculated using the 
equations 𝐶𝐿 = 𝐷𝑜𝑠𝑒∗𝐹
𝐴𝑈𝐶
 and 𝐶𝐿 = 𝑘𝑒 ∗ 𝑉𝑑, respectively, where ke is the elimination 
rate constant. Concentration-time profiles were created using GraphPad Prism 7 
(Version 7.0a, GraphPad Software, Inc., La Jolla, CA, USA).  
 PK parameters were also determined using population compartmental 
modeling (Phoenix Non-Linear Mixed Effects software, version 1.3, Pharsight 
Corporation, Mountain View, CA, USA). First order conditional estimation 
extended least squares method was used throughout the model building process. 
One- and two-compartment models were evaluated. A proportional error model 
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for between subject variability was used. Both additive and multiplicative error 
models for residual variability were evaluated. The best fit model was determined 
using visual inspection, goodness of fit plots, weighted residual plots, weighted 
sum of squared residuals, Akaike’s Information Criterion, and precision of model 
parameters.  
 The presence of a CYP3A4-inducing co-medication (such as PB) was 
evaluated as a covariate for its influence on TPM clearance. The relationship of 
the covariate and TPM clearance was modeled by the equation 𝐶𝑙 = 𝑡𝑣𝐶𝑙 ∗  𝑒𝑑𝐶𝑙 ∗
𝑒𝜂𝐶𝑙, where Cl is the clearance from the central compartment, tvCl is the typical 
value of the clearance from the population, dCl is the estimated value of the 
inducer effect, and Cl is the between-subject variability of clearance. A 
covariate was considered statistically significant if inclusion of the covariate 
resulted in a decrease in the objective function value (OFV) of at least 6.64 (p < 
0.01, 𝜒2, degree of freedom = 1). The final model was used to simulate of 5-, 10-, 
and 15-minute infusions IV TPM at doses ranging from 10-30 mg/kg. 
 
4.3.2.7 Electroencephalographic Analysis 
Sixteen electrode channels were continuously sampled at 399.6 Hz. A band-pass 
filter was applied to create 6 frequency bands: delta (1-4 Hz), theta (4-8 Hz), 
alpha (8-12 Hz), beta (12-25 Hz), low gamma (25-40 Hz), and high gamma (40-
120 Hz). In order to evaluate differences in EEG features, energy of each 
electrode within each frequency band was calculated in 1-second intervals by 
summing the square of the EEG signal amplitude within the 1 second window. 
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The average energy level was calculated for three 15-minute ranges: starting 
from 15-minutes pre-dose to dosing, from dosing to 15-minutes post-dose, and 
from 15-minutes post-dose to 30-minutes post-dose. The difference between 
averaged energy levels at pre-dose and each post-dose interval were calculated. 
P-values were generated by the Kruskal-Wallis test comparing the averaged 
energy level from pre-dose to the two averaged energy levels post-dose. 
 
4.3.3 Results 
4.3.3.1 Demographics and Adverse Events 
Demographics of the dogs are represented in Table 4.2.3-1. No adverse events 
were observed for either dose group throughout the course of the study. 
 
Table 4.3.3-1 Animal Demographics 
Subject 
Weight 
(kg) 
Breed Seizure Type Co-medications 
1 33 Coonhound Mix 
Focal and grand 
mal seizures 
Levetiracetam, 
zonisamide, phenobarbital 
2 29 
Labrador 
Retriever Mix 
Cluster seizures 
Levetiracetam, 
zonisamide, phenobarbital, 
potassium bromide 
3 15 Beagle None N/A 
4 29 Coonhound Mix None N/A 
5 35 Coonhound Mix 
Focal and grand 
mal seizures 
Phenobarbital 
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4.3.3.2 Non-Compartmental Analysis 
The concentration-time profiles of plasma 13C-TPM following the low- and high-
dose IV infusions are shown in Figure 4.3.3-1. Pharmacokinetic parameter 
estimates using non-compartmental analysis are summarized in Table 4.3.3-2. 
TPM clearance was greater and elimination half-life shorter in dogs receiving 
chronic PB.  The clearance was 0.5-0.7 L/hr/kg versus 0.1 L/hr/kg and 
elimination half-life 0.5-1 hour versus 3.7-5 hours in dogs with and without PB, 
respectively, suggesting hepatic enzyme induction by PB. Clearance, volume of 
distribution, and elimination half-life were similar for both dose groups studied. 
AUCINF approximately doubled as dose doubled suggesting dose-proportional 
pharmacokinetics.  
 
Figure 4.3.3-1 Plasma-Concentration Time Profiles Following IV Administration of a Low 
(10 mg/kg) and High (20 mg/kg) dose of stable-labeled TPM 
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Plasma TPM concentration-time profiles following oral administration are 
depicted in Figure 4.3.3-2. Cmax following oral administration ranged between 1.9-
2 μg/mL at 1-1.5 hours (Tmax), with a t1/2 between 1.7-2 hours in the two dogs on 
PHB. In the two dogs not on PB, a Cmax of 4.7-5.5 μg/mL at 0.5-1 hour was 
observed, with a t1/2 of 4 hours. Individual oral bioavailability ranged between 61-
102%. These results are summarized in Table 4.3.3-2. Similar to the IV 
Table 4.3.3-2 Pharmacokinetic parameter estimates generated 
from non-compartmental analysis following IV administration 
ID Group 
t1/2 
(hr) 
C1 
(µg/mL) 
AUCINF_obs 
(µg*hr/mL) 
V 
(L/kg) 
CL 
(L/hr/kg) 
1 LOW 0.47 29.2 13.7 0.50 0.73 
2 LOW 0.75 27.1 20.6 0.53 0.49 
3 LOW 3.71 30 83.5 0.64 0.12 
4 LOW 4.05 28.9 101 0.58 0.1 
3 HIGH 4.99 26.1 194 0.74 0.1 
4 HIGH 4.52 29.5 176 0.74 0.11 
5 HIGH 0.95 25.7 38.4 0.71 0.52 
LOW = 10 mg/kg dose. HIGH = 20 mg/kg dose. t1/2: elimination 
half-life; C1: first measured concentration; AUCINF_obs: observed 
area under the curve from time 0 to infinity; V: volume of 
distribution; CL: clearance. 
 
Figure 4.3.3-2 Plasma-concentration 
time profiles following administration 
of a single 5 mg/kg TPM oral dose 
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administration, the two dogs on PHB exhibited higher clearance rates, and 
consequently, shorter half-lives compared to the two dogs not on PB. 
 
4.3.3.3 Population Compartmental Analysis 
A two-compartment model with first-order elimination best fit the TPM 
concentration data following IV administration (Figure 4.3.3-2). Parameter 
estimates are provided in Table 4.3.3-4. A systematic bias in clearance based on 
dose was observed. The inclusion of whether the dog was on an enzyme-
inducing co-medication as a covariate resulted in a decrease in the OFV from the 
base model (difference in OFV = 25) and an improvement in the goodness of fit 
Table 4.3.3-3 Pharmacokinetic parameter estimates generated from 
non-compartmental analysis following PO administration 
ID 
t1/2 
(hr) 
Tmax 
(min) 
Cmax 
(µg/mL) 
AUCINF_obs 
(µg*hr/mL) 
V 
(L/kg) 
CL 
(L/hr/kg) 
F 
(%) 
1 2.02 90 1.92 4.73 2.13 0.73 69.2 
2 1.66 60 2.08 10.5 1.16 0.49 102 
3 3.98 30 4.73 25.7 0.69 0.12 61.7 
4 4.08 60 5.53 36.9 0.58 0.1 73.0 
Volume and clearance were adjusted for bioavailability. t1/2: elimination 
half-life; Tmax: time at peak concentration; Cmax: peak concentration, 
AUCINF_obs: observed area under the curve from time 0 to infinity; V: 
volume of distribution; CL: clearance; F: bioavailability. 
 
Figure 4.3.3-3 Observed versus predicted individual and population concentrations 
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plots and precision of parameter estimates. Therefore, the effect of an enzyme 
inducer on clearance was included in the final model. The presence of PB is 
estimated to affect TPM clearance by a factor of 5.64. Except for peripheral 
compartment clearance, all model-fitted parameters were estimated with good 
precision with all coefficients of variation below 25%. A multiplicative error model 
best described the residual error with an estimate of 15%, which is consistent 
with analytical error. Visual predictive check plots (Figure 4.3.3-4) illustrated the 
observed data percentiles fall within the 90% (5%-95%) model-predicted 
intervals.  
 
Table 4.3.3-4 Pharmacokinetic parameter estimates from a population compartmental 
analysis following an intravenous TPM (low and high doses) 
Model Parameter Estimate Stderr CV%  
Fixed Effect tvV 
(mL/kg) 
376 72.4 19.2 --- 
tvV2 
(mL/kg) 
298 56.0 18.7 --- 
tvCL 
(mL/(kg*min)) 
1.84 0.08 4.52 --- 
tvCL2 
(mL/(kg*min)) 
21.0 9.37 44.7 --- 
dCL 1.73 0.13 7.66 --- 
Random Effect  Estimate Stderr RSE% Shrink% 
BSVV 0.08 0.02 24.6 9.3 
BSVCl 0.02 0.01 53.4 9.18 
Residual error, 
CV% 
14.9 1.71 11.5 --- 
tvV: Typical value of volume of distribution from central compartment; tvV2: Typical value of 
volume of distribution from peripheral compartment; tvCL: Typical value of clearance from 
central compartment; tvCL2: Typical value of intercompartment clearance; dCL: Effect of PB 
presence on CL; BSV: between-subject variability; CV%: coefficient of variation; RSE%: 
relative standard error 
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4.3.3.4 Simulation Analysis 
Using the final model above, various infusion rates and doses were simulated 
(Figure 4.3.3-5). For dogs not on enzyme-inducing co-medications, simulated 
time-concentration profiles suggest that a 5-minute infusion of 20 mg/kg would 
achieve target concentration range of 20-30 μg/mL at 30-minutes post-dose. 
However, in dogs on enzyme-inducing co-medications, a dose between 25-30 
mg/kg infused over 5 minutes would be required to attain the same target range 
 
 
Figure 4.3.3-4 Visual predictive check plots of a population model for dogs not on PB 
and dogs on PB, respectively. Red and black lines represent the observed and 
simulated quantiles, respectively. 
 
Figure 4.3.3-5 Simulated Plasma Concentration Time Profiles Across Varying Doses 
Infused Over 5 Minutes in a dog not on PB and a dog on PB. Here, the yellow band is the 
desired range, and the black vertical line denotes 30 minutes post-dose. 
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4.3.3.5 Electroencephalographic Analysis 
EEG data of good quality were not attained for all animals due to electrical 
malfunctioning of the electrodes and/or data cards as some of the devices had 
been implanted for up to 5 years. In the dogs with a functioning device for EEG 
acquisition, intravenous TPM produced EEG changes shortly after the infusion 
which continued in the subsequent 40-60 minutes (Figure 4.3.3-6). Statistically 
significant positive energy differences in all 6 frequency bands across all 16 
channels were seen comparing the pre-dose time (-15 to 0 mins) to both post-
 
Figure 4.3.3-6 EEG normalized 
signals from beta and low gamma 
frequency bands averaged over 1-
minute intervals in one dog 
 
 
Table 4.3.3-5 Difference between energy levels averaged across low gamma and beta 
frequency bands before and after IV TPM in one dog 
Time Ranges 
(min) 
Frequency Bands 
Pre-
dose 
Post-
dose 
delta 
(1-4 Hz) 
theta 
(4-8 Hz) 
alpha 
(8-12 
Hz) 
beta 
(12-25 
Hz) 
low 
gamma 
(25-40 Hz) 
high 
gamma 
(40-120 
Hz) 
(-15, 
0) 
(0, 15) 16631.6
0* 
3997.93
* 
1250.46
* 
1214.93* 342.61* 265.21* 
(-15, 
0) 
(15, 
30) 
17765.5
7* 
3710.96
* 
1127.09
* 
972.23* 333.26* 220.43* 
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dose times (0 to 15 mins and 15 to 30 mins) (Table 4.3.3-5). Intravenous DZP 
also increased energy in frequencies >4 Hz (most prominently in beta and 
gamma frequency bands), and significantly decreased delta frequency energy in 
most channels (data not shown). 
 
4.3.4 Discussion 
This study is unique in that it evaluated both the pharmacokinetic and 
pharmacodynamics aspects of TPM in dogs with naturally occurring epilepsy. 
This is also the first study characterizing the effect of PB on TPM 
pharmacokinetics in dogs. We observed a 5.6 times greater CL in dogs on PB 
compared to those who were not. In addition, the three dogs on PB exhibited 
lower peak TPM plasma concentrations following oral dosing. This increase in 
clearance suggests that there is induction of hepatic enzymes that metabolize 
TPM. This has also been noted in humans, although the effect of enzyme 
induction in humans is more modest (~145% increase in clearance) (Clark, Kriel, 
Leppik, White, et al. 2013b). To explain this discrepancy, Caldwell et al found 
that while 82% of TPM is excreted unchanged in the urine in humans, only 28% 
is excreted unchanged in dogs (Caldwell 2005).Phenobarbital is a known inducer 
of CYP 3A4, the major enzyme responsible for TPM metabolism. A recent study 
evaluating the effects of chronic administration of PB on the pharmacokinetics of 
levetiracetam in dogs with epilepsy found similar results (Muñana, Nettifee-
Osborne, and Papich 2015). Potential drug-drug interactions should be taken into 
consideration when dosing TPM in both dogs and humans. Dose adjustments 
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are likely needed when TPM is used in conjunction with chronic enzyme-inducing 
or enzyme-inhibiting co-medications in dogs.  
              Although a limitation of the study is the small number of animals used to 
construct the population PK model, the utility of the model is to simulate 
concentration profiles for dogs both on and not on enzyme-inducing co-
medications. It has been noted that dogs respond to many of the same ASD 
therapies as humans. With the use of simulations, we can predict drug exposure 
from different dosing strategies and determine the optimal dosing regimen to 
attain the same concentrations that are considered therapeutic in human SE, as 
we did successfully in dogs with a PK study and a randomized clinical trial with IV 
fosphenytoin (Coles et al. 2015; Patterson et al. 2015). Based on case reports of 
TPM oral suspensions used to treat refractory SE, our goal target concentration 
range was 20-30 µg/mL. Our simulations suggest that these doses should be 
used in designing future a clinical trial in canine SE. 
 The significant changes between pre-dose EEG energy levels and those 
up to 30 minutes after IV TPM administration suggest sufficient and timely 
diffusion into the brain, suggesting that IV TPM may be a good candidate for 
treatment of seizure emergencies. Benzodiazepines in both rodent and dog 
model show significant increases in energy in frequencies greater than 4 Hz and 
decreases in delta frequency energy (Table 4.3.3-5), which is expected from prior 
studies. After IV TPM administration, we also see changes in these frequencies 
at 15 minutes. These observations suggest IV TPM may be beneficial for the 
treatment of status epilepticus. 
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               In conclusion, IV TPM doses of 10 and 20 mg/kg infused over 5 
minutes were shown to be safe and tolerable in dogs. Concurrent administration 
of PB increased the clearance of TPM approximately 5.6-fold. Simulations 
suggest that doses of 20 and 25 mg/kg of IV TPM are necessary to achieve a 
target concentration between 20-30 µg/mL in dogs not on PB and dogs on PB, 
respectively. A key strength of this study is the use of animals with naturally 
occurring epilepsy. The results of this study provide information on optimizing 
TPM therapy for future studies of canine SE, which will subsequently guide the 
design of IV TPM clinical trials of human SE. Future work includes conducting a 
phase II/III efficacy study in canine SE using the dose strategy determined from 
the PK modeling results of this study. 
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4.4 Development of Intravenous Topiramate for the Treatment of Refractory 
Status Epilepticus 
There is currently insufficient evidence to guide refractory SE therapy due to the 
rarity of the condition and difficulty in the interpretation of findings due to the 
complex interaction of drugs used in parallel and co-morbidities at this later stage 
of SE. Early results of a multinational, prospective audit of 488 patients with 
refractory and super-refractory SE reported that 74% of cases recovered from 
RSE, 22% died, and 4% had treatment withdrawn due to futility (Ferlisi et al. 
2015). Although anesthetic agents are useful in suppressing seizures, they are 
associated with a higher risk of systemic complications death independent of 
underlying medical conditions (Sutter et al. 2014). There is an unmet need for 
better control of refractory SE, ideally before the need for burst-suppression. The 
multiple mechanisms of action and neuroprotective properties of TPM make it an 
ideal drug to use when resistance to the recommended antiseizure drugs has 
occurred. 
Because oral TPM is an FDA-approved drug, the development of IV TPM 
has two possible routes: 1) temporary replacement for oral TPM therapy by 
showing that the IV formulation can be safe and bioequivalent to an oral product, 
or 2) conduct controlled safety and efficacy trials for a new indication, such as 
treatment for acute seizures and/or seizure emergencies. Single-doses of 100 
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mg IV TPM infused over 15 minutes has already been shown to be bioequivalent 
to 100 mg oral TPM and safe in healthy volunteers and a PK and safety study in 
patients with epilepsy or migraines taking oral TPM (Clark, Kriel, Leppik, Marino, 
et al. 2013; Clark, Kriel, Leppik, White, et al. 2013b). The next step for this 
direction could be to conduct a single- and multiple-ascending dose study to 
assess the safety and tolerability of higher doses of TPM and longer exposure of 
IV TPM. This information is needed for its development as a temporary 
replacement for oral TPM therapy considering patients with epilepsy can be 
prescribed at least the maximum recommended daily dose of 400 mg divided into 
two doses. For example, in case reports where TPM preparations were used to 
treat super-refractory SE, patients were administered up to 1000 mg TPM per 
day (Brigo, Bragazzi, and Igwe 2017). In addition, it would be useful to know the 
maximum tolerated duration of IV therapy for this same indication. This study 
would not replace the need for a safety and effectiveness clinical trial in SE, but 
these data would inform the safety of IV TPM for the treatment of seizure 
emergencies.  
The following proposed studies have a primary objective of characterizing 
the safety of higher IV TPM doses and its effectiveness in treating refractory SE 
in dogs. 
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4.4.1 IV Topiramate for the Substitution of Oral Topiramate 
4.4.1.1 Study Rationale 
Multiple dose studies have not been conducted to evaluate the safety of larger 
single doses of IV TPM and multiple infusions of IV TPM with respect to infusion 
site adverse effects.  
 
4.4.1.2 Study Objective 
The primary objective of this study is to characterize the safety and 
pharmacokinetics of single- and multiple-ascending doses (SAD/MAD) of IV 
TPM. Pharmacokinetic parameters estimated from the SAD studies will be used 
to simulate exposures in the MAD studies, and adjust infusion rates if necessary. 
The results of these studies will inform labelling recommendations on the 
maximum duration of replacement therapy and the maximum tolerated dose that 
could be safely infused in situations of emergent seizures. 
 
4.4.1.3 Study Population 
Equal proportions of male and non-pregnant and non-breastfeeding female 
patients >18 years of age stable on TPM at daily doses between 300-400 mg will 
be recruited for the single ascending (SAD, six patients per dose cohort and two 
planned cohorts). Patients who are stable on TPM at daily doses between 200-
400 mg will be recruited for the multiple ascending dose studies (MAD, six 
patients per dose cohort and three planned cohorts). Patients must not be on any 
interacting co-medications (a comprehensive “excluded concomitant medication” 
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will be provided). Being stable on oral TPM is defined as having received the 
same dosing regimen for at least the past 4 weeks, and without plans to adjust 
the regimen during the study period. The SAD/MAD study can be conducted in 
parallel.  
 
4.4.1.4 Study Design 
The SAD study will be an open-label study. Patients will receive their half of their 
daily TPM dose (150-200 mg) as a stable-labeled infusion over 15 minutes 
(stable-labeled IV TPM described in Clark et al 2013). All patients will be 
instructed to take the remaining half of their daily dose as oral tablets 12 hours 
after study drug infusion, and as prescribed every day after for the remainder of 
the 96-hour study period. Infusion sites will be monitored for adverse effects such 
as tenderness and swelling. If two of six patients have a DLT, the next cohort will 
receive the same dose. If only one patient experiences a DLT, the next cohort 
will receive the next higher dose of 200 mg IV TPM infused over 15 minutes. The 
study will repeat until three or more people per SAD level have a DLT or 200 mg 
IV TPM has been completed. If the 150 mg single dose is determined to be safe, 
simulations will be done to predict exposures for the Cohort 4. This will also be 
done following the 200 mg single dose.  
The MAD (Cohorts 3-5) study will also be an open-label study. The first 
MAD cohort (Cohort 3) will receive 100 mg of stable-labeled IV TPM over 15 
minutes twice daily for two weeks. In Cohorts 4 and 5, patients will receive half of 
their daily dose of IV TPM infused over 15 minutes twice daily for two weeks if 
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the corresponding infusion was determined to be safe during the SAD study. The 
study will repeat until three or more people per MAD level have a DLT or a daily 
dose of 400 mg IV TPM has been completed. 
 
4.4.1.5 Sample Collection 
For the SAD studies, blood samples pre-injection, and at 15- and 30-minutes, 1, 
2, 4, 6, 12, 24, 48, 72, 96 hours following IV infusion will be collected to 
determine the pharmacokinetics. For the MAD studies, blood samples pre-
injection, and at 1,12, 24, 48, 72, 96, 120, 240, and 336 hours following IV 
infusion will be collected to determine the steady-state pharmacokinetics.  
 
Figure 4.4.1-1 IV TPM SAD/MAD Study Schematic 
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4.4.1.6 Pharmacokinetic Analysis 
Plasma TPM concentration-time data will be analyzed using non-compartmental 
analysis and population compartmental modeling approaches. First order 
conditional estimation extended least squares method will be used throughout 
the model building process. The best fit model will be determined using visual 
inspection, goodness of fit plots, weighted residual plots, weighted sum of 
squared residuals, Akaike’s Information Criterion, and precision of model 
parameters. PK parameters estimated from the SAD cohorts will be used to 
predict exposures in the MAD cohorts and to adjust infusion rates, if needed. 
Infusion rates may need to be adjusted at higher dose levels to ensure the 
maximum concentration (Cmax) does not exceed those observed following oral 
TPM dosing. For example, if the Cmax following 200 mg dose is higher than 
predicted based on data from previous studies (Clark, Kriel, Leppik, Marino, et al. 
2013; Clark, Kriel, Leppik, White, et al. 2013a), the infusion length can be 
increased.  
 
4.4.1.7 Challenges and Limitations 
A challenge to this particular study may be the number of dropouts due to the 
neuropsychiatric adverse effects such as decreased working memory, verbal 
fluency, attention and psychomotor speed, especially in the MAD cohorts (Ngee 
Lim et al. 2016; Ahmed et al. 2014). 
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4.4.1.8 Expected Results and Alternative Approaches 
 
Based on the demonstrated bioequivalence between the 100 mg oral and IV 
formulations, I expect to see a bioequivalence up to the single 200 mg doses. 
Furthermore, based on the safety and tolerability seen in dogs at up to 20 mg/kg 
infused over 5 minutes (using the FDA HED, this would be equivalent to a 775 
mg dose in an average 70 kg adult), I expect to see drowsiness, mild sedation, 
and impaired psychomotor functions at 400 mg daily dose, which may or may not 
be more severe than what the patient has already experienced on stable therapy 
of oral TPM. This may also not be of great concern, considering patients who will 
be requiring replacement of oral therapy will likely be in an acute care setting, 
where these impairments can be monitored. Single- and multiple-ascending dose 
studies are common first-in-human studies used to determine the maximum 
tolerated dose and to perform preliminary food/formulation effect and drug-drug 
interaction testing (Shen et al. 2019). This study is designed to show the 
safety/tolerability of higher doses and of multiple infusions. The results of the 
MAD study will be used to determine whether there is an upper limit to the 
duration of IV replacement therapy. An alternative approach is to conduct the 
SAD/MAD study in healthy volunteers. This would eliminate some confounders 
such as co-medications, co-morbidities, and/or bias in recruiting patients who 
require higher doses of TPM (who may have more severe forms of epilepsy). 
However, with healthy volunteers, one can ethically compare the adverse effects 
of IV TPM infusion with a placebo infusion. 
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4.4.2 Design of a Clinical Study of Intravenous Topiramate for the Treatment 
Established Status Epilepticus in Dogs 
4.4.2.1 Study Rationale 
I previously demonstrated that 20 mg/kg IV TPM infused over 5 minutes was 
safe, well-tolerated, and able to attain therapeutic concentrations for at least 20 
minutes following the start of infusion in dogs with naturally-occurring epilepsy. 
Although I observed changes iEEG power within 15- and 30-minutes of IV TPM 
infusion, I still lack the evidence to conclude that IV TPM is able to terminate 
CSE. Therefore, a double-blinded, randomized, controlled study is needed to 
evaluate the safety and effectiveness of IV TPM for the treatment of established 
CSE. The results of this study would be used to inform the design of a clinical 
trial in human established SE. 
 
4.4.2.2 Study Objective 
The primary objective for this study is to demonstrate the effectiveness and 
safety of IV TPM as a treatment for established CSE is as effective and as safe 
as IV LEV. 
 
4.4.2.3 Study Population 
Dogs (5-40 kg in body weight) admitted into an emergency/urgent veterinary 
medical clinic with a clinical diagnosis of convulsive status epilepticus defined as 
continuous convulsions lasting >5 min, or 2 or more recurrent convulsions 
without regaining consciousness between seizures within the last 12 hours and 
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seizures are continuing to occur or likely to reoccur without recovery in between, 
have received adequate doses of a BZD either before arriving in the hospital or 
after a dose in the hospital, and have a recurrent seizure prior to consenting. 
Canine patients may be excluded from the study for the following reasons: owner 
not wishing to participate, anoxic cause for status epilepticus, or metabolic cause 
for status epilepticus (i.e. must have normal blood glucose, calcium, bilirubin, etc. 
on admission bloodwork). 
4.4.2.4 Study Design 
A double-blinded, randomized, multicenter non-inferiority study in canine patients 
with SE who have failed adequate rounds of benzodiazepines (Figure 5.4.2-1). 
The study involves the collection of one blood sample immediately post-infusion, 
 
Figure 4.4.2-1 IV TPM Study Schematic 
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one 10 minutes after the start of study drug infusion, and one at 2 hours after the 
start of study drug infusion (at measurement of primary endpoint). 
 
4.4.2.5 Endpoints 
4.4.2.5.1 Primary Endpoint 
Termination of seizure within 2 hours of infusion without recurrence of seizures 
within 12 hours of dosing. Clinical cessation of SE consists of absence of clinical 
seizures and improving responsiveness. Absence of apparent seizures will be 
determined clinically. Responsiveness will be determined by patient’s response 
to verbal command or noxious stimuli. This study design was modeled after a 
prospective, double-blinded, randomized, placebo-controlled study assessing the 
effectiveness of IV FOS terminating CSE within 2 hours without seizure 
recurrence in 12 hours (Patterson et al. 2015).  
4.4.2.5.2 Secondary Endpoints 
Safety/tolerability (degree and duration of ataxia and sedation, heart rate, blood 
pressure, EKG monitoring, SpO2 measurement, need for intubation) within 2 
hours of study drug infusion, seizure cessation at 2 hours after drug 
administration, need for rescue therapy, time to next seizure, 12-hour responder 
rate, discharge status, presence of subtle CSE via EEG monitoring (when 
available), and plasma drug concentrations at pre-infusion, 10 minutes, and 2 
hours after the start of study drug infusion. The collection of these secondary 
endpoints will not only inform on the safety of the study infusions, but also how 
drug exposures may affect the primary and secondary endpoints. 
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4.4.2.5.3 Blinding/Unblinding and Randomization 
Patients, veterinary emergency department study team members, PIs, and 
clinical coordinating centers are blinded to the treatment assignment. Emergency 
unblinding may be required if the treating team feels that a patient’s care requires 
knowledge of what study drug was given. Emergency unblinding will not be 
performed within 2 hours of the start of study drug infusion with the exception of 
veterinarian judgment that it is necessary for the safety or care of the patient or 
because of unanticipated situations accommodated by study procedures. The PK 
study PIs and laboratory scientists will know the assay results but will remain 
blinded to response until the completion of the study. Drug concentration data will 
not be disseminated until the completion of study. 
Randomization for this study will be 1:1 between 20 mg/kg IV TPM and 60 
mg/kg IV LEV. 
 
4.4.2.6 Sample Size 
The primary objective of this study is to demonstrate that the number of patients 
whose seizures terminate within 2 hours of study drug infusion without seizure 
recurrence in 12 hours in the IV TPM group is not inferior to that in the IV LEV 
group by more than a noninferiority margin of 10%. The null hypothesis of 
inferiority will be tested using a one-sided test with an 80% power and a 
significance of 5% (one-sided probability of a type I error of 0.05). IV LEV 
demonstrated a 24-hour responder rate of 56% in a prospective, double-blind, 
randomized placebo-controlled study of IV LEV and IV saline for the treatment of 
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CSE (Hardy et al. 2012). In this study, once a seizure occurred in the emergency 
department, canine patients were given an IV BZD followed immediately by 
either IV LEV or normal saline, and success was defined as seizure termination 
without recurrence within 24 hours. The sample size required is 340 per 
treatment arm (a total of 680 canine patients), which takes into account a 10% 
inflation to account for loss of follow up, protocol deviation (inclusion/exclusion 
criteria violation), and/or repeat enrollment of the same subject. 
 
4.4.2.7 Study Drug 
IV TPM (10 mg/mL in 10% Captisol®, manufactured by Ligand Pharmaceuticals) 
and IV LEV (commercially available as a 100 mg/mL injectable solution, diluted 
with normal saline to formulate a 30 mg/mL solution) will be used for this study.  
 
4.4.2.7.1 Dose Rationale 
A 20 mg/kg TPM infused over 5 minutes in dogs will attain plasma concentrations 
associated with successful termination of refractory SE in people. Although my 
simulations suggest that a 20 mg/kg IV TPM dose would only stay above the 
target concentrations for 20 minutes after start of drug infusion in canine patients 
chronically taking PB, in order to preserve a double-blinded study, only one dose 
of IV TPM can be used. The chronic use of PB or other enzyme-inducing co-
medications will be recorded and used as a stratification in the statistical 
analysis.  The corresponding dose for LEV is 60 mg/kg infused over 5 minutes, 
representing the standard of care dose for treatment of BZD-refractory SE. The 
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concentrations were chosen so that volumes of the two study drugs would be 
identical based on weight. A Dosing Chart will be provided to enable veterinary 
clinicians to administer the same volume of either drug based on kg bodyweight. 
 
4.4.2.8 Study Protocol 
Dogs arriving at the study centers for emergency treatment of seizures will be 
considered for enrollment. If they meet the inclusion criteria, and informed 
consent is obtained, dogs will be entered into the study and assigned a 
randomized, blinded treatment. A central-line catheter will have been placed at 
this time per standard of care protocol. After consent is obtained, the canine 
study patient will receive the randomized treatment: either 20 mg/kg IV TPM 
infused or 60 mg/kg IV LEV infused over 5 minutes. An aggressive rescue 
treatment plan, based on the standardized treatment protocol in place at each 
institution, will be initiated if the canine patient’s convulsions do not diminish 10 
min after the completion of the infusion or completely stop by 15 min or if motor 
seizure activity re-occurs within 12 hours. All subjects entered into the 
randomization phase will be observed for at least 12 hours after treatment with 
the study drug and the owners will receive $1500 towards their veterinary care. 
Appropriate tests will be performed to diagnose the cause of the CSE. If a dog 
does not survive, a post-mortem exam will be requested. 
 
4.4.2.9 Sample Collection 
Blood samples will be collected from the central-line catheter pre-infusion, and at 
10 minutes and 2 hours following study drug infusion. 
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4.4.2.10 Data Analysis Plan 
All canine patients who receive study medication will be included in the analysis 
and stratified based on the use of chronic enzyme-inducing medications such as 
PB. Continuous demographic and baseline variables such as sex, age, weight, 
laboratory values (complete blood count, serum chemistry, and bile acids), 
number of previous BZDs prior to study treatment, and duration of SE and/or 
number of seizures prior to arrival, will be tested between treatment groups using 
a two-sample t-test or Mann-Whitney test; categorical variables such as sex, 
neuter status, breed (if known), history of epilepsy diagnosis, seizure etiology, 
and seizure type (if history of epilepsy) will be tested using a Chi-square test. If 
any of the subgroups are expected to be less than 5 in count, Fisher’s exact test 
will be used.  
The primary endpoint will be compared between TPM and LEV groups 
using the Chi-square test.  
Secondary endpoints including the time to next seizure will be compared 
between groups using a log rank test. Seizure cessation at 2 hours after drug 
administration, need for rescue therapy, 12-hour responder rate, discharge 
status, and presence of subtle CSE via EEG monitoring will be compared 
between groups using Chi-square test. In addition, these binary secondary 
endpoints will be compared across clinic sites using the Cochran-Mantel-
Haenszel test. 
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4.4.2.10.1 Pharmacokinetic Analysis 
TPM and LEV concentration-time data will be analyzed using non-compartmental 
analysis and population compartmental modeling approaches. First order 
conditional estimation extended least squares method will be used throughout 
the model building process. The best fit model will be determined using visual 
inspection, goodness of fit plots, weighted residual plots, weighted sum of 
squared residuals, Akaike’s Information Criterion, and precision of model 
parameters. Covariates of interest will include presence of co-medications (such 
as bromide, imepitoin, etc), sex, neuter status, breed, age, weight, serum 
laboratory values (particularly liver function tests), and clinic sites. 
 
4.4.2.11 Challenges and Limitations 
The challenges and limitations of this study are highly similar to those mentioned 
previously in section 5.2.2.10. The additional challenge of this particular study is 
recruitment. Due to the more advanced stage of SE, it would not be unexpected 
for owners to feel that additional treatment may be futile. To offset this, a stipend 
will be rewarded to be put towards the cost of hospitalization.  
 
4.4.2.12 Expected Results and Alternative Approaches 
I anticipate that IV TPM will prove to achieve seizure cessation within 2 hours of 
dosing without seizure recurrence within 12 hours as effectively as IV LEV, and 
that it will be as safe as IV LEV. This will lead to consideration of IV TPM as a 
treatment for CSE and will encourage human clinical trials. If IV TPM does not 
exhibit a noninferior effect compared with IV LEV, it is possible that our dose 
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selection was not appropriate, and perhaps a higher dose may have been 
necessary. An alternative approach to account for this would be to introduce an 
adaptive dose-escalation design, adding a higher dose if the initial dose appears 
safe but inadequate. This approach was used in a study evaluating the 
effectiveness of IV levetiracetam for the treatment of CSE and acute repetitive 
seizures (Hardy et al. 2012). If animals exhibit toxicity and/or seizure protection is 
not obtained, I will conclude that it is unlikely that the treatment represents an 
improved approach to treat established SE and human subjects will be spared 
from expensive clinical trials that may subject them to risk. Another approach 
would be to compare the effectiveness of IV LEV + normal saline with IV LEV + 
IV TPM. This design would be considered a placebo-controlled trial in which I 
would test for superiority instead. The advantage of conducting a noninferiority 
trial instead is the smaller sample size, especially if the difference in efficacy of IV 
LEV and IV TPM is small. 
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Status epilepticus is a life-threatening neurological emergency defined as 
abnormally prolonged seizure (>5 mins) that can have long-term consequences 
including neuronal cell injury and rewiring of neuronal networks (Trinka et al. 
2015). Despite having evidence-based guidelines for the management of 
convulsive SE, approximately 30% of cases fail to respond to first-line therapies 
and progress to more serious conditions with high mortality rates (Treiman et al. 
1998; Logroscino et al. 1997; Vignatelli, Tonon, and Alessandro 2003). Further, 
up to 50% of established SE cases fail to respond to second-line therapies, and 
as high as 94% of refractory SE cases do not respond to a third treatment 
(Malamiri et al. 2012; Agarwal et al. 2007; W. B. Chen et al. 2011; U. Misra, 
Kalita, and Maurya 2012; Lyttle et al. 2019; Dalziel et al. 2019; Gujjar et al. 2017; 
Mundlamuri et al. 2015; Nene et al. 2019; Treiman et al. 1998). Thus, there 
remains an unmet need for more effective and safer drugs to better manage this 
condition at all stages. 
 
The main objective of my dissertation is to develop alternative therapies for 
seizure emergencies. As part of my work, I provided a review of human and 
canine epilepsy and SE and discussed the translatability of research between the 
two diseases. My work in CNS-acting drugs spanned across the drug 
development pipeline and included the development of 1) ALLO for the treatment 
of SE, 2) LCM for the treatment of established SE, and 3) TPM for the treatment 
of established SE.  
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Allopregnanolone is a naturally-occurring neurosteroid that is a positive allosteric 
modulate GABAA receptors that has potential as an early treatment of SE. My 
working hypothesis is ALLO would be beneficial in the early treatment of SE 
based on its novel mechanism of action and ability to get into the brain quickly. 
The specific aims of my project were to characterize the PK, PD, and 
safety/tolerability following single doses of IV and IM ALLO in dogs. I found that 
following IV dosing, ALLO exposure increases proportionately with dose within 
the doses used in my studies (1-4 mg/kg). Behavioral responses and iEEG data 
illustrate the rapid onset of effect following IV ALLO administration which were 
dose-dependent. This information was used to determine the dose for a future 
efficacy study. A dose of 2 mg/kg infused IV over 5 minutes is predicted to result 
in plasma ALLO concentration well above the plasma EC50 but below levels 
associated with heavy sedation. IM ALLO has great potential to be useful as a 
first-line treatment for SE, but the current formulations do not attain high enough 
plasma concentrations to alter iEEG activity. Therefore, in order to continue IM 
ALLO development, alternate approaches to increased early drug concentrations 
should be explored. A limitation to IM dosing is that given the current formulation, 
administration of a larger dose within a small injection volume is not feasible. 
Alternatives to overcome this limitation include increasing the water solubility, 
using different administration strategies, and/or optimizing the IM formulation by 
adding multiple co-solvents and/or small volumes of an organic solvent. As a 
next step in the development of IV ALLO for the first-line treatment of SE, I 
designed a prospective, double-blinded, randomized non-inferiority study in 
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canine patients with SE to test my hypothesis that IV ALLO is just as effective as 
IV DZP. An alternative first-line treatment for SE will improve patient (canine and 
human) care by preventing progression to later, more severe stages of SE and 
critical care admission.  
 
Lacosamide is an antiseizure drug that enhances the slow inactivation of voltage-
gated sodium channels and has potential as a treatment for established SE. Its 
use, particularly in critically-ill patients, is limited by cardiac safety concerns. My 
working hypothesis is that IV LCM increases the risk for PR prolongation, 
especially in the critically-ill population. The specific aim of my project was to 
estimate the prevalence of PR prolongation in the critically-ill patient population 
following IV LCM administration. While I found no significant difference between 
the median pre- and post-dose PR interval, the prevalence of PR prolongation 
was estimated to be 8%, which is higher than the prevalence of 0.4% reported in 
ambulatory patients with epilepsy. I also found that the occurrence of PR 
prolongation following IV LCM administration is positively associated with age, 
the total daily dose of LCM, and serum potassium levels. This suggests there is a 
subpopulation of critically-ill patients who are at higher risk of PR prolongation. 
However, considering that these results are generated from a small number of 
events (n=7/88) without a control group, additional work should be conducted to 
verify my findings. For example, a prospective study to calculate the true 
prevalence of PR prolongation and identify clinical predictors of PR prolongation 
would be used to further help address concerns for its use in the critically ill 
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population and/or seizure emergencies. To address this need, I designed a 
prospective observational study of PR prolongation in critically-ill patients who 
have been administered IV LCM matched to a control group by age, admission 
date, and ICU. Developing IV LCM as an alternative treatment for established SE 
by characterizing the patients in whom it can be used safely (without concern for 
cardiac conduction disturbances) would improve patient care by preventing the 
progression to refractory stages of SE and the use of TLAs, which have an 
inherent risk of systemic complications on their own and increased risk for 
rebound seizures. 
 
Topiramate is an antiseizure drug that potentiates GABA current and antagonize 
AMPA/kainite receptors and has potential as an adjunctive treatment for 
refractory SE. My working hypothesis is that IV TPM would be beneficial as an 
adjunctive treatment for established SE based on its multiple mechanisms of 
action and low potential for drug-drug interactions. The specific aims of my 
project were to characterize the PK, PD, and safety/tolerability following single 
doses of IV TPM in dogs. My major finding included IV TPM at 10- and 20-mg/kg 
was 1) safe and well-tolerated, 2) resulted in a statistically significant change in 
iEEG activity within 15 minutes of drug infusion, and 3) co-medication with PB 
was associated a 5.6-fold higher clearance. With these results, I determined a 
dosing regimen for a clinical trial design in CSE. In order to inform the design of 
clinical trial demonstrating safety and efficacy in human established SE, I 
designed a double-blinded, randomized, multi-center noninferiority study in 
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canine patients with SE who have failed three rounds of BZDs to test my 
hypothesis that IV TPM is just as effective as IV LEV. Another pathway to the 
development of IV TPM is as a temporary replacement for oral TPM therapy. 
Single-dose 100 mg IV TPM bioequivalence has been demonstrated, however 
the safety of higher loading doses and repeated doses of IV TPM is still 
unknown. To address these safety concerns, I designed an open-labeled single- 
and multiple-ascending dose study in patients stable on oral TPM. IV TPM as 
another alternative treatment for the treatment of established SE would improve 
patient (canine and human) care by preventing progression to refractory stages 
of SE and the need for TLAs. 
 
The majority of my work was conducted in dogs with and without naturally-
occurring epilepsy. Although studies conducted in animals are typically thought of 
as “preclinical,” I would like to emphasize that our animals are patients, too. The 
studies conducted resemble Phase I/II dose-escalation studies aimed at 
characterizing the PK, safety, and early markers of PD of a new compound in 
people/patients. As mentioned in Chapter 1.3.3, dogs have naturally-occurring 
epilepsy and SE with etiologies, pathology, and phenomenology that closely 
mimic the human disorder. The advantages of using canine SE as a translational 
platform for therapeutic research include the ability to evaluate behavioral 
responses, accommodate human devices, and estimate a response rate to 
potential therapies for human SE. Therefore, the results of my canine studies will 
provide, at the very least, considerations for clinical trial designs in people.  
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My research suggests that there are promising therapies in development for the 
management of SE, which will significantly improve patient lives by offering safer 
use of current antiseizure drugs or more effective therapies. There are many 
pathways into which these projects can take, including conducting clinical trials in 
dogs with naturally-occurring SE and single- and multiple-ascending dose studies 
in patients. 
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